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Abstract 
Based on the belief that it is a locomotor control structure, the pedunculopontine tegmental 
nucleus (PPTg) has been considered a potential target for deep brain stimulation (DBS) for 
Parkinson’s disease (PD) patients with symptoms refractory to medication and/or stimulation 
of established target sites. To date, a number of patients have been implanted with PPTg 
electrodes with mostly disappointing results. Exact target site in PPTg, possible mechanisms of 
PPTg-DBS and likely potential benefits need to be systematically explored before consideration 
of further clinical application. 
The research described here approaches these questions by (i) investigating the role of the 
PPTg in gait per se; (ii) developing a refined model of PD that mimics the underlying 
pathophysiology by including partial loss of the PPTg itself; (iii) adapting a wireless device to let 
rats move freely while receiving DBS; and (iv) investigating the effect of DBS at different sites 
in the PPTg on gait and posture in the traditional and refined model of PD. 
Underlining the concern that understanding the PPTg as a locomotor control structure is 
inadequate, the experiments showed that neither partial nor complete lesions of PPTg caused 
gait deficits. The refined model showed hardly any differences compared to the standard one, 
but the effect of DBS in each was very different, highlighting the need to take degeneration in 
the PPTg into consideration when investigating it as a DBS target. The differential results of 
anterior and posterior PPTg-DBS show the critical importance of intra-PPTg DBS location: 
Anterior PPTg electrodes caused severe freezing and worsened gait while some gait 
parameters improved with stimulation of posterior PPTg. 
The results suggest mechanisms of PPTg-DBS beyond the proposed activation of over-inhibited 
PPTg neurons, including aggravation of already dysfunctional inhibitory input by anterior PPTg-
DBS and activation of ascending projections from posterior PPTg to the forebrain. 
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  Chapter 1   General Introduction 
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Studies of post-mortem human brain, work with animal models, and the intimate connection it 
holds with the basal ganglia (BG), it all indicates that the pedunculopontine tegmental nucleus 
(PPTg) has a role in Parkinson's disease (PD). The introduction of subthalamic nucleus (STN) 
deep brain stimulation (DBS) to clinical practice has been a consistent success in the treatment 
of parkinsonian symptoms and other conditions like dystonia and essential tremor. Since 2005 
DBS has also been applied to the PPTg in attempt to address symptoms of Parkinsonism with a 
focus on symptoms refractory to dopamine (DA) medication – gait and postural disturbances, 
freezing of gait (FOG) – and for patients not considered good candidates for STN-DBS. 
However, there is doubt about whether the PPTg will ever be considered an established target 
for DBS in PD: there is controversy about its actual potential, the nature of symptoms that 
might be addressed with it, stimulation parameters, and a major question about the optimal 
site for stimulation within the PPTg and the effects that can be expected by stimulating 
different locations within it.  
1. Parkinson’s disease 
1.1. Clinical features 
It was not until 50 years had passed after James Parkinson’s publication “An essay on the 
shaking palsy” in 1817 (Parkinson, 2002) when this neurological disorder was first called 
“Parkinson’s disease” by Jean-Martin Charcot, who made tremor the main symptom, 
correcting the understanding that the slowness of movement results from a weakness of the 
muscles (Lanska, 2010). Today, four symptoms are recognised as cardinal features of PD: 
resting tremor, rigidity, akinesia and postural instability. A flexed posture and FOG are also 
recognised among the classic features (Jankovic, 2008). In addition, patients can show further 
motor symptoms secondary to the cardinal symptoms such as hypomimia, dysarthria, 
dysphagia and sialorrhea, micrographia, shuffling gait and festination, dystonia and glabellar 
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reflexes (see Table 1.1). Non-motor symptoms include cognitive impairment such as dementia 
(affecting up to 80% of patients in advanced stages of PD; (Aarsland et al., 2003) or deficits in 
executive functioning (Chaudhuri and Schapira, 2009), which can already occur in early stages 
of the disease. Other non-motor symptoms can be anhedonia, apathy, depression, anxiety, 
sleep disorders, autonomic symptoms such as bladder disturbances and orthostatic 
hypertension, gastrointestinal symptoms including nausea and constipation and sensory 
disturbances affecting vision and smell [(for a more detailed review please refer to (Chaudhuri 
et al., 2006; Chaudhuri and Schapira, 2009)]. Individual patients experience different 
symptoms –or rather combinations of symptoms – with diverse degrees of severity. How much 
it finally affects the individual person’s quality of life depends of course on the stage of the 
disease and the severity of the symptoms but also on their lifestyle, profession, social and 
familial situation. 
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Parkinson's disease symptoms 
Motor symptoms     
tremor  resting tremor (4-6Hz) in limbs with distal 
predominance, "pill-rolling" tremor  
   
rigidity  increased muscular tone to palpation at rest, reduced 
distension to passive movement and increased 
resistance to stretching 
   
hypokinesia  reduced frequency and amplitude of spontaneous 
movement 
   
bradykinesia  slowness of movement, reduced speed when initiating 
and executing a single movement and progressive 
reduction of amplitude of repeated movements 
   
postural instability   
   
FOG  difficulties initiating gait or interruption of ongoing gait 
  
 
shuffling gait  
   
festination  quickening and shortening of normal strides 
   
problems arising from chair   
   
decreased arm swing   
   
micrographia  abnormally small handwriting 
   
slow activities of daily living   
   
bulbar dysfunction   
hypomimia  reduced facial expressions 
dysarthria  motor speech disorder 
dysphagia  swallowing difficulties 
sialorrhea  excessive production of saliva 
hypophonia  "weak" voice 
   
Myerson's sign  unhabituated glabellar reflex: primitive reflex of eye 
blinking elicited by tapping on the forehead, which 
normally ceases after a few tabs 
   
blepharospasm  increased blinking or spasms of eyelid closure 
   
postural deformities   
striatal deformities  abnormal postures of hand and foot 
scoliosis  abnormal curvature of the spine to the side 
camptocormia   abnormal flexion of the trunk in standing or walking 
which disappears in supine position 
Table 1.1. Motor and non-motor symptoms in Parkinson’s disease. 
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Parkinson's disease symptoms 
Non-motor symptoms     
Neuropsychiatric symptoms   
depression   
apathy  diminished motivation 
anhedonia  loss of pleasure in previously enjoyable activities 
anxiety and panic attacks   
cognitive dysfunction  bradyphrenia ("slowed thinking"), verbal fluency 
deficit, executive dysfunction 
attentional deficit   
hallucinations, illusions, 
delusions 
  
dementia   
confusion   
   
Sleep disorders   
REM behaviour disorder  parasomnia manifested by vivid dreams associated 
with dream enactment behaviour 
excessive daytime somnolence   
insomnia   
   
Autonomic symptoms   
bladder disturbances   
sweating   
orthostatic hypotension  sudden fall of blood pressure when standing 
up/stretching 
erectile impotence   
   
gastrointestinal symptoms   
reflux, vomiting   
nausea   
constipation   
   
Sensory symptoms   
ageusia  lack or impairment of the sense of taste 
anosmia  loss of the sense of smell 
Pain   
Paraesthesia  "pins and needles" 
visual dysfunction   i.a. impairment of spatial contrast sensitivity, visual 
acuity, reduced contraction amplitude (Armstrong, 
2011) 
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1.2. Towards the understanding of the disease 
About one hundred years after Parkinson’s essay, cell loss in the substantia nigra (SN) could be 
linked to parkinsonian symptoms and 140 years after the publication Carlsson and colleagues 
identified DA as an independent neurotransmitter involved in the mechanisms behind the 
pathology. This was confirmed by Ehringer and Hornykiewicz who proved that there were 
decreased DA levels in the striatum of PD patients (Bjorklund and Dunnett, 2007b; Jankovic, 
2008). These findings not only led to the discovery and establishment of L-3,4-
dihydroxyphenylalanine (L-DOPA) as an effective treatment for parkinsonian symptoms in the 
late 1950s and 60s but also to the understanding of the involvement of midbrain DA neurons 
in motor control (and of course, later in reward signalling during learning: see for example 
(Redgrave et al., 2008; Schultz, 2006). This ultimately led to the identification of 
neuropathological processes that cause movement disorders such as PD. Consequently, rapid 
progress was made and models of BG functioning were formulated. 
1.2.1. Basal Ganglia circuitry 
The BG are a group of interconnected nuclei and form an essential component of various 
parallel cortico-subcortical circuits in which information from cortical areas is processed in a 
collection of interconnected nuclei and returned to the cortical areas from which the 
information originated, passing via the thalamus. In addition, these processes are modulated 
by intimately connected midbrain and brainstem structures which in return receive 
information from the BG themselves. The BG are described as being comprised of the caudate 
nucleus and the putamen (which, together form the dorsal part of the striatum: in primate the 
caudate and putamen are separated by the internal capsule; in non-primate brains they form 
one complex, the caudate-putamen), the globus pallidus (GP; with its two separate external 
and internal segments GPe and GPi respectively), the STN and SN, which divides into pars 
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compacta (SNc) and pars reticulata (SNr). Putamen and GP as an entity are also called the 
lenticular nuclei (Gerfen and Bolam, 2010; Wichmann et al., 2002). 
It should be noted that the ventral striatum constitutes a further part of the BG. The dorsal 
striatum includes the caudate and putamen as noted above, and receives DA input from SNc. 
The portion below is the ventral striatum: the nucleus accumbens (NAcc) core and shell, as 
well as the olfactory tubercle, which receive DA input from the ventral tegmental [VTA; 
(Humphries and Prescott, 2010; MacDonald et al., 2011)]. 
Since the early 1980s it has been acknowledged that the BG are more than a structure of 
“pure” motor control but that they are anatomically and topographically and also functionally 
more complex than that. In the Robert Wartenberg Lecture in 1982 David Marsden highlighted 
that the “the striatum takes in information from virtually all areas of the nervous system to 
undertake some unknown transformation into instructions to the output zones of the GPi and 
SNr whose own output is coded in relation to motor behavior” [(Marsden, 1982) p. 518].  
Rather than causing a “more” or “less” of movement by activating individual pathways of the 
BG circuits [‘scaling and focusing model’; see (DeLong and Wichmann, 2009)] facilitating 
desired movements and inhibiting unwanted movement, it is assumed that the BG have a role 
in action selection processes, an ability crucial for every organism and an “evolutionary ancient 
problem” (Redgrave et al., 2011), a function that critically involves learning. Only one “final 
common motor path” (Redgrave et al., 1999) can be executed at a time, so that the most 
advantageous action needs to be selected from all possible ones in any situation.   
The “segregated circuit hypothesis” (Alexander et al., 1986; Middleton and Strick, 2000) 
describes how information originating from different cortical areas enters and leaves the BG 
maintaining largely functional territories throughout the individual circuits and re-enters the 
same cortical areas it originated from. Haber and colleagues describe how the topography 
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results in a tight anatomical and functional organisation with interconnected thalamic and 
cortical afferents terminating in the same striatal area, from where the functional topography 
is continued to the BG output nuclei and maintained back to cortex via the thalamus (Haber, 
2003). However, they also highlight the necessity to extend this concept of parallel processing 
by the notion of integrative circuits by which information from separate loops can influence 
each other (Haber, 2003; Haber et al., 2000). 
The resulting loop architecture enables an integration of different types of information and a 
functional role beyond simple motor functions. “Motor”, “cognitive”, and “limbic” loops 
connect different cortical, subcortical and thalamic areas in a similar manner [also often 
divided into “motor, associative, sensory and limbic” (Redgrave et al., 2011) or including 
“oculomotor” and “orbitofrontal” loops (Joel and Weiner, 2000; Obeso et al., 2008; Voorn et 
al., 2004; D. I. G. Wilson et al., 2009)] . Given the relevance of the motor circuit for this study 
the following descriptions will focus on this, but it is important to point out that those parallel 
loops are not always closed and information can spread between loops (Joel and Weiner, 
1994; Miyachi et al., 2002), allowing for a role beyond motor control by integrating various 
functions giving rise to behaviour, which rarely can be classified as purely “motor”.  
Efferents from cortical motor areas project topographically to the putamen - the “motor 
portion” of the striatum (Wichmann and Dostrovsky, 2011). A minor part projects directly to 
the STN, which constitutes the hyperdirect pathway. It is suggested that the cortico-
subthalamic pathway is separate from the corticostriatal pathway, meaning that a different 
type of information might be processed separately at that point (Parent and Parent, 2006). 
Information leaving the dorsal striatum takes two different pathways: either the direct, 
monosynaptic way innervating the BG output nuclei GPi (entopeduncular [EP] nucleus in 
rodents) and the SNr or the indirect, polysynaptic one, which involves the GPe and the STN. 
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These corticostriatal projections to striatal medium spiny neurons (MSNs) express D1 
receptors and are involved in the activation of the direct pathway;  they are distinct from those 
projecting to D2-expressing MSNs, which are involved in the activation of the indirect pathway 
(Lee et al., 2005). The BG output from GPi/SNr is mainly directed toward the ventrolateral (VL) 
and ventral anterior (VA) nuclei of the thalamus which form reciprocal connections with the 
BG and also project back to cortical areas, closing the cortical-subcortical-cortical motor loop. 
Interestingly VA and VL also innervate the intralaminar thalamic nuclei (the centromedian 
nucleus [CM] and the parafascicular nucleus [Pf]) both of which receive important cholinergic 
input from PPTg and the laterodorsal tegmental nucleus (LDTg) and are crucial in procedural 
learning, providing salience information to the striatum (Kimura et al., 2004). GPi/SNr make 
descending connections with midbrain and brainstem targets such as the superior colliculus 
(SC) and, relevant to this study, the PPTg, with which the BG form reciprocal connections (see 
Chapter 2.3.). Figure 1.1. summarises the intrinsic circuitry of the BG motor loop.  
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Figure 1.1. Cortico-subcortical circuit model representing the so called motor circuit. Red arrows 
indicate inhibitory connections, green arrows excitatory connections. This figure is lacking further 
connections of the PPN with BG nuclei, most notably its inhibitory afferents from the BG output 
nuclei GPi/SNr. For further information on PPTg connectivity please refer to Chapter 2.3.2. 
Abbreviations: CM, centromedian nucleus of the thalamus; CMAr, rostral portion of cingulate motor 
area; CMAd, dorsal portion of cingulate motor area; CMAv, ventral portion of cingulate motor area; 
GPe, external segment of the globus pallidus; GPi, internal segment of the globus pallidus; M1, 
primary motor cortex; Pf, parafascicular nucleus of the thalamus; PMd, dorsal premotor cortex; PMv, 
ventral premotor cortex; PPN, pedunculopontine nucleus; SMA, supplementary motor area; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; 
VApc, ventral anterior nucleus of thalamus pars parvocellularis; VLm, ventrolateral nucleus of 
thalamus pars medialis; VLo, ventrolateral nucleus of thalamus pars oralis; VLcr, ventrolateral 
nucleus of thalamus rostral pars caudalis; c, caudal; cl, caudolateral; d, dorsal. Image reproduced 
from (DeLong and Wichmann, 2007). 
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The direct pathway results, when activated, in an inhibition of the GPi and the SNr which 
means a reduction of inhibitory BG output, leading to a disinhibition of targeted 
thalamocortical neurons and facilitation of the intended movement. The indirect pathway has 
an opposite effect when activated: it increases BG output by disinhibition of its activity and 
therefore increases the inhibition of thalamocortical projections, suppressing unintended or 
competing movements (DeLong and Wichmann, 2007; Galvan and Wichmann, 2008). 
However, this is a very simplified model of BG functioning. Those intrinsic circuits are not that 
clear cut as mentioned above; many striatal projections have collaterals projecting to both 
segments of the GP, extending beyond functional domains (Levesque and Parent, 2005; Parent 
et al., 2000; Wu et al., 2000). Another mechanism causing an integration of circuits is through 
complex non-reciprocal connections between structures such as feedforward connections 
from the ventral striatum to the dorsal striatum via midbrain dopamine neurons (Haber, 2003; 
McFarland and Haber, 2002). Neither does this model acknowledge subcortical loops 
connecting the PPTg, SC, periaqueductal grey, cuneiform, habenula and parabrachial nuclei to 
the BG, offering important modulatory influence (McHaffie et al., 2005; Mena-Segovia et al., 
2004; Redgrave and Coizet, 2007; Winn et al., 2010). The lateral habenula for example  
provides inhibitory input to midbrain dopamine neurons via the RMTg (Balcita-Pedicino et al., 
2011; Hong et al., 2011) responding inversely to stimuli associated to reward, omission and 
delivery of reward compared to DA neurons (Matsumoto and Hikosaka, 2007). It further 
ignores important connections of the BG circuit with cerebellar circuits (Hoshi et al., 2005). 
Further, some authors include the VTA and NAcc into descriptions of the BG [for example (Yin 
et al., 2006)]. 
The rate model of the pathophysiology of PD describes firing rate changes in the BG after 
striatal DA loss as a result of the disturbances in the activity of the direct and indirect pathway. 
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Decreased activation of D2-expressing MSNs presents a reduction of inhibition of 
corticostriatal transmission causing increased activity along the inhibitory indirect 
striatopallidal pathway, reducing the firing rate in the GPe which results in disinhibition of STN 
activity and facilitation of GPi firing (Breit et al., 2006; Mitchell et al., 1989; Vila et al., 1997). In 
a similar manner it was suggested that a decrease of D1-expressing MSNs leads to reduced 
activity along the direct pathway resulting in an increased activity in the BG output nuclei, but 
this has not been directly demonstrated (Wichmann and Dostrovsky, 2011). The consequence 
of the increased inhibitory BG output would cause a reduction in thalamocortical activity and 
increased inhibitory output onto downstream brainstem targets (see Figure 1.2.). 
 
Figure 1.2. Shift of balance of BG activity towards the indirect pathway in Parkinson’s disease 
according to the ‘rate model’.  Black arrows indicate inhibitory connections, gray arrows excitatory 
connections. The thickness of the arrows corresponds to their presumed activity. Abbreviations: CM, 
centromedian nucleus of thalamus; CMA, cingulate motor area; Dir., direct pathway; D1 and D2, 
dopamine receptor subtypes; GPe, external segment of the globus pallidus; GPi, internal segment of 
the globus pallidus; Indir., indirect pathway; M1, primary motor cortex; Pf, parafascicular nucleus of 
the thalamus; PMC, premotor cortex; PPN, pedunculopontine nucleus; SMA, supplementary motor 
area; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic 
nucleus; VA, ventral anterior nucleus of thalamus; VL, ventrolateral nucleus of thalamus. Image 
reproduced from (Galvan and Wichmann, 2008). 
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However, the rate model fails to explain clinical findings: contrary to what the model would 
suggest, lesions of the thalamus or GP did not lead to worsening of hypokinesia or 
bradykinesia, nor did it cause dyskinesias (Marsden and Obeso, 1994). Furthermore, the firing 
rates predicted by the rate model do not always correspond to findings in Parkinson’s models: 
instead of the expected reduced firing rate in GPe and increased firing rate in GPi, several 
studies have found no significant changes in individual structures [GPi: (Wichmann et al., 
1999); motor cortex: (Doudet et al., 1990; Goldberg et al., 2002; Rubin et al., 2012)]. GPe-
lesion induced rate changes in BG nuclei similar to changes seen after 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) had no behavioural effects (Soares et al., 2004). 
It is another distinct abnormality of BG activity that replaces the exclusive firing rate models: 
prominent changes of BG firing patterns, such as bursts and oscillatory patterns and abnormal 
synchronization have been found in parkinsonian animals but have also been recorded by DBS 
electrodes implanted in PD patients (for exhaustive summaries see (Eusebio and Brown, 2007; 
Galvan and Wichmann, 2008; Hammond et al., 2007; Wichmann and Dostrovsky, 2011). 
Synchronized oscillatory activity was consistently shown at multiple levels of the BG-cortical 
loop [for example (Brown and Williams, 2005; Priori et al., 2004)] and is largely understood to 
be the hallmark of activity in PD, which is suggested to correlate with motor deficits 
(Hammond et al., 2007). In animal models of PD and in PD patients (‘OFF’ L-DOPA) increased 
burst activity was measured from STN, GPe and GPi forming oscillatory activity of neuronal 
spike trains and local field potentials (LFP). Throughout the extrastriatal BG significant 
oscillatory activity frequently occurred at a high alpha/ low beta frequency range of 10-35Hz 
[other report 8-30Hz, called ‘basal ganglia beta frequency band’ by (Hammond et al., 2007)]. 
This oscillatory activity can form synchronous activity among neurons within individual nuclei 
and coupled between individual structures such as the STN, GPi and cortex (Gatev et al., 2006); 
or, as reported by Heimer and colleagues, between GPe neurons, between striatal tonically 
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active interneurons and between those two populations (Heimer et al., 2006). Beta-band 
activity is suppressed by treatment with dopaminergic drugs, correlating with motor 
performance (Brown, 2006; Heimer et al., 2006; Kuhn et al., 2004; Marceglia et al., 2006). As a 
consequence of excessive synchronization it is believed that information coding through 
spatial and temporal patterning by individual neurons or groups of neurons is limited causing 
inappropriate motor performance (Wichmann and Dostrovsky, 2011). Beta band oscillations 
are present in non-parkinsonian patients (Sochurkova and Rektor, 2003), healthy rodents 
(Leventhal et al., 2012) and non-human primates (Courtemanche et al., 2003) and suppression 
of this beta band activity was related to movements. Prior to and during voluntary movement 
(self-paced and externally paced) beta band oscillations in LFP of STN and GPi were also shown 
to be reduced in PD patients (Kuhn et al., 2004; Priori et al., 2002) and increased during no-go 
tasks that require motor inhibition (Kuhn et al., 2004). It is suggested that the elevated levels 
of synchrony might be more resistant to this movement related suppression (Hammond et al., 
2007). It is not yet well understood how DA loss can lead to this changed oscillatory activity but 
it is very likely that the profound DA degeneration is the key cause of it.  
This model of PD pathophysiology has its problems as well: (i) these changes do not account 
for all behavioural manifestations; (ii) not all of the PD symptomatology responds to 
dopaminergic medication and neither can DA medication always attenuate excessive BG 
synchrony; (iii) neuronal changes have been reported before the manifestation of motor 
deficits in PD models (Bezard et al., 1999); and (iv) neuronal changes have been observed after 
the onset of parkinsonian symptoms, making these changes unlikely to be the cause of the 
phenotype.  
The above described models of BG circuitry and dysfunction have led to immense advances in 
the treatment of movement disorders. However, it shows that the understanding needs to be 
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extended and a better model of PD developed – discussion around the involvement of the 
PPTg is an example of this. Moreover, it is important to recognise that the underlying 
anatomical brain pathology of PD goes beyond DA degeneration in SN. 
1.2.2. Underlying brain pathology of PD 
The most important hallmarks of PD are considered to be Lewy neurites (LN) and Lewy bodies 
(LB), associated with damage to the SNc and consequential progressive loss of DA neurons. But 
SN is not the first and only structure to undergo PD-related degeneration (Del Tredici et al., 
2002). It is always accompanied by extranigral pathology which Braak and colleagues have 
assessed and categorised temporally, proposing a topographical development of affected 
structures along the time course of the disease. They describe an ascending development in six 
stages reporting the first lesions in stage 1 to appear in the medulla oblongata, the dorsal IX/X 
motor nucleus, the olfactory bulb and/or the intermediate reticular zone. In stage 2 these are 
extended by degeneration in the caudal raphe nuclei, reticular nuclei and the coeruleus-
subcoeruleus complex. Non-motor symptoms like impaired sense of smell and autonomic 
dysfunction usually precede motor dysfunctions by several years (Gaenslen et al., 2011; 
Winkler et al., 2011). The characteristic SN degeneration does not start before stage 3 
according to Braak, when the typical PD motor symptoms arise, around the same time that LNs 
start to appear in the posterior PPTg (for more details on PPTg degeneration see Section 2.1.2. 
of this chapter).  Over the course of time these lesions augment and the structure gets 
affected more severely; additionally prosencephalic areas and the basal forebrain show signs 
of degeneration as well (stage 4). At later stages of the disease when patients show severe PD 
symptoms limbic structures and the neocortex are affected as well (Braak et al., 2003).  
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1.3. Gait and freezing of gait 
In this section the disturbances related to gait and in particular to FOG will be discussed in 
more detail, because they seem to differ to other motor symptoms in the response to 
dopaminergic medication, and because in the PPTg-DBS literature a particular focus is put on 
FOG and associated falls. FOG constitutes a very common feature of PD, but it differs in various 
aspects from the other cardinal symptoms. It is described as a brief, episodic absence or 
notable reduction of forward progression of the feet, despite the intention to walk (Nutt et al., 
2011). Patients experience a feeling of “being glued to the ground”. Without depreciating the 
other cardinal symptoms of PD FOG has a significant impact on quality of life (Moore et al., 
2005), increases the risk of falls (Bloem et al., 2001; Bloem et al., 2004; Moore et al., 2007; 
Schaafsma et al., 2003) which may lead to severe injuries, the risk of nursing home admission 
and mortality (Gray and Hildebrand, 2000; Hely et al., 1999). A further problematic 
characteristic of this symptom is the difficulty of assessing its frequency and severity 
objectively due to its paroxysmal and unpredictable nature (Fahn, 1995). Given its distinct 
response to L-DOPA (see below) in comparison with other symptoms it seems to be linked to a 
different or more complex pathophysiology than other common symptoms of PD. 
PD patients with FOG can experience an inability to start walking (“start hesitation”) or 
continue to walk (“destination hesitation”), but FOG can also present itself as “trembling in 
place” *at frequency of 3-8Hz; (Moore et al., 2008)+ and “shuffling forward” *an increase in 
cadence with a decreased step length (Nieuwboer et al., 2001)]. It is mostly triggered when 
initiating walking, turning (“turning hesitation)”, passing through narrow spaces, negotiating 
obstacles, reaching a target, in situations of stress, or during dual tasks (Hausdorff, Balash, et 
al., 2003; Schaafsma et al., 2003). 
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While visual stimuli like narrow doorways or obstacles can cause a freezing episode, sensory 
cues can also act as “releases”: using external temporal or spatial stimuli (Okuma, 2006; 
Spildooren et al., 2012; Velik et al., 2012), patients can learn to facilitate movement (gait) 
initiation and continuation (Nieuwboer et al., 2007). In clinical practice patients are taught to 
use external or internal cues (Snijders et al., 2008), such as imagining or choosing targets for 
stepping, or visualising climbing a stair in order to initiate a step. By focussing on the stepping 
the patient might be increasing cortical control supporting impaired subcortical motor control 
(Rahman et al., 2008), or the effect of cueing might be due to an increase of attention and 
distraction from an increased cognitive load caused by external stimuli or in dual task 
situations (Nieuwboer, 2008). 
Traditionally FOG is understood as a motor symptom found in advanced PD (Macht et al., 
2007). FOG occurs in about 53% if patients in advances stages (Giladi, 2001). However, up to 
26% of patients also experience this symptom during earlier stages (including pre L-DOPA 
exposure) (Giladi, McDermott, et al., 2001; Giladi, Treves, et al., 2001; Lamberti et al., 1997). 
Early FOG is associated with cognitive decline and depression rather than bradykinesia, rigidity 
and tremor (Bartels et al., 2003; Giladi, McDermott, et al., 2001). Other main risk factors for 
the development of FOG are severe impairment of gait, balance and speech.  
FOG can be differentiated into “off”-FOG and “on”-FOG. FOG that occurs in a patient’s “off”-
period is in general responsive to DA treatment and to DBS of STN or GPi. “On”-FOG, however 
is either not responsive (Krause et al., 2004) or the response to DA treatment decreases over 
time (Bloem et al., 1996). This, and the fact that many PD patients never experience FOG, 
suggests a different, extranigral, non-dopaminergic pathophysiology. Furthermore, FOG is also 
present in other hypokinetic, extrapyramidal movement disorders, such as progressive 
supranuclear palsy (PSP), pure akinesia syndrome (Williams et al., 2005), multiple system 
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atrophy [MSA (Gurevich and Giladi, 2003)], corticobasal degeneration (Rinne et al., 1994), 
higher level gait disorder (Giladi et al., 2007), vascular parkinsonism  (Factor et al., 2002), 
normal pressure hydrocephalus (Giladi et al., 1997), and focal frontal lesions (Nadeau, 2007). 
This shows that disruptions at different levels of common neural networks may still lead to 
similar symptoms. Regarding FOG in PD it has been suggested that the physiological 
mechanism responsible for it may lie in the brainstem – possibly in the PPTg and locus 
coeruleus (LC) (Grimbergen et al., 2009). 
A number of studies have investigated the relation between FOG in PD and other symptoms, 
and identified characteristics of FOG patients which separate them from PD patients that do 
not experience FOG. They describe factors that correlate with FOG occurrence and severity in 
order to describe predisposing risk factors or ideally formulate hypotheses about the nature 
and reason for FOG. (i) Abnormal gait pattern generation and sequencing of gait, also 
described as gait rhythmicity, can be related to FOG (Iansek et al., 2006; Nieuwboer et al., 
2001). FOG during walking might be a “sequence effect” of gradually decreasing step length 
and increased stance phase, which in turn can be caused by an altered timing and premature 
muscle activation and termination patterns (Nieuwboer et al., 2004). General stride to stride 
variability, and the ineffective bilateral coordination found in FOG patients might support 
and/or exacerbate freezing episodes (Chee et al., 2009; Hausdorff, Schaafsma, et al., 2003; 
Plotnik et al., 2005). The latter is likely contributing to freezing during turning and gait 
initiation when coordination is more complex and independent control of both legs is required 
(Plotnik et al., 2007, 2008). (ii) Problems with implicit learning and automatic task performance 
might explain problems in dual task situations (Hallett, 2008) and for patients with difficulties 
in executive functioning. Gait and posture can be understood as skilled and automated 
movements. Problems with these functions can be compensated for by additional executive 
control. Indeed, PD patients show an increased brain activity associated with automatic 
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movements compared to healthy controls indicating the need for recruitment of more 
executive control to compensate for inefficient brain activity in executing automatic 
movements (Wu and Hallett, 2005). But employing more cognitive resources to make up for 
dysfunctional automaticity might mean that in a situation of increased cognitive demand, such 
as in a dual task situation, there is a risk of cognitive overload (Heremans et al., 2013). (iii) A 
strong association between executive dysfunction and FOG has been shown repeatedly (Giladi 
and Hausdorff, 2006). Implicit learning and automatic task performance was deficient in PD 
patients and suggested to be worse in patients with a higher incidence of falls (Hallett, 2008). 
Patients showing unsteady and arrhythmic gait in dual task situations also showed more 
deficits in executive functioning and it was suggested that the worse the deficit the higher the 
risk of FOG (Yogev et al., 2005). FOG correlates with cognitive decline, particularly executive 
dysfunction such as deficient set-shifting and conflict resolution (Naismith et al., 2010) and 
early FOG was associated with cognitive decline and depression rather than rigidity and 
bradykinesia (Giladi and Hausdorff, 2006; Giladi, McDermott, et al., 2001). The performance in 
verbal fluency tasks, the frontal assessment battery, and ten-point clock test were related to 
“on”-state FOG (Amboni et al., 2008). From all of this, it has been suggested that FOG is 
primarily a cognitive impairment rather than a motor disturbance (Browner and Giladi, 2010) 
and that “freezers” might have more difficulties in attending to this increased cognitive 
demand for the organisation, adaptation and generation of gait pattern. (iv) Perceptual 
judgement and visuospatial processing deficits have also been suggested to contribute to FOG 
(Johnson et al., 2004). Freezing while going through narrow and confined spaces might reflect 
an impaired integration of vision with spatial memory – patients report judgement errors like 
feeling too big to fit through the door frame for example (Lee et al., 1998). 
The variety of symptoms and the variability in their occurrences, the findings regarding FOG 
and the correlation that can be drawn between certain symptoms, the anatomical and 
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functional complexity of the BG, and the pathological changes beyond the SN – all this leads to 
the hypothesis that at least some of the symptoms in PD, like gait disturbances and FOG, are 
the result of cognitive impairment rather than motor disturbances. How is the PPTg involved in 
this? 
2. Pedunculopontine tegmental nucleus 
The pedunculopontine tegmental nucleus has no standardised name or abbreviation. Some 
authors call it the pedunculopontine nucleus (PPN or PPT) or the tegmental pedunculopontine 
nucleus (TPP), and an older literature uses the Latin form, nucleus tegmenti 
pedunculopontinus (NTPP), though this is rarely used now. The human DBS literature primarily 
uses the abbreviation “PPN”. However, some have used this abbreviation to describe the 
“pedunculopontine area” and a few have also distinguished between the PPTg and PPN, the 
PPTg being a particular structure within the pedunculopontine area, or calling the PPTg the 
rodent correspondent to the human PPN. This laboratory has consistently followed the 
convention of abbreviating pedunculopontine tegmental nucleus to “PPTg” and this is how it 
will be referred to in this thesis, referring to the human and animal pedunculopontine 
tegmental nucleus for consistency. This is the abbreviation used in Paxinos and Watson’s 
stereotaxic atlases of the rat and mouse brain (Paxinos and Watson, 2005), the most widely 
used of their kind.  
2.1. PPTg involvement in PD 
As described above the pathological hallmark of PD is DA neuron degeneration in the SN. 
William Langston, however, describes this as being merely the tip of the iceberg and points out 
that it means neglecting the fact that the neuropathology is not confined to this part of the 
brain (Langston, 2006). Damage is present in a variety of structures – see the discussion of the 
Braak hypothesis earlier – but it is the PPTg in particular that has received increased attention 
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in the past few years [see for example (Pahapill and Lozano, 2000)]. The most convincing 
argument for moving away from the restricted focus on DA degeneration in the search for 
more effective treatment options is the fact that DA cell loss cannot explain all of the 
symptoms that PD patients may suffer from: several very debilitating symptoms are refractory 
to DA replacement medication, leading to the belief that other lesions in the brain may be 
contributing to the diverse symptomatology of PD (Hirsch et al., 1988). 
There are several excellent reviews on PPTg involvement in BG functioning and PD that the 
reader can refer to (Hamani et al., 2007; Inglis and Winn, 1995; Mena-Segovia et al., 2004; 
Pahapill and Lozano, 2000; Winn, 2006; Winn et al., 1997). In the following, the focus will lie on 
the change of PPTg firing activity in PD and PPTg neuron degeneration. Section 3.3. of this 
chapter will then highlight therapeutic targeting of the PPTg with DBS and which effect this has 
on symptoms and neuronal activity of the circuits involved.  
2.1.1. Change of firing activity 
In animal models of PD, and also in PD patients, changes in PPTg neuronal activity have been 
observed. Increased 2-deoxyglucose (2-DG) uptake was reported by Mitchell and colleagues 
[Figure 1.3.; (Mitchell et al., 1989)] in MPTP-treated primates and confirmed in rodents by 
Carlson and colleagues (Carlson et al., 1999) – it is assumed that this reflects increased 
synaptic activity and therefore the pathologically increased GABAergic (γ-aminobutyric acid 
releasing), inhibitory influence from afferent structures, the pallidum and SNr, causing over-
inhibition of the PPTg [see also (Palombo et al., 1990)]. More recently others have reported a 
decrease of the metabolic marker cytochrome oxidase subunit I in MPTP-treated primates, 
interpreting this as a decreased activity of PPTg neurons (Gomez-Gallego et al., 2007), or 
decreased metabolic markers in a fluoro-2-DG-positron emission tomography (PET) study in 
rats (Jang et al., 2012). Lesioning the GPm in PD patients has been shown to alleviate 
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symptoms, which might be due to removal of the exaggerated inhibitory input onto the PPTg 
(Lang et al., 1999; Lee et al., 2000). However, Gubellini states that “electrophysiological 
support for the hypothesis of PPN hypoactivity in PD state is poor”  (Gubellini et al., 2009) and 
Carlson points out that an increase of 2-DG uptake does not necessarily have to be interpreted 
as a product of increased inhibitory input, but might potentially also represent hyperactivity of 
the PPTg itself (Carlson et al., 1999). Others did indeed show increased activity by means of 
extracellular recording (Breit et al., 2001; Breit et al., 2005; Zhang et al., 2008) and by measure 
of expression of cytochrome oxidase messenger RNA (Orieux et al., 2000) (Figure 1.3.), which 
seems to be related to the increased activity observed in the STN, as this decreased after STN 
lesions (Breit et al., 2001; Jeon et al., 2003). Others again found no change at all (Heise and 
Mitrofanis, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Changes of metabolic activity of the PPTg in PD models. LEFT: 2-DG autoradiograph of 
unilaterally MPTP-treated monkey, showing increased 2-DG uptake in the ipsilateral PPTg, reflecting 
the activity of its afferents, presumably of hyperactive pallidal, nigral and subthalamic inputs. 
Abbreviations: III, oculomotor complex; bc, brachium conjunctivum; ppn, pedunculopontine nucleus. 
Image reproduced from Mitchell et al., (1989). RIGHT: Measurement of metabolic activity of STN-
projecting PPTg neurons showing significantly higher COI mRNA expression in 6-OHDA lesioned rats 
compared to sham lesioned rats. Photomicrographs show PPTg neurons labeled by WGA–HRP 
revelation (A, B) and COI in situ hybridization (E1, E2, F). Image reproduced from (Orieux et al., 
2000). 
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2.1.2. Loss of neurons 
As pointed out above progressive cell loss of dopaminergic neurons in the SN is not the only 
pathophysiological characteristic of PD. Neuronal loss is present in various brainstem nuclei 
including subnuclei of the reticular formation, the raphe system and the coeruleus-
subcoeruleus complex (Braak et al., 2003). In the PPTg, cell loss of 40 – 57% of large PPTg 
neurons was identified, averaged across various levels along the rostrocaudal axis of the PPTg 
(Hirsch et al., 1987; Zweig et al., 1989). Loss of cholinergic and non-cholinergic neurons, 
including substance P, was noted in idiopathic PD and also in post-encephalitic PD, PSP and 
MSA (neurological disorders that can present themselves in atypical parkinsonian forms where 
severe impairment of gait and balance is a prominent feature as well) (Halliday, Blumbergs, et 
al., 1990; Halliday, Gai, et al., 1990; Halliday, Li, et al., 1990; Hirsch et al., 1987; Jellinger, 1988; 
Schmeichel et al., 2008). In the study by Rinne and colleagues (Rinne et al., 2008), the average 
loss of cholinergic neurons was similar to that reported by Zweig and colleagues (36%), but 
non-cholinergic neurons were also reduced in number by 23% and the overall reduction of all 
neurons in the PPTg across the rostrocaudal axis was reported as 27%. Cell degeneration and 
atrophy was found in surviving neurons showing a 14% (all neurons) to 26% (cholinergic 
neurons only) decrease in cell size (Figure 1.4.). According to Braak and colleagues the degree 
of cholinergic cell loss correlated with disease severity according to the Hoehn and Yahr stages 
(Braak et al., 2003; Goetz et al., 2004; Rinne et al., 2008). In vivo cholinergic PET studies in PD 
patients and Parkinson’s disease associated dementia patient confirmed this cholinergic deficit 
(Hilker et al., 2005; Shinotoh et al., 1999) and PD fallers had significantly decreased thalamic 
cholinergic innervation compared to non-fallers (Bohnen et al., 2009; Bohnen et al., 2012). 
Significant loss of brainstem cholinergic innervation from PPTg was also found in patients with 
PSP (Jellinger, 1988). This is of interest since PPTg and in particular cholinergic involvement has 
been predominately related to gait and postural deficits and cholinergic cell loss was shown to 
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be greater (Karachi et al., 2010) and thalamic cholinergic innervations fewer in fallers than in 
non-fallers (Bohnen et al., 2009; Bohnen et al., 2012). 
2.1.3. Relationship of PPTg degeneration to loss of dopamine neurons in SN 
The simultaneous appearance of cholinergic and dopaminergic neuron degeneration in PD 
suggests the possibility of common aetiologic factors causing degeneration or cell loss in the 
SN and PPTg, which directly projects to the SNc and receives input from the SNr (Hirsch et al., 
1987). According to Braak and colleagues (Braak et al., 2003) both nuclei, SN and PPTg, initially 
show degeneration through development of LN and inclusion of LB in stage 3, leading to 
substantial damage and cell loss in the SN and PPTg in stage 4. However, in early Parkinsonism, 
PPTg neurons are intact, which could either mean that they might contribute to the 
maintenance of DA functioning or that their increased activity leads to the degeneration of DA 
neurons. The nature of this relationship – protective, destructive or indifferent? – remains 
unknown.  
 
 
Figure 1.4. (A) Distribution of all large neurons in the PPTg (stained with Luxol fast blue) and (B) of 
cholinergic neurons (stained for an antibody against ChAT) in different levels on the rostro-caudal 
axis of the PPTg in controls and PD patients. Image reproduced from (Rinne et al., 2008). 
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The literature allows the support of all three possibilities: In 1984 McGeer and McGeer showed 
DA cell death after kainic acid lesions of the rostral PPTg in rats, hypothesising the PPTg lesion 
was causing a pathological stimulation of the nigral DA cells (McGeer and McGeer, 1984).  
Having shown PPTg hyperactivity in 6-hydroxydopamine (6-OHDA) rat models of PD Breit and 
colleagues also suggest that this hyperactivity might cause excitotoxic excitatory drive on DA 
neurons which allows the speculation that reversing this destructive input by stimulation of 
STN or the PPTg itself might be neuroprotective (Breit et al., 2006; Takada et al., 2000). 
Preservation of cholinergic cells in the PPTg in the two most common PD models – MPTP-
treated monkey and 6-OHDA-lesioned rat could also be shown (Heise et al., 2005; Herrero et 
al., 1993). While it is apparent that the mechanisms leading to the pathophysiology and 
symptomatology are different in idiopathic PD and PD models [although the mechanisms of 
the toxins come close - causing oxidative stress and mitochondrial dysfunction (Blandini et al., 
2000)] it does not only show the limitations of the models but also suggests that the abnormal 
circuits – overactive glutamatergic excitatory input from the STN  – do not cause PPTg 
degeneration in these models. A different group however has found significant reduction of 
cholinergic PPTg neurons in aged MPTP-treated monkeys, but not young ones (Grabli et al., 
2013; Karachi et al., 2010). The age-related atrophic changes in PPTg cells (George et al., 2006; 
Zhang et al., 2005) might contribute to the susceptibility to MPTP toxicity or to the lack of 
functioning DA target neurons and/or afferent input. Confirming the results of the study by 
Heise and colleagues but contrasting Karachi’s findings, by means of design-based stereology, 
it has been shown that also in rats 6-OHDA induced DA cell loss does not cause a decrease in 
cholinergic cells, however, Pienaar and colleagues (Pienaar and van de Berg, 2013) revealed a 
significant loss of non-cholinergic neurons.  
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2.2. Interspecies differences 
It is argued that there are significant differences of anatomical organization and connectivity of 
the PPTg between rats and primates. For example, one argument is that the evolution from 
quadrupedal to bipedal gait caused anatomical differences between species which are 
therefore reflected in the structure and organisation of various nuclei in monkeys and rats 
(Alam et al., 2011),. Given the remarkable preservation of the PPTg through evolution with 
very similar structure and pattern of connections in all studied species from teleost fish to 
human  [(Brantley and Bass, 1988), teleost fish; (Medina and Reiner, 1994), pigeon; (Manaye et 
al., 1999), human; (Mesulam et al., 1989), human; (Marin et al., 1997), amphibians; (Rye et al., 
1987), rat); for reviews see (Martinez-Gonzalez et al., 2011), (Winn, 2008)] this argument does 
not appear strong enough to explain fundamental differences in the results of behavioural 
experiments found in the literature. There are differences of strength of connections with 
particular structures or subregions (Alam et al., 2011) but it remains unknown whether these 
differences can account for the apparently conflicting results found in lesion studies in rats and 
monkeys.  
2.3. PPTg anatomy and physiology 
2.3.1. Neurochemical diversity and heterogeneous structure of the PPTg 
The PPTg is a highly heterogeneous structure at cellular, molecular and electrophysiological 
level, composed not only of a collection of neurons of different neurochemical phenotypes but 
also of neurons with distinct connectivity, with functionally distinct neuronal systems reaching 
to forebrain structures as well as to the spinal cord. 
Situated in the mesopontine tegmentum of the rostral brainstem, the PPTg has strong 
reciprocal connections with the BG and many other ascending and descending connections. It 
reaches rostrally from the caudal pole of SN, just below the red nucleus, to the lateral tip of 
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the superior cerebellar peduncle caudally. Dorsally it lies just beneath the cuneiform nucleus 
and its more caudal part is medially adjacent to the LDTg (Inglis and Winn, 1995; Winn, 
2006).These borders are conventionally defined by the column of cholinergic neurons of that 
structure because experimental work has for a long time focused on this cell group (Mesulam 
et al., 1983). However, these borders seem to extend dorsally and medially from the 
cholinergic population given the actual neurochemical complexity of the PPTg (Mena-Segovia 
et al., 2004). 
Apart from cholinergic neurons, which constitute the cholinergic cell group Ch5, the PPTg 
consists of glutamatergic, GABAergic and peptidergic neurons [i.a. substance P and atrial 
natriuretic peptide; (Ryan and Gundlach, 1995; Vincent et al., 1986)] which are interdigitated 
but not homogenously distributed throughout the structure (Lavoie and Parent, 1994; 
Mesulam et al., 1983; Wang and Morales, 2009; Winn, 2006). Small amounts of serotonergic 
and tyrosine hydroxylase (TH) containing neurons (dopamine or noradrenaline containing) 
have been found in the PPTg of the guinea pig (Leonard et al., 1995) but have not been 
confirmed in the rat (Winn, 2006). Populations of cholinergic neurons have been reported to 
co-express glutamate, GABA and NADPH-diaphorase (the synthetic enzyme for nitric oxide 
[NO]) and neuropeptides such as substance P (Charara et al., 1996; Jia et al., 2003). More 
recent studies using in-situ hybridization in combination with immunohistochemistry revealed 
that less than 5% of cholinergic neurons co-express GABA or glutamate (Wang and Morales, 
2009). 
The distribution of neurons and their connectivity support the idea of at least two functionally 
distinct regions within the PPTg. This consideration of functional dichotomy is important for 
the present study because of the possibility that PPTg-DBS has different effects dependent 
upon the exact location of the stimulation in PPTg.   
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The focus on the cholinergic population of the PPTg led to the assumption that this is its 
largest population of neurons. However, GABAergic and glutamatergic neurons outnumber 
cholinergic neurons – in anterior PPTg there are twice as many GABAergic neurons than 
cholinergic neurons, and in posterior PPTg the concentration of glutamatergic neurons is 1.5 
times higher (Wang and Morales, 2009). The number of cholinergic neurons increases toward 
the caudal end - this is where cholinergic neurons are packed densely. In the anterior portion 
they are distributed more sparsely (Mena-Segovia et al., 2009). Therefore, the neurochemical 
distribution has been shown to be as follows: in the anterior part 40% of the neurons are 
GABAergic, 37% glutamatergic and 23% cholinergic; in the posterior part the glutamatergic 
neurons are more densely concentrated with 50%, 31% are cholinergic and 19% GABAergic 
(Wang and Morales, 2009).  
The segregation into anterior and posterior [by others also named rostral and caudal; or pars 
dissipata and pars compacta; for example (Martinez-Gonzalez et al., 2012) (Pienaar and van de 
Berg, 2013) respectively] is possible and commonly made according to differences in number 
and arrangement of cholinergic neurons, but there is no definite hallmark for such a division. 
Mena-Segovia and colleagues suggest a separation according to the concentration of 
GABAergic neurons which they found to lead to a split in the middle of the structure on the 
rostro-caudal axis. This leaves the anterior half as a predominantly GABAergic part and the 
posterior half more evenly mixed (Mena-Segovia et al., 2009). This segregation seems to 
coincide with and likely contribute to the functional topography of the PPTg [see (Alderson et 
al., 2006, 2008; Andero et al., 2007; Inglis et al., 2001); see chapter 2.4.5.)]. 
Electrophysiologically, neuronal subtypes of differing discharge properties have been 
identified: There are two types of cholinergic neurons: type I are slow firing neurons coupled 
to phasic increases in cortical fast frequency oscillations during sleep and type II, fast firing and 
29 
 
coupled to downstate of cortical slow oscillations (Mena-Segovia, Sims, et al., 2008). Two types 
of non-cholinergic neurons have also been described: type I are fast firing neurons that are 
associated with cortical slow oscillations and type II, neurons that are very slow (even 
quiescent) and independent of cortical activity (Ros et al., 2010). 
2.3.2. Connectivity of the PPTg 
The subdivision into anterior and posterior is further supported by a neurochemically diverse 
connectivity of the PPTg with most parts of the brain. Many detailed and exhaustive reviews 
have been dedicated to PPTg connectivity (Martinez-Gonzalez et al., 2011; Winn, 2006). In the 
following the relevant connections are summarised with a focus on a differentiation of 
efferent and afferent projects to the anterior and posterior part of the structure where this is 
applicable and known. Figure 1.5. illustrates the most important PPTg connections. 
The PPTg has extensive connections with a variety of structures above and below. It has (1) 
connections to the musculature via the spinal cord and connections with other brainstem 
nuclei. Furthermore, it is strongly connected with (2) the thalamus and also holds connections 
with (3) frontal areas. However, most prominent is its influence on (4) the BG and the input it 
receives from here, supporting the proposal that the PPTg should be understood as a part of 
the BG family (Mena-Segovia et al., 2004).  
(1) PPTg neurons project to the inferior and superior colliculi (IC, SC). These projections arise 
from cholinergic neurons predominantly from posterior PPTg and non-cholinergic ones from 
anterior PPTg (Beninato and Spencer, 1986; Motts and Schofield, 2009). The PPTg also sends 
efferents from a mix of cholinergic and non-cholinergic neurons of the posterior part to other 
brainstem structures such as the pontine and medial reticular formation (Nakamura et al., 
1989; Semba et al., 1990; Takakusaki et al., 1996), nucleus pontis oralis (Garcia-Rill et al., 
2001), the motor trigeminal (Fay and Norgren, 1997a, 1997b, 1997c), the medulla (Skinner, 
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Kinjo, Ishikawa, et al., 1990), the medulla oblongata (Nakamura et al., 1989) and spinal cord 
(Rye et al., 1988; Skinner, Kinjo, Henderson, et al., 1990). PPTg afferents from the brainstem 
target preferentially the posterior part and arise from the IC and SC (Redgrave et al., 1987; 
Semba and Fibiger, 1992), the dorsal raphe (Steininger et al., 1997), the LC (Jones and Yang, 
1985) and spinal cord (Semba and Fibiger, 1992). Further, the PPTg is intimately connected 
with the LTDg (Semba and Fibiger, 1992; Winn et al., 2010). 
 (2) The thalamus is heavily innervated by the PPTg (Hallanger et al., 1987; Hallanger and 
Wainer, 1988) and has an impact on several thalamic structures [i.a. mediodorsal, ventral 
anterior, ventro-lateral and parafascicular, centromedian and centrolateral thalamic nuclei; 
(Erro et al., 1999; Kobayashi et al., 2007). The input is predominantly cholinergic from the 
posterior PPTg. Essentially all thalamic cholinergic innervation comes from the PPTg, LDTg and 
parabigeminal nucleus; the VL thalamic nuclei for example receive over 50% of their 
cholinergic afferents from the PPTg (Capozzo et al., 2003; Holmstrand and Sesack, 2011; 
Kolmac and Mitrofanis, 1998). In the cat (Steriade et al., 1988) and monkey (Lavoie and Parent, 
1994) the input was shown to be topographically organized, though the exact patterns are yet 
to be described. Given the important impact on the thalamic burst firing and its output to 
neocortex and striatum such an organization is likely – Pf neurons for example that receive 
solely input from the PPTg project directly to the striatum (Kobayashi et al., 2007). 
 (3) The cortical influence of the PPTg arises mainly via mono- or polysynaptic connections via 
the thalamus, but there is some evidence for direct projections to medial and sulcal frontal 
cortical areas (Saper and Loewy, 1982). The PPTg further projects to sites of non-specific 
cortical input, such as from anterior and posterior PPTg to the lateral hypothalamus (Ford et 
al., 1995; Semba and Fibiger, 1992), from the anterior portion to the nucleus basalis 
magnocellularis (Semba and Fibiger, 1992), which sends a bulk of cholinergic input to cortex. 
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Auditory (Schofield, 2010) and motor (Matsumura et al., 2000) cortex send projections to the 
PPTg and so does the extended amygdala (Zahm et al., 2001). 
4) Through direct and indirect connections essentially all BG nuclei receive input from the 
PPTg. Anterior PPTg projects directly to the GPi (EP in rodents) and SNc (Charara and Parent, 
1994; Lavoie and Parent, 1994; Semba and Fibiger, 1992) through glutamatergic, GABAergic 
and cholinergic input. Posterior PPTg innervates VTA (Charara et al., 1996) and STN (Kita and 
Kita, 2011). These afferent projections are also through glutamatergic, GABAergic and 
cholinergic. Non-cholinergic input is nine times higher than cholinergic efferents from the 
PPTg, though the latter form denser innervations by creating much larger terminal fields (Kita 
and Kita, 2011). Via the STN PPTg can influence the activity of the GPe and the striatum via 
SNc, VTA and the GPe-STN pathway, and there are also direct projections to the striatum 
(Saper and Loewy, 1982). Afferent innervation – and therefore forming reciprocal connections 
– comes from the STN and GPi (glutamatergic) and further BG output arises from SNr, 
innervating anterior PPTg (GABAergic) (Parent et al., 2001; Semba and Fibiger, 1992). 
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Figure 1.5. Illustration of the location, connections and composition of the PPTg.  
Panel A. Sagittal view on a rat brain section (taken from the atlas of Paxinos and Watson). Schematic 
representation of the principal afferent and efferent connections of the PPTg with forebrain and 
brainstem nuclei. Black arrows represent cholinergic connections, dotted arrows GABAergic, and 
dashed arrows glutamatergic connections. Grey arrows represent unclassified connections. Panel B. 
Schematic graded distributions of glutamatergic, cholinergic and GABAergic neurons within the PPTg. 
The gradient represents the rostro-caudal distribution of each neuron type based on the cell 
identification of Wang and Morales 2009 and Mena-Segovia et al., 2009. Abbreviations: GPe globus 
pallidus externa, GPi globus pallidus interna, LC locus coeruleus, LH lateral hyphothalamus, LDTg 
laterodorsal tegmental nucleus, SC superior colliculus, SN substantia nigra, STn subthalamic nucleus, 
VTA ventral tegmental area. Image reproduced from Gut and Winn, 2012. 
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2.4. PPTg functions  
2.4.1. Motor 
In the early literature the PPTg was understood and commonly portrayed as a motor structure. 
This idea has carried forward to the recent literature and been related to movement disorders 
including the search for potential treatment options in PD. Predominantly early work published 
on PPTg-DBS in PD patients is based on the assumption that “The pedunculopontine nucleus 
(PPN) is an integral component of the midbrain locomotor region and plays an important role 
in the initiation and maintenance of walking behaviour” (Mazzone et al., 2005); “The 
pedunculopontine nucleus (PPN) is a key part of the reticular activating system and 
mesencephalic locomotor region...” (Androulidakis et al., 2008); or that “The 
pedunculopontine tegmental nucleus (PPTg) is a part of the upper brainstem locomotor region 
that has an important role in the control of gait and muscle tone...” (Mazzone et al., 2009); and 
that “...gait failure is induced by PPN lesion or dysfunction...” (Karachi et al., 2010). This 
supposed PPTg-MLR association, however, is a doubtful basis for PPTg-DBS.  
The mesencephalic locomotor region (MLR) is an area in the mesencephalon described as a 
brainstem command centre, which, together with the diencephalic locomotor region, was 
thought to regulate the activity level of the spinal central pattern generators. It is defined 
functionally (rather than anatomically; the precise targets for electrical or chemical activation 
for the studies mentioned bellow have been a point of debate) as an area from which it is 
possible to elicit locomotor activity on a treadmill in decorticate animals (Skinner, Kinjo, 
Henderson, et al., 1990; Skinner, Kinjo, Ishikawa, et al., 1990) the speed of the activity 
depending on stimulation strength. Some describe it as being located at the mesopontine 
border at the caudal pole of the cholinergic pedunculopontine and the cuneiform nuclei others 
include the cholinergic PPTg as crucial/important part of or even synonymous with the MLR  
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(Garcia-Rill, 1991). Induction of controlled locomotion was possible on a treadmill in the 
decerebrate rat (and cat) applying low amplitude current pulses to (presumed) cholinergic 
PPTg neurons (Garcia-Rill et al., 1987; Garcia-Rill et al., 1990). Stimulation induced locomotion 
could be blocked by injections of the muscarinic receptor antagonist atropine sulphate into the 
medioventral medulla, where efferent cholinergic fibres from PPTg terminate (Garcia-Rill et al., 
1987).  
However, this locomotion inducing effect is also possible after stimulation of other structures 
within the so called MLR area, including the cuneiform nucleus, the SC, central gray, lateral 
lemniscus, the pontomedullary locomotor strip, Probst’s tract, the parabrachial nucleus and 
periaqueductal gray (Coles et al., 1989; Garcia-Rill et al., 1983; Steeves and Jordan, 1984).  
With the brainstem being disconnected from descending control from higher systems it is not 
surprising that stimulation of structures with descending projections to the spinal cord can 
drive locomotion (not leaving much opportunity for much more than this), especially given 
that treadmill locomotion was the only behaviour presented to engage in. Further, electrical 
and chemical (L-sodium glutamate/NMDA, kainic acid, picrotoxin and bicuculline) stimulation 
of the region of the PPTg in rats (non-decorticate) could manipulate locomotor activity (Milner 
and Mogenson, 1988; Mogenson and Wu, 1988); injecting L-sodium glutamate and the GABA 
antagonist picrotoxin for example was reported to increase locomotor activity (Brudzynski and 
Wang, 1996). Interestingly, when the primate PPTg was inhibited by local injection of the 
GABA agonist muscimol, a significant decrease of motor activity was observed (Nandi et al., 
2002). Conversely, stimulating the PPTg with the GABA antagonist bicuculline, after the same 
primate had been made Parkinsonian by MPTP, has been reported to alleviate akinesia (Nandi 
et al., 2002). 
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This input onto other brainstem structures and the spinal cord however does not prove that 
the main role of the PPTg is locomotor control or its production. On the contrary: decorticate 
animals even seem to be able to select appropriate simple movements in the homecage, 
retaining the ability to eat, groom, climb, and also to swim, albeit being a little awkward 
conducting those tasks, and are able to improve on some tasks with practise (Grill and 
Norgren, 1978; Humphries et al., 2007). Furthermore, the PPTg has been proven not to be 
critical for the production of locomotion. A series of experiments in this laboratory and by 
others could not show that bilateral PPTg lesions caused by electrolytic lesions (Homs-Ormo et 
al., 2003) or – as in most cases – fibre-sparing excitotoxins reduce spontaneous locomotor 
activity in locomotor boxes (photocell cages), locomotor behaviour in the home cage (Inglis, 
Allen, et al., 1994), circular corridor, or exploratory behaviour in the open field (Alderson et al., 
2003; Dellu et al., 1991; Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 1994; Olmstead and 
Franklin, 1994; Steiniger and Kretschmer, 2004; Swerdlow and Koob, 1987; D. I. G. Wilson et 
al., 2009), nor have an effect on amphetamine-induced locomotion (Alderson et al., 2003; 
Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 1994; Olmstead and Franklin, 1994; Steiniger 
and Kretschmer, 2004) [for an extensive review see (Winn, 2006)]. Further, a comprehensive 
examination of the performance of rats bearing bilateral lesions on the radial arm maze 
confirms the lack of a locomotor deficit. Despite changes in the overall performance these do 
not reflect deficits of their motor behaviour. Keating and colleagues (Keating and Winn, 2002) 
for example showed that the measures of speed of the rats moving along the arms are not 
decreased but that the rats fail to select the correct arms. In a similar manner it is possible to 
suggest that learning deficits after PPTg lesions could have been confounded for locomotor 
deficits in a study conducted by Bechara and colleagues (Bechara and van der Kooy, 1992) 
where the task required the acquisition of conditioned locomotion. The presented locomotor 
deficit might therefore rather represent difficulties to make an association between the 
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reinforcing event and the motor behaviour. Likewise Matsumura and colleagues (Matsumura 
et al., 1997) measured neuronal activity in PPTg of non-human primates while they were 
conducting a simple operant task and found changes in activity in response to arm movements 
that were preceding movement onset. They interpreted these changes as related to 
movement initiation and execution; however it is interesting to point out that these 
movements were conducted during an operant task where movements were made in the 
context of a learned stimulus-reward association. Locomotor activity did not differ comparing 
lesioned and sham operated rats after systemic administration of d-amphetamine or its direct 
infusion into the NAcc (Inglis, Dunbar, et al., 1994). Alderson and colleagues showed that while 
the levels of spontaneous locomotion were not affected in lesioned rats over all sessions when 
they were treated with saline, the locomotor response to the first injection of d-amphetamine 
did not differ from shams either (Alderson et al., 2003). Locomotor sensitisation to the drug, 
however, was attenuated by PPTg lesions (which was not caused by locomotor-incompatible 
stereotyped behaviour including/or rearing). This confirms previous findings of rats with 
bilateral excitotoxin PPTg lesions which did not show any impairment either in gross regulatory 
mechanisms such as eating and drinking and maintaining their body weight or in spontaneous 
or d-amphetamine induced locomotor activities (Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 
1994). However, the same lesions caused significant interruption of the development of a 
conditioned place preference to morphine or amphetamine (Olmstead and Franklin, 1994). 
Taking into consideration the heterogeneity of the PPTg’s anatomy and functional dissociation 
regarding the development of sensitization of nicotine in an IV self-administration paradigm 
(Alderson et al., 2006), Alderson and colleagues compared bilateral lesions to the anterior part 
of the PPTg to lesions of the posterior part regarding spontaneous locomotion and in response 
to repeated nicotine administrations (Alderson et al., 2008). They showed for the first time 
that bilateral lesions of the anterior PPTg but not posterior PPTg generate a deficit in baseline 
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activity. This was not replicated in a later study published by Wilson and colleagues where 
neither anterior nor posterior PPTg lesions caused deficits in free locomotor testing (D. I. 
Wilson et al., 2009). Despite the rats not showing any impairment immediately after surgery 
during operant testing the locomotor tests were conducted with a delay of 2 months after 
surgery, which might present a plausible explanation for the conflicting findings. 
These consistent findings are contrasted by PPTg lesion studies in non-human primates where 
excitotoxic lesions – kainate – of the PPTg in monkeys were reported to induce akinesia and 
other parkinsonian symptoms (Aziz et al., 1998; Kojima et al., 1997; Munro-Davies et al., 1999). 
Kojima and colleagues described hemiparkinsonian symptoms, flexed posture, hypokinesia in 
the contralateral upper limb and muscular rigidity after unilateral PPTg lesions, also induced by 
kainic acid in macaque monkeys (Kojima et al., 1997). Munro-Davies and colleagues reported 
transient hypokinesia when only one side of the brain was lesioned, which developed further 
to include profound paucity and slowness of movement after a subsequent lesion in the 
contralateral side (Munro-Davies et al., 1999). Kainic acid is a very potent and difficult 
excitotoxin that (in the rat at least) induces strong seizures and lesions remote from the site of 
injections. Further, motor assessment in these studies was conducted immediately after 
recovery from surgery and was reported to abate a few days later or after one to two weeks in 
monkeys with larger lesions caused by a higher dose of kainic acid. Given the seizure 
promoting activity, the possibility of lesions comprising neighbouring structures of the PPTg 
and the general malaise during the first days after surgery which may confound behavioural 
data, these studies have to be interpreted with caution [for more details please refer to (Winn, 
2006)]. Thermal lesions of the PPN region were also described to cause a transient hemi-
parkinsonian state in a normal macaque monkey (Aziz et al., 1998). The deficits declined after 
a week, more permanent deficits were caused with bilateral lesions. Radiofrequency lesions 
damage fibres of passage and the possibility of this damage being the cause for motor 
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problems needs to be included in the interpretation of these results. Finally, in an inactivation 
study Nandi and colleagues reported reduced activity in normal primates after administration 
of GABA agonist muscimol (Nandi et al., 2002). The dose of the agonist used was 40x higher 
than the dose used in this lab for successful inactivation of PPTg that caused learning deficits 
(Maclaren et al., 2013). Evidently, a monkey brain is bigger and there is not necessarily a linear 
correlation between concentration and effect, but this enormous difference allows the rise of 
concern.  
In a more recent paper, Karachi and colleagues  presented data from PPTg lesioned macaques 
(without dopaminergic depletion) which displayed gait deficits in form of decreased step 
length and speed, postural changes, as well as rigidity in the extremities without affecting the 
global motor behaviour as observed in the home cage (Karachi et al., 2010). These monkeys 
did not develop akinetic features as the previous PPTg lesion studies in monkeys which can be 
attributed to more concise lesions – however gait deficits only occurred in monkeys that 
received a very high dose of the fusion toxin Dtx-UII (urotensin II-conjugated diphtheria toxin). 
This toxin is selective for cholinergic neurons at the appropriate concentrations in rat (Clark et 
al., 2007) but the concentrations used here led to a loss of 70-80% of non-cholinergic neurons, 
making the lesions non-selective, as the authors report themselves. Lesioning the PPTg of 
MPTP-treated macaques – to our knowledge the only other study that examines the 
behavioural effect of a combination of PPTg lesions and DA degeneration in the SN – led to an 
increase of global activity and step speed, as well as an increase – not statistically significant – 
of step length. The authors further reported a slight increase in balance deficits and adverse 
postural changes, which however were not significant either (Grabli et al., 2013). 
Clinical lesion reports of PPTg lesions are rare but occasionally drawn upon to support the 
locomotor hypothesis. In those cases of lesions caused by stroke and haemorrhage in the 
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caudal midbrain and at the pontomesencephalic junction causing gait initiation problems and 
ataxia the involvement of neighbouring structures cannot be excluded – in both cases it is 
suggested that the lesions must have been extensive (Hathout and Bhidayasiri, 2005; Masdeu 
et al., 1994). More confined lesions of the pontine region in a single case study caused FOG, 
leg stiffness and intermittent rest tremor (Kuo et al., 2008). Other reports, in contrast, draw a 
strong association of pontine stroke lesions with executive dysfunction (Omar et al., 2007; 
Vataja et al., 2003).  
Is the notion of a MLR necessary at all (Allen et al., 1996) or does it rather tempt to assign 
discrete/ discriminable functions to individual brain structures, neglecting their often diverse 
connections with other structures and their integrated roles? Evidence that, while involved, 
the PPTg is not necessary for locomotion clearly challenges the notion of the PPTg being 
synonymous with the MLR. After studying the stepping-inducing sites in the brainstem Garcia-
Rill himself now states that “as far as the PPN is concerned,..., we concluded that this was not 
a locomotion-specific region” (Garcia-Rill et al., 2011). Many years of dedicated study of the 
PPTg – of anatomy and function – have shown that for this structure it is true: the role is an 
integrative one. Ros and colleagues describe the large variability of projections from PPTg 
neurons, which gives an idea of how the PPTg could be involved in diverse behavioural 
processes including the control of movement, but also sensorimotor coordination, sleep-wake 
mechanisms, attention and autonomic functions (Ros et al., 2010) as well as reinforcement 
processes and learning (Alderson et al., 2005). In the following sub-chapters I will describe 
those functions that are possibly relevant to the understanding of the PPTg within the context 
of movement disorders. This does not only apply to rodent studies or work on non-human 
primates. An increasing number of studies of PPTg-DBS in PD patients do not limit their 
observations to motor functions. A few studies show for example increased activity of most 
cortical (bar occipital and parietal areas) and many subcortical structures induced by PPTg-DBS, 
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proving a much more far-reaching role than simply the activation of movement patterns in the 
spinal cord. Further, the notion of an integrative structure that is not limited to a locomotor 
function is supported by the interest of neurologists in the effect on PPTg stimulation on 
cognitive and autonomic functions (grammar, executive functions). The lack of clear results of 
PPTg-DBS on motor deficits and the search of effects on, and hence involvement in, a much 
broader spectrum of functions proves my initial statement that the association of the PPTg 
with the MLR is a doubtful basis for PPTg-DBS and a wider perspective on the functions of the 
PPTg is required to understand its role in movement disorders. 
For an extensive review of the role in PPTg in sleep, anxiety, reward perception and 
motivation, reinforcement and learning, and attention please refer to the exciting exhaustive 
reviews (Inglis and Winn, 1995; Mena-Segovia et al., 2004; Pahapill and Lozano, 2000; Winn, 
2006).  
2.4.2. Ascending reticular activation system and sleep 
Cholinergic neurons located in the upper brainstem forming the Ch5 and Ch6 cell groups are 
considered to form wake promoting connections with higher brain regions. They provide major 
innervations to the thalamic relay nuclei, the intralaminar and reticular thalamic nuclei, as well 
as the lateral hypothalamus,  basal forebrain and the prefrontal cortex (Hallanger et al., 1987; 
Satoh and Fibiger, 1986) and change their firing patterns from rapid firing during wakefulness 
and REM (rapid eye movement) sleep to slow firing during non-REM sleep (Steriade et al., 
1993). The PPTg has therefore been considered part of the ascending reticular activation 
system, playing a role in behavioural state switching, and to have a key part in sleep – and to 
be precise, in the generation of REM sleep (Deurveilher and Hennevin, 2001). However, it is 
now clear that these firing pattern changes are not simple (Mena-Segovia and Bolam, 2011) 
and, moreover, many other sources have also an arousal influence and/or change their firing 
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patterns along different wakefulness and sleep states. These include projections from the 
parabrachial nucleus, the LC and raphe nuclei (Lu et al., 2006) as well as several forebrain 
neuronal systems [see (Saper et al., 2010)]. Moreover, an involvement in modulating states as 
suggested by changing firing patterns does not automatically mean a participation in the 
switching process itself. In fact, lesions of the PPTg showed only minimal effects (Lu et al., 
2006) or no effect at all (Deurveilher and Hennevin, 2001) on the amount of wakefulness and 
REM sleep. A recent study, however, suggests that, despite an equal distribution of sleep and 
wake states in PPTg lesioned rats and controls, the number of transitions between states, 
mainly wake and REM states (Petrovic et al., 2013), differs. While the PPTg seems to be 
involved in behavioural state control, it clearly cannot be considered a master switch for sleep-
wake transition, not changing the amount of sleep and even REM sleep. 
2.4.3. Reward perception and motivation 
Do rats have an altered reward perception and/or changes in motivation after PPTg lesions? 
Most likely not. Conditioned place preference using different sucrose solutions is not impaired 
after PPTg lesions (Alderson et al., 2001): rats seem to be able to appreciate the rewarding 
nature of the stimulus independently of the deprivation state. Furthermore, they adjust their 
net energy intake accordingly to accommodate increased sucrose solution consumption 
(Keating et al., 2002). Even though the breaking point drops when undergoing a progressive 
ratio (PR) schedule, this does not show a deficit of reward perception - or motivation for that 
matter – since the responding of the non-reinforced lever is significantly increased (Alderson et 
al., 2002). In tasks that involve collecting rewards in radial mazes the motivation to find a 
reward is the same in PPTg lesioned rats as in control rats: they might make errors when 
selecting the arms, but the speed in which they are moving around the maze to find food 
pellets remains the same (Keating and Winn, 2002; Taylor et al., 2004) and changes in the 
42 
 
reward value (food pellets changed to chocolate drops) are perceived as well (Taylor et al., 
2004).  
2.4.4. Attention 
Testing attention separately from other psychological functions is notoriously difficult. It is 
conceivable that the PPTg is well positioned to serve this function: the ability to decide which 
aspects of the environment are relevant and which are not is indispensable for successful 
adaptive behaviour so it is likely an evolutionary early function – quick processing of incoming 
sensory data when considering so called bottom-up attentional processes is a vital survival 
skill. In a test of sustained attention PPTg lesioned rats performed less successfully than 
controls, failing to respond timely to a light cue, which improved with lengthening of the visual 
signal (Kozak et al., 2005). This might point towards a deficit in attentional processing but 
cannot rule out deficits in other processes involved in this task, like movement and learning. 
When replicating the experiment a detailed analysis of the reason for the increased number of 
omissions showed that the animals did indeed notice and respond to the light, but not with 
the correct behaviour (Rostron et al., 2008), which would suggest an action selection problem 
rather than an attentional problem. It therefore cannot be ruled out that the increased time to 
respond only increased the chance to conduct the correct behaviour, rather than providing 
more time to notice and react to the cue. Increasing the attentional load, instead of decreasing 
as described by Kozak and colleagues, by introducing distracting noises and decreasing the 
salience of the cue caused a worsening in the performance of the PPTg lesioned rats (Inglis et 
al., 2001), which could support the hypothesis of an attentional impairment caused by PPTg 
lesions. But again, an action selection process problem cannot be excluded because the 
introduced distractions might not only distract attentional processes, but also other processes 
such as selection or execution of actions. 
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2.4.5. Learning 
It can be shown that the PPTg is involved in complex associative processing. Lesions of the 
PPTg affect responding for conditioned reinforcement under d-amphetamine. PPTg lesioned 
rats show an increased rate of response on non-reinforced levers, as opposed to control rats 
that learn to discriminate between the levers and focus almost exclusively on the reinforced 
lever. This indiscriminate lever pressing reflects a disruption in the process of reward-related 
behaviour but not motor deficit per se  (Inglis, Dunbar, et al., 1994). The same inability to learn 
the association between a conditioned stimulus and a reward has been shown in experiments 
using different experimental paradigms after bilateral excitotoxic lesions of the whole PPTg: in 
a visual autoshaping task (Pavlovian conditioning based on a spatial discrimination task) and 
conditioned reinforcement (instead of having to discriminate between two stimuli rats learn a 
stimulus reward association and need to transfer this in the testing session to a new response) 
rats with PPTg lesions were unable to learn the required associations (Inglis et al., 2000). 
Complex cognitive processing as required to complete the delayed spatial win-shift radial maze 
task has also shown to be affected by whole bilateral PPTg lesions in the absence of any 
locomotor deficits, an effect that cannot be attributed to disrupted motivation, because 
measures of speed were not decreased. Here it made no difference whether or not the rats 
received the lesions before or after being trained on the task. They made significantly more 
errors than sham operated rats and showed therefore impairment in making the appropriate 
choice of the arm to enter in the maze (Keating et al., 2002; Keating and Winn, 2002). Given 
the strong connections to midbrain DA neurons and their importance for establishing 
associations between action and reinforcement (Schultz, 2002), an involvement of the PPTg in 
drug reward was expected. Responding for intravenous self-administration of amphetamine 
(Alderson et al., 2004), heroin (Olmstead et al., 1998), cocaine (Corrigall et al., 2002) and 
nicotine (Corrigall et al., 1994; Corrigall et al., 2001) is affected by lesions or inactivation of the 
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whole PPTg; they appear to abolish the ability to learn a specific contingency between an 
action and its outcome, unless the association between action (lever pressing) and reward 
(outcome) has been made prior to the lesion. However, when the requirements for obtaining a 
reward change, rats with PPTg lesions that previously performed well show impairments 
(Alderson et al., 2002; Alderson et al., 2004). PPTg lesioned rats increased inappropriate 
responses to the non-reinforced lever on a (PR) schedule when schedule requirements 
increased, showing difficulties to update the learned action outcome associations and making 
therefore the wrong choices of actions. These data strongly support the contention that the 
PPTg is involved in learning about the selection of appropriate actions rather than movement 
per se. Another method of studying the behavioural functions of the PPTg is inactivation of the 
structure by direct pharmacological manipulations by for example infusion of the GABA agonist 
muscimol into the PPTg (Samson and Chappell, 2001). PPTg inactivation was used to test its 
effect on the sensitivity of contingency degradation between actions (lever pressing) and 
outcomes (food reward): when the action outcome association was degraded saline treated 
rats reduced rates of lever pressing whereas muscimol treated rats maintained previous lever 
pressing rates, showing a deficit in updating of the action outcome association (Maclaren et 
al., 2013). Kobayashi and colleagues showed how the PPTg could transform a sensory cue into 
a behavioural action by providing DA neurons with information about sensory input: in a 
reward-based performance task different populations of PPTg neurons responded not only to 
the reward itself, but also to the cue indicating the reward. The magnitude of the predicted 
reward correlated with the PPTg firing rate (Kobayashi and Okada, 2007; Okada et al., 2009). 
Short latency responses to sensory input had been shown before (Dormont et al., 1998; Reese 
et al., 1995). Further evidence showed that PPTg neurons respond not only to sensory 
information per se, but also to the value of that input. VTA DA firing responses in rats 
developed in response to learned cues that were signalling reward delivery. This change in 
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firing pattern from tonic to burst firing in midbrain DA neurons is implicated in reward related 
learning (Mena-Segovia, Winn, et al., 2008). Uwe Maskos explains how the cholinergic neurons 
of the mesopontine tegmentum, including the PPTg, may be essential for this change: 
restoration of the high-affinity nicotinic–cholinergic receptor subunit β2 in the VTA restores 
burst firing, which is completely absent in the mouse knockout of the same receptor subunit 
(Maskos, 2007, 2008). This phasic DA response was suppressed by unilateral PPTg inactivation 
(Pan and Hyland, 2005). In monkeys Kobayashi and colleagues found that the PPTg responds to 
reward and reward related cues even before DA neurons respond (Kobayashi and Okada, 
2007; Okada et al., 2009) (Figure 1.6.): In a primate visually guided reward task, 
electrophysiological recordings proved PPTg activity in response to stimuli predicting reward 
and to actual reward delivery itself, depending on reward magnitude. PPTg may therefore 
forward sensory information to the BG that has already been analysed regarding its salient 
aspects (reward predicting stimuli, reward itself, magnitude of reward). This role in 
sensorimotor decision-making has very recently been confirmed in mice that were performing 
a spatial choice task. Electrophysiological recording of PPTg activity showed neuron activity 
related to movement direction and outcome (Thompson and Felsen, 2013). 
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Figure 1.6. Single-neuron activity recorded from the PPTg of monkeys performing a visually guided 
saccade task in which the predicted reward value corresponded to the shape of the fixation target. 
Two groups of neurons were identified: FT = fixation target neurons; neurons responding to FT onset 
and RD = reward delivery neurons; neurons significantly more active after reward delivery. The level 
of activity varied according to the magnitude of expected reward and actual reward, respectively. 
Panels A –F show responses of FT and RD neurons to task events. Red represents large reward trials 
and green small reward trials. A,D, Rastergrams of FT and RD neuron activity; blue squares and 
circles = cue onset; black bars = saccade target onset; black triangles = saccade onset; blue bars = 
reward delivery. B,E, Spike-density functions of activity presented in A and D. C,F, Spike-density 
functions (averaged data); black bars indicate the periods of FTon, STon, and RD as denoted. 
Responses are aligned to the FT onset, ST onset, and RD throughout. Image reproduced from (Okada 
et al., 2009). 
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Based on the anatomical and behavioural findings that allow making a dissociation between 
the anterior and posterior part of the PPTg this laboratory tested anterior and posterior PPTg 
lesioned rats on different reinforcement schedules that differed in the number of actions 
required to gain food reinforcement (fixed ratio; FR) and the probability of reinforcement on a 
given action (variable ratio; VR) and extinction, in which they learned to inhibit responding in 
the absence of reinforcement (D. I. Wilson et al., 2009). Rats with posterior PPTg lesions made 
fewer correct bar presses than sham lesioned rats on all reinforcement schedules. Anterior 
PPTg lesions did not interrupt learning to bar press in low FR and higher VR schedules. 
However, anterior lesioned rats showed a behaviour that can be described as disorganized 
response control: in some schedules rats made more checks for food prior to its signalled 
delivery, more inconsequential bar presses between food delivery and food consumption, and 
more bar presses throughout extinction. The data confirm previous findings: anterior, but not 
posterior, PPTg lesions influenced locomotion (Alderson et al., 2008), whereas posterior, but 
not anterior, PPTg lesions altered self-administration of nicotine (Alderson et al., 2006).  
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3. Treatment for PD 
3.1. Medical treatment 
Only four years after the identification of DA as an independent neurotransmitter in 1957 
Walther Birkmayer and Oleh Hornykiewicz in Vienna and Andre Barbeau, Ted Sourkes and 
Gerald Murphy in Montreal initiated the first trials of L-DOPA in PD patients (Bjorklund and 
Dunnett, 2007a). Today, L-DOPA in combination with a peripheral dopa-decarboxylase 
inhibitor (benserazide or carbidopa) is considered the gold standard of PD therapy. The 
response to L-DOPA, however, is not predictable and depends on the clinical phenotype and 
stage of progression of the disease. The initial motor improvement is said to lie between 20% 
and 70% (Fahn et al., 2004). Tremor is often difficult to treat and an improvement is 
sometimes only seen after a long duration of treatment. Axial symptoms are little responsive 
all together. Early adverse events to L-DOPA administration are nausea, anorexia, faintness, 
hypomania, depression and delirium (Isaacson and Hauser, 2009). A slow and gradual 
optimization of the drug therapy can often avoid those problems. 
Long term difficulties with L-DOPA are however more problematic. Motor fluctuations and 
involuntary movements (chorea, athetosis, and dystonia) are common features after long term 
use of L-DOPA. Initially they can be controlled by adjustments of dose and inter-dose interval. 
Additionally, DA agonists (pramipexole, ropinirole, rotigotine, piribedil) can, at least partially, 
substitute L-DOPA to reduce dyskinesias. Administration of the glutamate antagonist 
amantadine can also reduce dyskinesias and anticholinergic drugs (benztropine, biperiden) can 
reduce painful dystonia. Catechol-O-methyltransferase inhibitors (COMTIs; entacapone and 
tolcapone) can prolong the effects of L-DOPA.  
Alternatives to L-DOPA are DA agonists – though these are rarely sufficient and L-DOPA will be 
necessary with time. Selective type B monoamine oxidase inhibitors (selegiline, rasagiline) are 
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well tolerated, but are also less efficacious. Apomorphine, a strong non-selective DA agonist, is 
water soluble and lipophilic and therefore suitable for intravenous, subcutaneous and 
transdermal routes. As a rapid rescue from severe off periods it can be injected 
subcutaneously but it is also offered as a pump for programmed infusion in order to more 
effectively control off-periods. Those injections can however, apart from other possible side 
effects of apomorphine (Pietz et al., 1998) cause skin problems and the formation of 
subcutaneous nodules. A further advanced treatment is the delivery of L-DOPA in form of an 
intestinal gel by an intra-jejunal pump. Tube blockages and dislocations are adverse events to 
be considered (Olanow et al., 2014). 
Despite many different alternatives, which all bring some kind of side effects (most of which 
are tolerable) the main difficulties of fluctuating medication response, troublesome 
dyskinesias and/or L-DOPA unresponsive symptoms remain. Further available options are 
different surgical approaches. 
3.2. Deep brain stimulation 
The pioneering work on DBS for movement disorders was conducted and published by the 
French neurosurgeon Benabid and colleagues from Grenoble in 1987 in a paper called 
“Combined (thalamotomy and stimulation) stereotactic surgery of the ventral intermediate 
(VIM) thalamic nucleus for bilateral Parkinson disease” (Blomstedt and Hariz, 2010). It presents 
an alternative to ablative stereotaxic surgery, also pioneered by the group from Grenoble. The 
STN as a target was introduced in 1993 (Pollak et al., 1993): from this point forward not only 
tremor could be treated with DBS but also other cardinal symptoms of PD and levodopa-
induced motor complications.  
The advantages of DBS compared to surgical destruction of tissue are obvious: it does not 
involve making a lesion, is theoretically reversible (in that it can be switched off) and 
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stimulation parameters can be adjusted post-operatively: Stimulation frequency, intensity and 
pulse width can be changed until maximal efficacy with minimal adverse effects can be 
achieved; also adapting to the course of the disease. The stimulation leads have several 
contacts which can be activated, deactivated and combined to produce a stimulation field that 
has the best effect. Today, DBS of STN, thalamus and GP are considered evidence-based 
routine treatments (Volkmann, 2007), which are nevertheless invasives procedures and 
therefore to be considered after thorough evaluation of alternatives. PPTg-DBS remains an 
experimental intervention. 
3.3. Deep brain stimulation of the pedunculopontine tegmental nucleus 
In recent years a considerable amount of articles have been published on PPTg-DBS in PD 
patients. Table 1.2. summarises the majority of those publications. The table, however, cannot 
be considered exhaustive, because articles on special single case studies describing for 
example rare side effects during PPTg-DBS [oscillopsia (Jenkinson et al., 2012); urinary 
incontinence (Aviles-Olmos et al., 2011)] or conditions other than PD [patient with multiple 
system atrophy with PD symptoms (Acar et al., 2011); primary progressive freezing gait 
disorder patient (Ostrem et al., 2010; Wilcox et al., 2011); PSP patient (Brusa et al., 2009)] 
were excluded. Pure anatomical reviews without direct references to surgical procedures were 
not included either. A more detailed analysis of these publication reveals that the actual 
amount of studies that offer information about the clinical benefit of PPTg-DBS is limited, 
especially considering that several publications report on the same patient cohort. (Where 
apparent this is remarked in the table.) Between 2008 and 2013 a total of 23 reviews on PPTg-
DBS were published (13 of which exclusively focusing on the PPTg, the rest on DBS targets with 
reference to the PPTg). Not included in this list are numerous publications on the potential of 
the PPTg as a target for PD, reviewing the anatomy and animal studies [for example (Hamani et 
al., 2007)] few papers discuss different surgical techniques that aim to improve PPTg targeting 
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and other focus on electrophysiological and metabolic changes in the brain during PPTg-DBS. 
The remaining studies assessed different clinical dimensions, motor deficits, cognitive abilities, 
sleep disturbances: 
The first pioneering studies appeared encouraging (Mazzone et al., 2005; Plaha and Gill, 2005; 
Stefani et al., 2007). The authors reported safe surgical implants of DBS leads in the PPTg and 
presented subjective reports of improved feeling of ‘well-being’ and of improved motor 
symptoms. Subsequent studies, however, did not deliver the same promising results and early 
improvements could possibly be attributed to placebo effects; follow-ups reported a decline of 
the transient gait amelioration (Stefani et al., 2013). The first double-blind trials proved the 
importance of careful assessment of the potential results of the stimulation: in blind conditions 
these studies did not show motor improvements with PPTg-DBS as measured by the Unified 
Parkinson’s Disease Rating Scale (UPDRS) – a widely used tool to assess the impact of the 
disease and the degree of disability it causes, covering motor and non-motor features affected 
in the daily life and as assessed in the clinical setting (Ferraye et al., 2010; Goetz et al., 2007; 
Moro et al., 2010) – and by objective freezing measures (Ferraye et al., 2010). The main focus 
was on postural instability and gait difficulties (PIGD); when assessed by either corresponding 
items of the UPDRS or by objective gait measures (Thevathasan, Cole, et al., 2012) these 
symptoms showed improvement with PPTg-DBS – but only FOG and/or falls were reported to 
improve with PPTg-DBS, subjectively (Ferraye et al., 2010) and objectively (Thevathasan, Cole, 
et al., 2012), not gait parameters such as stride length. ‘StartReact’ – an acceleration of a 
response after a loud auditory stimulus – was shown to be deficient in patients with freezing 
problems and could be restored by PPTg-DBS (Thevathasan, Pogosyan, et al., 2011). Reaction 
time in various attentional tasks (Thevathasan et al., 2010) and working memory tasks 
(Alessandro et al., 2010; Costa et al., 2010) improved, but not the accuracy of the responses; 
improvement was also found in verbal fluency, executive functioning and delayed recall 
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(Alessandro et al., 2010; Ceravolo et al., 2011). Further, it was reported that an increase of 
REM duration could be achieved with PPTg-DBS (Lim et al., 2009; Romigi et al., 2008).  
Thus, in terms of motor outcome of PPTg-DBS, the results of the clinical trials published so far 
offer heterogeneous and moderate results and an overall lack of consistent improvement. 
Surgical and experimental protocols differed substantially across the research groups. PPTg 
electrode implants were unilateral, bilateral or combined with STN-DBS or caudal zona incerta 
(cZi)-DBS; and surgical techniques for accurate targeting differed, the importance of which was 
highlighted by Mazzone and colleagues when showing considerable individual anatomical 
variability from patient to patient (Mazzone et al., 2013). Specific targeting within the PPTg 
varied as well – the Italian group implanted electrodes in caudal parts of the PPTg (Insola et al., 
2012; Mazzone et al., 2008) but others were placed rather rostrally (Alessandro et al., 2010; 
Moreau et al., 2009). Thevathasan and colleagues have pointed out the importance of 
considering the placement within the PPTg itself (Thevathasan, Pogosyan, et al., 2012)– a 
suggestion strongly supported by the heterogeneous anatomy, physiology and connectivity of 
the PPTg – and a fact clearly supported by data from this lab. Patient selection was not 
consistent either across the trials; disease duration, symptomatology and diagnosis and 
response to medication differed, very likely having an impact on the underlying 
pathophysiology – possibly and importantly the degree of degeneration in the PPTg itself – and 
therefore differing responses to the treatment.  
 
 
 
Table 1.2. Summary of studies published up to date on PPTg-DBS in PD patients (pages 53-55) 
 Authors 
no of 
patients Type of assessment Key points 
    Mazzone et al. 2005 2 surgical; intraoperative 
clinical score 
safe surgery 
    
Plaha and Gill 2005 2 clinical (motor) slight improvement of UPDRS part III, today it is suggested 
that this was rather a placebo effect 
    
Stefani et al. 2007 6 clinical (motor) PPN not as good as PPN+STN 
    
Pierantozzi et al. 2008 6 spinal reflex excitability spinal cord excitability: increased Hoffman reflex threshold 
normalized with PPN DBS 
    
Androulidakis et al. 2008 6 electrophysiological 
(EEG, microelectrode 
recording) 
alpha oscillatory synchronization in PPN area and coupling 
with cortical EEG, promoted by levodopa 
    
Weinberger et al. 2008 5 electrophysiological 
(microelectrode 
recording) 
different electrophysiological characteristics 
    
Strafella et al. 2008 1 functional imaging (PET 
rCBF) 
increased activity in subcortical areas, especially thalamus 
    
Romigi et al. 2008 1 polysomnography increase of REM episodes with LFS, STN DBS and PPN DBS 
improve sleep architecture disruptions (nocturnal 
awakenings, increased stage I and wakefulness after sleep 
onset and decrease REM), but only PPN DBS increases REM 
duration 
    
Aravamuthan et al. 2008 healthy 
Ps 
imaging (DTI); surgical connections for surgical targeting 
    
Mazzone et al. 2008 13 surgical ventriculography vs CT scan 
    
Zanini et al. 2009 5 clinical (motor, 
cognitive) 
overall cognitive profile did not change, grammar improved 
(but also with STN DBS) 
    
Ballanger et al. 2009 3 functional imaging (PET 
rCBF) 
increased blood flow in subcortical and cortical areas 
    
Costa et al. 2010 5 clinical (motor, 
cognitive) 
RT improved in working memory tasks but not  accuracy; 
facilitation of speed of processing possibly through 
modulation of attentional resources 
    
Lim et al. 2009 5 polysomnography REM duration increased, probably by lowering the REM sleep 
threshold 
    
Arnulf et al. 2010 2 polysomnography increased alertness with LFS, increased propensity to sleep 
with 60-80Hz 
    
Alessandro et al. 2010 6 clinical (cognitive, sleep 
scales) 
improvements, RT decreased in WM task, patients from 
previous study 
    
Ferraye et al. 2010 6 clinical (motor) previously implanted with STN DBS; STN DBS ON throughout 
study, double blind, some better, some no improvement, 
some worse, PIGD did not respond to stimulation, bilateral 
better than unilateral; lack of strict correlation between lead 
position and performance 
    
Shimamoto et al. 2010 4 electrophysiological 
(microelectrode 
recording); surgical 
electrophysiological identification of PPTg for implantation 
surgery 
    
Moro et al. 2010 6 clinical (motor) double blinded, no benefits, only subjective report of 
reduced falls, 50-70Hz 
    
Khan et al. 2010 13 surgical use of implanted guide tube 
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patients Type of assessment Key points 
 
Stefani et al. 2010 
 
6 
 
functional imaging (18-
FDG PET); clinical 
(cognitive) 
 
improvement of attentive and executive domains, increased 
metabolic activity in cortical and limbic areas, patients from 
previous study 
    
Thevathasan et al. 2010 11 clinical (cognitive, 
motor) 
improved RT 
    
Yeh et al. 2010 8 electrophysiological 
(microelectrode 
recording) 
suggesting direct somatosensory inputs to PPTg 
    
Tsang et al. 2010 7 electrophysiological 
(microelectrode 
recording, EEG) 
PPTg activity during movement preparation and execution, 
modulated by DA medication 
    
Peppe et al. 2010 5 clinical (motor) uncertainties, patients from previous study 
    
Schweder et al. 2010 1 imaging (DTI) suggesting neuroplasticity after LFS 
    
Ceravolo et al. 2011 6 functional imaging (18-
FDG PET); clinical 
(cognitive, motor) 
PPN ON better than PPN OFF (verbal long term memory; 
executive functions), increased cortical metabolism, but only 
minor and variable motor benefit, patients from previous 
study 
    
Khan et al. 2011 7 clinical (motor) PPTg + cZi, improvement of axial subscales UPDRS when 
stimulated in combination 
    
Thevathasan et al. 2011 8 clinical (motor); RT and 
startle reflex tasks 
‘StartReact’ absent in FOG patients, PPTg-DBS improved this; 
“Optimization of motor systems releasing pre-programmed 
movement may not be the only mechanism by which PPTg-
DBS may improve gait" 
    
Thevathasan et al. 2011 5 clinical (motor) improvement of gait freezing (gait and falls questionnaire), 
UPDRS not sensitive to this treatment 
    
Caliandro et al. 2011 3 electromyography 
(Tibialis anterior) 
cases individually presented 
    
Thevathasan et al. 2012 7 electrophysiological 
(microelectrode 
recording) 
correlation of alpha oscillation and gait performance, case for 
topographical dissociation of PPTg: posterior PPTg relevance 
in gait 
    
Thevathasan 2012 7 clinical (motor) FOG, double blinded, freezing improved but not objective 
gait measures, patients from previous study 
    
Khan et al. 2012 4 functional imaging (15O-
H20 PET); clinical 
(motor) 
PPN + cZi increased blood flow, improved control of 
symptoms when medicated 
    
Khan et al. 2012 5 clinical (motor) PPN + cZi, on-medication;  improvements only when 
stimulated in combination 
    
Mazzone et al. 2012 14 oromotor movements jaw movements may be restored, patients from previous 
studies 
    
Insola et al. 2012 10 surgical obtaining Obex-to-brainstem distance by P16 and P14 latency 
measurements 
    
Peppe et al. 2012 5 clinical (sleep scales) 1 year follow up, improvement of night time sleep and 
daytime sleepiness  
    
Schrader et al. 2013 1 clinical (motor) PPTg, GPi and combined, individually: mild effect on gait 
ignition and FOG, combined: marked effect 
    
Mazzone et al. 2013 28 imaging (MRI); clinical 
(motor) 
no correlation between lead position, contact setup and 
clinical outcome, patients from previous studies 
    
Neagu et al. 2013 2 electrophysiological 
(microelectrode 
recording) 
bilateral STN DBS, recording from unilateral PPN electrodes, 
demonstrating functional connection 
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4. Parkinson’s disease models 
Traditional PD models have provided a great amount of information about PD pathophysiology 
and treatment options. However, when trying to understand the involvement of the PPTg in 
this condition and the possibility of targeting this structure with DBS the actual physiological 
condition of the PPTg in PD needs to be mimicked in more detail. As discussed above DA 
depletion alone is not enough to account for all symptoms seen in PD: the PPTg is affected by 
neurodegeneration as well (as are other brainstem structures). Stimulating a fully intact 
structure will clearly have different effects compared to stimulating a structure that shows 
partial cell loss which therefore needs to be taken into account. 
4.1. 6-hydroxydopamine 
Very early models of PD were created by means of reserpine or haloperidol injections in 
rodents and rabbits. This does not cause nigral dopaminergic cell degeneration but only 
mimics symptomatic characteristics of the disease. In order to also mimic the 
pathophysiological state of PD the toxin 6-OHDA is widely used in rats (Duty and Jenner, 2011; 
Emborg, 2004). It has to be stereotaxically injected either into the SN itself, the medial 
forebrain bundle (MFB) or the striatum because it does not cross the blood-brain-barrier. 6-
OHDA causes selective catecholaminergic cell death through a combination of oxidative stress 
and mitochondrial respiratory dysfunction once inside the cell. The many different effects it 
has leading to the cell death resemble processes also apparent in PD [for more details see 
(Duty and Jenner, 2011)]. Infusion site and the amount of toxin determine the extent and 
severity of DA depletion. Medial forebrain bundle and SNc injection sites are most often used 
to induce very extensive lesions, but the DA depletion can spread to include the A10 neurons 
of the VTA. Infusion of the toxin into the striatum can cause very severe lesions as well – 
depending on the number of infusions and toxin concentration – but can be more controlled, 
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spares (however not completely) VTA cell loss and induces cell death retrogradely. Kirik and 
colleagues tested different doses and injection sites comparing the extent of DA depletion and 
the behavioural effect (Kirik et al., 1998). They showed that rats with extensive DA depletion 
caused by striatal injections over four injection sites showed strongest behavioural effects 
measured as deficit in skilled paw use. This observation is in line with results from a 
comparison of two bilateral 6-OHDA models, which both received striatal injections into the 
same sites but using different concentrations: the higher concentration caused a more reliable 
and more persistent behavioural effect (Gut, 2009). For many purposes unilateral lesions can 
be sufficient, but when both sides of the body need to be tested, such as in gait, bilateral DA 
depletions are required. This means that post-operatively the animals will suffer from a period 
of marked aphagia, making them reliant on being hand fed. The choice of model clearly 
depends on the scientific question at hand but it needs to be pointed out that this traditional 
6-OHDA model is limited as the degeneration in PD is not restricted to DA neurons (Hirsch et 
al., 1987; Rinne et al., 2008; Zweig et al., 1989). Especially in the light of the development of 
new therapeutic methods targeting affected brainstem nuclei this limitation needs to be 
addressed as the restriction to DA neurons is not only untrue to the actual underlying 
pathophysiology but is also not enough for the symptoms of interest (Grabli et al., 2013). 
Therefore, when targeting the PPTg with DBS electrodes or when recording from the PPTg it is 
questionable if those findings are comparable to the human condition because those 
traditional models do not take into account the degeneration in the PPTg (Alam et al., 2011) 
making a refined model necessary (Pereira et al., 2011). 
4.2. Combination of dopamine depletion in SN and lesions of the PPTg 
Only one study has been published that examines the behavioural effect of a combination of 
PPTg lesions and DA degeneration in the SN in Parkinson’s models *in non-human primates 
(Grabli et al., 2013)] despite the increasing number of PPTg-DBS studies in patients and the few 
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experimental (and mainly electrophysiological) approaches in rodents (Alam et al., 2012; 
Capozzo et al., 2009; Rauch et al., 2010; Saryyeva et al., 2011). A few studies have been 
conducted combining DA depletion and PPTg lesions, not to test the effect on behaviour, but 
their effect on SNr and STN firing and thalamic firing [(Breit et al., 2006) and (Yan et al., 2008) 
respectively]. Matsumura and colleagues (Matsumura and Kojima, 2001) administered MPTP 
to a monkey that was already bearing kainic acid lesions of the PPTg and report that these 
developed only mild – if any – parkinsonism compared to MPTP models without PPTg lesions. 
Given the marked degeneration in the PPTg in PD patients it is important to develop a model 
that considers these changes, especially when this very structure is the one to be targeted for 
DBS. 
4.3. Deep brain stimulation of the PPTg in rodent models of Parkinson’s 
disease 
The effect of PPTg lesions on STN activity in parkinsonian rats was assessed before (Breit et al., 
2005; Breit et al., 2006) and the only other PPTg stimulation studies in PD rats focused on its 
modulatory effect on electrophysiological activity of other structures, mainly the STN, in 
anaesthetised hemi-parkinsonian rats (Alam et al., 2012; Capozzo et al., 2009; Saryyeva et al., 
2011). Despite the interest in PPTg-DBS for PD and the conflicting results in the clinical 
literature there is to date only one published study in which the PPTg was targeted with 
stimulation electrodes in a rodent PD model to assess the potential of DBS in this structure as a 
therapeutic target (Rauch et al., 2010). However, those animals had an intact PPTg on both 
sides. Rauch and colleagues found that stimulation with different frequencies of the intact 
PPTg in a 6-OHDA lesioned rat had complex effects on different parameters of motor activity 
and postural stability: whereas the stimulation with a high frequency or low frequency but 
high intensity seemed to improve the postural instability, limb use and motor activity 
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worsened, which in return could be improved by low frequency stimulation with a low 
intensity. 
5. Aims 
There is a need for a detailed and controlled investigation of the potential role of the PPTg in 
the treatment of PD symptoms. This Introduction has highlighted many reasons for this:  
 The underlying brain pathology of PD includes extranigral degeneration. 
 The PPTg is highly interconnected with the BG and other structures such as the 
thalamus and brainstem structures. 
 Electrophysiological changes in the PPTg (and in BG structures that are closely 
connected to the PPTg) have been shown in PD models and patients. 
 The evidence regarding the functions of the PPTg, meticulously accumulated over 
decades, provide a consistent picture of the role of the PPTg beyond motor control. 
 Particular PD symptoms do not respond to dopaminergic medication: the relationship 
of these symptoms to PPTg cell loss and further functional disturbances match the 
functional role of the PPTg. 
 PPTg-DBS in Parkinsonian patients has very inconsistent results. 
 There is an uncertainty in the experimental literature about the functions of different 
parts of the PPTg.  
On this basis a series of experiments was conducted to define more accurately what the 
potential for PPTg-DBS might be, in order to make predictions about what effects might be 
expected from which parts of the PPTg following DBS.  
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In order to confirm and expand on the literature showing that the lack of a fully functioning 
PPTg does not cause motor deficits, the effect of both full and partial PPTg lesions on gait and 
posture was assessed; the results are presented in Chapters 3 and 4.  
By adding a partial lesion of the PPTg to bilateral destruction of SNc DA neurons, the 
traditional PD rodent model was refined to mimic better the pathological state in PD. Chapter 
4 reports on the comparison of this novel model with the traditional 6-OHDA model.  
Doubting the effect of PPTg-DBS as a corrective means of gait deficits on the basis that the 
PPTg is more highly interconnected and possess a more complex functionality than 
hypothesised by the majority of the PPTg-DBS literature, the effect of PPTg-DBS on gait was 
examined. The clear functional and structural differences between anterior and posterior PPTg 
raise the question whether the consequences of PPTg-DBS are dependent on location within 
the PPTg, as well as the question whether the effects might differ. Therefore different sites 
within the PPTg were targeted with DBS and their effect on gait and also L-DOPA induced 
dyskinesias were compared (Chapter 5). Clarity about this is an essential precursor to decisions 
about which patients might be considered best candidates for PPTg-DBS and to which PPTg 
sites DBS should be targeted. 
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  Chapter 2 General Methods      
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1. Subjects 
A total of 134 adult male Lister-Hooded rats (Harlan Olac Ltd, Bicester, UK) were used for this 
project; 26 for pilot work and 108 for experiments. The rats were housed in a temperature and 
humidity controlled environment under a 12h light/dark cycle (lights on at 6am [7am during 
UK daylight saving time]). All animals were single housed as soon as the behavioural training 
started: they had to be on food control because of the sensitivity of the gait analysis device to 
weight changes. Once the target weight for surgery and testing was reached animals were 
weighed daily and the food was adjusted accordingly, but never below 15 g/rat/day, in order 
to maintain a stable weight. Water was available ad libitum in the homecages. The cages 
consisted of a solid plastic base with a wire mesh top, measuring 36 cm x 56 cm x 23 cm or     
25 cm x 45 cm x 15 cm in the case of the experiment described in Chapter 3. Whenever 
possible the cages were environmentally enriched with plastic tubes or perspex huts. For the 
DBS studies access to the food hoppers was blocked off and the wire mesh tops were covered 
with semi-transparent plastic sheets to avoid loss of the headcaps. For the experiments 
described in Chapter 3 and 4 the target weight for surgery was 330g, which was increased to 
380g for the DBS studies (Chapter 5) in order to increase headstage stability. Actual weights 
and group sizes are stated in the corresponding chapters. Compliance with the Animals 
(Scientific Procedures) Act 1986 and European Communities Council Directive of 24/11/86 
(86/609/EEC) was maintained throughout the project. 
All behavioural testing was conducted during the light phase. All care was taken not to disrupt 
the animals during the dark phase. However, in the case of high maintenance PD models some 
interaction with the rats during the dark phase was inevitable in order to provide them with 
the care they needed. 
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2. Surgical procedures 
Depending on the experimental design and group affiliation rats underwent 1, 2 or 3 surgeries, 
allowing a 7-day recovery period between every 2 surgeries. Surgeries comprised either 
stereotaxically guided infusion of neurotoxic agents and/or stereotaxically guided implantation 
of stimulating electrodes. All surgeries were performed on “Model 900” Kopf stereotaxic frame 
(David Kopf, Tujunga, CA, USA) in a clean surgical environment. The following rodent models 
underwent a single or combinations of several surgical procedures: 
Rats with bilateral PPTg lesions: Two surgeries each comprising unilateral infusions 
of ibotenic acid into anterior and posterior PPTg. 
 
Rats with partial PPTg lesions: The same procedure using a lower concentration 
of the toxin. 
 
Rats with bilateral DA depletion of the 
SNc: 
Bilateral infusion of 6-OHDA into the striatum 
distributed over 4 different sites along the rostro-
caudal axis in 1 surgery. 
 
Rats with a combination of DA depletion 
and partial bilateral PPTg lesions: 
3 surgeries starting with unilateral infusions of 
ibotenic acid into the PPTg followed by DA 
depletion in the third surgery. 
 
Rats with either bilateral DA depletion or 
rats with combined lesions with bilateral 
implantations of stimulating electrodes 
into either anterior or posterior PPTg: 
The corresponding procedures as described above, 
during the DA depleting surgery the electrodes 
were implanted subsequently. 
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2.1. Anaesthesia 
Rats were anaesthetised using isoflurane (Abbot Laboratories Ltd, Maidenhead, UK) in an 
induction box, starting at a concentration of 0% isoflurane increasing this to 5% isoflurane at 
an approximate rate of 1 %/min in O2 delivered at 4 L/min (care was taken that reflexes were 
lost before the concentration was increased from 3% to 4%) before being placed into the 
stereotaxic frame where anaesthesia was maintained through a facemask (specifically 
designed for the Kopf stereotaxic frame) at 2-2.5% isoflurane in 1.2-1.6 L/min O2.  
2.2. Bilateral PPTg lesions  
The non-steroidal anti-inflammatory analgesic Rimadyl (carprofen 0.05 ml/rat, 5% w/v; s.c., 
Pfizer Ltd, Kent, UK) was administered subcutaneously, the head shaved, the skin cleaned and 
disinfected with povidone-iodine (Henry Schein Animal Health, Dumfries, UK). A midline 
incision was made and the skull exposed by scraping the periosteum from the skull, removing 
all soft tissue, holding the incision open with artery clamps. The incisor bar of the stereotaxic 
frame was then elevated. The height was determined by multiplying the distance between the 
interaural line and the back of the incisor bar by the sine of 8°29’ (0.147) as described by 
Whishaw and colleagues (Whishaw et al., 1977). Craniotomies were made using a hand held 
dental drill guided under a surgical microscope after measurements were taken for the burr 
holes at the specific locations (see the relevant experimental chapters for coordinates). The 
infusion of 0.09 – 0.12M ibotenic acid  (solution in phosphate buffer; final pH adjusted to pH 
7.0 using 2m NaOH; Sigma-Aldrich, Gillingham, Dorset, UK](please see the details in Chapter 3) 
was performed by pressure injection from a drawn glass micropipette (tip diameter 30-40µm) 
made from borosilicate capillary tubes (1.16 – 1.19 mm o.d.; 0.49 mm i.d.) pulled into pipettes 
on a pipette puller (Model 720 Needle Pipette Puller, David Kopf, Tujunga, CA, USA) with the 
tip broken off to the appropriate diameter under a light microscope. With the pipette filled 
with the toxin and held by an electrode holder on the stereotaxic frame, the measurements 
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were re-taken, dura cut with a sterile 29 ga needle and the pipette carefully lowered into the 
brain. Air pressure was applied manually by a syringe connected to the pipette via polythene 
tubing and released once the target volume has been in infused, as indicated by a scale on the 
pipette. The pipette was then left in situ for 5 min after infusion and then slowly lifted. This 
procedure was repeated for a second infusion. Subsequently the skull and wound edges were 
cleaned with saline and the wound closed with Michel clips (Henry Schein Animal Health, 
Dumfries, UK). Before being placed into a heated recovery cage rats were treated with 1-1.5 ml 
of Hartmann’s solution (approximately 1 ml/h of surgery injected intraperitoneally; Baxter 
Healthcare Ltd, Norfolk, UK) for fluid maintenance accounting for the time that the rat was not 
able to drink, as well as with 0.02 ml of benzodiazepine (Diazepam, 5 mg/ml; Henry Schein 
Animal Health, Dumfries, UK) to reduce the risk of convulsive activity, also injected 
intraperitoneally. Rats were closely monitored during the entire post-operative recovery 
period because convulsive activity and barrel-rolling have to be expected after this procedure 
(for more details see Chapter 3). In order to create bilateral lesions surgeries were performed 
in 2 separate unilateral procedures separated by 7 days to reduce the risk of a fatal outcome 
from complications during the post-surgery recovery phase. 
2.3. Partial PPTg lesions 
Exactly the same procedure was performed as described above, but with a concentration of 
0.06M of ibotenic acid.  
2.4. Bilateral DA depletions of the SNc (6-OHDA lesions) 
The non-steroidal anti-inflammatory analgesic Rimadyl (carprofen 0.05 ml/rat, 5% w/v; Pfizer 
Ltd, Kent, UK) was administered subcutaneously, the head shaved, the skin cleaned and 
disinfected with povidone-iodine. A midline incision was made and the skull exposed by 
scraping the periosteum from the skull, removing all soft tissue, holding the incision open with 
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artery clamps. The nose bar was then set to 0 mm [following (Kirik et al., 1998)]. Craniotomies 
were made using a hand held dental drill guided under a surgical microscope view after 
measurements were taken for the burr holes bilaterally above the striatum in order to deliver 
the toxin at 4 sites on each side at the following coordinates (in mm): (1) AP: + 1.3 (measured 
from Bregma), ML: ± 2.6 (measured from midline at the skull surface), DV: - 5.0 (measured 
from Dura); (2) AP: + 0.4, ML: ± 3.0, DV: - 5.0; (3) AP: - 0.4, ML: ± 4.2, DV: - 5.0; (4) AP: - 1.3, 
ML: ± 4.5, DV: - 5.0. Care was taken to avoid damage to dura during the drilling process. Toxin 
infusions were made via a 30 ga cannula connected to a 10 µl SGE syringe (Speck & Burke, 
Alva, UK) (containing 70% alcohol) via polythene tubing (containing sterile distilled water) 
mounted in a Harvard microdrive pump (PHD 22/2000; Harvard Apparatus, Inc., Holliston, MA, 
USA). After filling the cannula with toxin (leaving an air bubble between water in the tubing 
and the toxin in order to check the flow of the infusion) and re-measuring the coordinates with 
the cannula (secured by an electrode holder on the stereotaxic frame) dura was cut with a 
bent tip of a 29 ga needle and the cannula lowered into position. At a rate of 1 µl/min 7 µg 
(free base weight) of 6-OHDA-hydrochloride (Sigma-Aldrich, Dorset, UK) dissolved in 2 µl of 
0.1% L-ascorbic acid /0.9% saline was infused into each of the 4 sites of both sides of the brain. 
The cannula was left in situ for 2 min after the infusion before carefully retracting it. The toxin 
was weighed out before the surgical procedure, kept on ice and only dissolved just before the 
infusion to avoid oxidation. Subsequently the skull and wound edges were cleaned with saline 
and the wound closed with Michel clips (Henry Schein Animal Health, Dumfries, UK). Before 
being placed into a heated recovery cage rats were treated with 2-2.5 ml of Hartmann’s 
solution (approximately 1 ml/h of surgery; Baxter Healthcare Ltd, Norfolk, UK). 
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2.5. Combination of DA depletions and partial bilateral PPTg lesions 
(Combined lesions) 
Rats that received what in the following will be called ‘combined lesions’ underwent 3 
separate surgeries. During the first 2 bilateral partial PPTg lesions were created as described 
above. Following a further 7 days of recovery the DA depleting procedure was performed. The 
burr holes for microinfusions of ibotenic acid into the PPTg of rats used in the DBS experiments 
were filled and covered with Gelfoam (Pfizer Ltd., New York, USA) before closing up in the 
attempt to keep the holes as clean as possible for an accurate implantation of the electrodes 
through the same holes (see below). 
2.6. Electrode implantation 
For DBS experiments rats of the DA depletion group and rats with combined lesions received 
implantations of concentric bipolar electrodes into either the anterior or posterior PPTg. These 
procedures were conducted during the same surgery as the infusion of 6-OHDA for DA 
depletion. After the last infusion of 6-OHDA into the striatum the skull was cleaned and dried 
and bone wax (Henry Schein Animal Health, Dumfries, UK) was used to close the burr holes 
above the striatum. The nose bar was then elevated to create a horizontal angle of 8°29’ 
between the incisor bar and the interaural line (see above). In the case of a rat with solely a DA 
depletion at this point burr holes were drilled above the anterior or posterior PPTg on both 
sides using the same coordinates as stated for the PPTg lesion procedure. In case of a model 
with combined lesions the Gelfoam was removed from the burr holes above the PPTg and the 
hole was cleared as much as possible to allow for measurement from dura or to allow for a 
close enough approximate. If necessary the burr hole was slightly enlarged to allow the view 
onto a clean area of dura. Five to 6 stainless steel round-head machine screws with sharply cut 
threads (0-80 x 1/8 and 0-80 x 3/32); Plastics One, Roanoke, VA, USA) were screwed into the 
skull, 1 or 2 at the front, 2 between midline and the striatal burr holes and 2 behind lambda, 
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placing them in a slight angle to the skull surface to increase headcap stability. At this point the 
skull was cleaned and dried again to increase adhesion of the dental cement (see below). With 
an electrode (for details about the electrode design and material please see Chapter 5) 
secured into the electrode holder on the stereotaxic frame measurements were taken and the 
electrode was then lowered carefully into place (anterior or posterior PPTg) after widening the 
dura incision. Covering temporarily the other PPTg burr hole with bone wax the electrode was 
fixed onto the skull and neighbouring screw using a methyl methacrylate based dental acrylic 
(Simplex Rapid, Kemdent Works, Wiltshire, UK). Once the dental cement had dried the 
electrode was detached from the holder and the guiding cannula attached to the electrode by 
means of dental acrylic to aid implantation was carefully removed. This procedure was 
repeated for the implantation of the second electrode. Anode and cathode of the electrodes 
were then carefully connected to the headstage (see details about the headstage in Chapter 5; 
right-hand side electrode was always connected to the first row of connectors, left-hand side 
electrode to the second row, the cathode of each electrode was always connected to the left 
connector, anode to the right one). The headstage was then fixed with more dental cement in 
a layering manner to increase stability taking care it is level with the skull surface. Finally the 
wound edges were washed with saline solution. Once removed from the stereotaxic frame rats 
were given an i.p. injection of 2.5 ml Hartmann’s solution (Baxter Healthcare Ltd, Norfolk, UK). 
3. Post surgery animal care 
PPTg lesioned animals did not require any special care following the immediate post-surgery 
recovery. After the immediate post-operative recovery period they did not show any apparent 
deficits that would compromise their well-being.  
Bilaterally DA depleted rats (including the combined group) show severe aphagia. The animals’ 
weight was strictly monitored after surgery and animals were hand fed with Liquid Rat Diet 
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(LD’82, Shake and Pour, control, BioServ, Frenchtown, NJ, USA) twice a day to secure a stable 
weight. Additionally they received 2 ml Hartmann’s solution on the first day after surgery.  
Rats carrying headstages received 0.05 ml subcutaneous injections of the non-steroidal anti-
inflammatory analgesic Rimadyl for 2 days post surgery.  
4. Behavioural procedures 
4.1. Food restriction 
All rats used in this project were kept on food control before (at the latest starting with the 
pre-surgical baseline testing) and after surgery to maintain a constant weight avoiding 
interference of the rats' body weight with the behavioural data from the CatWalk. The rats’ 
weight was taken daily at about the same time and the food was adjusted accordingly. 
4.2. CatWalk training and testing 
Gait testing was conducted on the CatWalk (CW) 7.1 (Noldus, Wageningen, Netherlands). The 
principle working mechanisms of the CW are well explained by Hamers and colleagues 
(Hamers et al., 2006). In brief, rats traverse a 100 cm x 12 cm x 0.6 cm glass walkway, 
motivated by their own homecage being present at the other end of the CW, for them to 
return to directly after testing. Green LEDs arranged alongside the glass floor project into the 
glass. This light gets scattered once the rats’ paws touch the surface, illuminating the contact 
area; a high-speed camera sitting underneath the walkway capture these reflections and 
transmit the captured video clips to the connected computer. These video clips can then be 
analysed with the corresponding CW software. Prior to pre-surgery testing the rats were 
trained for 10-12 days on the CW to assure that they were able to complete at least 3 
consecutive runs fulfilling the criteria of runs free from any interruptions such as stopping, 
rearing or jumping off the CW. During testing, runs that did not meet these criteria were 
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repeated (see details regarding slowing and freezing in PD models in Chapter 5). The mean of 3 
runs was calculated for each testing session. 
4.3. CatWalk settings 
The camera’s lens aperture was set at 1.4 - 1.6. For the full PPTg lesion experiment the 
software was set to 3990 for contrast and brightness was set to - 290 with a pixel intensity 
threshold of 12 and pixel number threshold of 7. For the combined lesion experiment the 
brightness was set to - 330 and maintained for the DBS studies.  
4.4. Gait parameters 
Base of support  
(BOS) 
This parameter measures the distance (in mm) between the two forepaws 
or the two hind paws. It serves as an indicator for gait stability. A large BOS 
can compensate for an unstable gait (Hamers et al., 2006).  
Duty Cycle The stance phase is the duration of contact of a paw with the walkway in a 
step cycle. But since the stance duration depends on the overall walking 
speed this parameter is expressed as a percentage of the duration of the 
step cycle [stance / (stance + swing) x 100%]. This parameter is an indicator 
for the stability of the animal. Shorter swing duration and longer stance 
duration can compensate for an unstable gait (Hamers et al., 2006). 
Support The support formula describes the number of paws that are on the glass 
plate at any time during a run expressed as the relative duration (in percent) 
of contact with the ground of all combinations of numbers of paws. The 
combinations analysed here are diagonal pair of paws and three paws. 
Swing Speed This describes the velocity measure in m/s of the paws during the phase 
when it has no contact with the walkway (= swing). It is calculated as stride 
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4.5. Freezing of Gait 
Some rats showed moderate to severe freezing during testing. In the combined lesion study 
(Chapter 4) rats showed mostly gait hesitation in the middle of a run (slowing down and 
coming to a stop) which most likely reflects destination-hesitation according to the 
classification of Fahn (Fahn, 1995; Schaafsma et al., 2003) (rather than hesitation in tight 
quarters, given that the rat had already been in and had been walking through the narrow 
space of the CW before the freezing started). This type of freezing was not recorded separately 
– usually the repetition of the run led to a run that fulfilled the required criteria. In the DBS 
studies however some rats were suffering from severe start hesitation. If this did not change 
after several minutes the rat was placed back into the homecage for a short rest and the test 
was then repeated. Should the rat still not cross the walkway it was carefully encouraged by 
gentle tapping or pushing. If no run at all or not the required 3 runs could be recorded the 
performance was recorded as such (freezing leading to <3 runs or freezing leading to complete 
lack of data for the day). 
length / swing duration. 
Stride Length This is the distance (measured in mm) between two successive placements 
of the same paw. 
Print Position Print position is the distance (expressed pixels) between the position of the 
hind paw and the position of the previously placed front paw on the 
ipsilateral side within the same step cycle. This also belongs to the group of 
parameters assessing the regularity of the animal’s gait patterns. Most 
rodents place their hind paw at the previous position of the forepaw (best 
chance for a safe placement) and with increased step length the hind paw 
tends to be placed in front of the front paw. 
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4.6. Stimulation protocol (intensity setting, battery changes and regular 
checks) 
According to the experimental design (please see the Chapter 5 for details) chronic stimulation 
was carried out by attaching and securing the DBS device (for full details see Chapter 5) to the 
headstage on the rats’ skull. But first, stimulation frequency and pulse width were 
programmed in C on a Sony Vaio laptop using the software IAR Embedded Workbench IDE (IAR 
Systems Ltd., Chalgrove, UK) and uploaded onto the DBS device connecting it to the computer 
using a debug-interface module (MSP-FETU430IF, Texas Instruments, Dallas, USA) and a 
custom-built reprogrammer circuit. The stimulation intensity was then manually set to the 
lowest point possible (~30 µA) by tightening the appropriate trimmer on the outside of the 
device, reading the emitted intensity off by means of a connected oscilloscope (TDS 3032, 
Tektronix, Beaverton, USA). Then, the threshold for stimulation-induced behavioural side-
effects was determined for each rat individually in a step-wise procedure. Care was taken to 
make each stimulation epoch no longer than approximately 20 sec with at least 1 min in 
between. The device was attached to the headstage and only loosely secured to reduce the 
time spent manipulating the headstage. The rat was then sat into an empty cage bottom, then 
the device was switched on and the rat closely observed. Typical side effects were slowing or 
an arrest of exploratory behaviour up to “freezing” and “staring”, erected whiskers and/or 
ears. If no side effect was seen, the device was detached, the intensity increased by 20 µA and 
re-attached to the headstage and the test repeated. Once one or several of the above 
described side effects were detected the intensity was reduced by 20% of this side effect 
inducing intensity and re-tested on the animal. In the case of continued side effects the 
intensity was further reduced. Once satisfactory stimulation intensity was determined the 
device was wrapped in parafilm to protect it from dirt and water, securely fixed onto the 
headstage and switched on. The rat was then returned into its homecage. 
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Red LEDs on the device corresponding to the connected electrodes indicated functioning of 
the device. The devices were checked at least twice a day. Every other day the battery of the 
device was changed because preceding tests showed that at similar stimulation settings a 
stable energy supply could be guaranteed for 48h. Battery changes were quick and offered a 
chance to check the stimulation settings when the device was briefly detached from the rat’s 
head. This procedure took no longer than 2-3 min.  
4.7. L-DOPA injections and scoring of abnormal involuntary movements  
Before the start of DBS and after completion of CW testing under the condition of chronic 
stimulation the rats received injections of L-DOPA (see Chapter 5 for full details). Immediately 
after the injection they were returned to their homecage but kept under close observation 
(with the top of the cage removed) to classify and quantify L-DOPA induced abnormal 
involuntary movements (AIMs). Ratings of behaviour were made using a modified version of 
the Creese-Iversen scale (Creese and Iversen, 1973). Behaviour was rated as follows: 1: normal 
(absence of any AIMs); 2: active with bursts of stereotyped sniffing and rearing; 3: continuous 
stereotyped sniffing and rearing over the entire area of the cage; 4: stereotyped behaviour in 
one place (for example up and down head movements, crossing and lifting of the forelegs); 5: 
additional bursts of stereotyped licking or gnawing of paws, legs or sides (self-mutilation) 
and/or gnawing of the cage; 6: continuous licking and/or gnawing. For each animal the time 
was noted for which they displayed these 6 different stages of AIMs. Care was taken to check 
for behavioural changes every 5 min at minimum. In case of self-mutilation rats were offered 
an alternative to gnaw on (wooden chewing stick or a piece of cloth) and in very severe cases 
rats were removed from the cage and held by the observer to prevent further biting. No rats 
came to any permanent harm and were all able to move freely following instances of self-
biting. 
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Thirty min after the L-DOPA injection the rats were supposed to be tested on the CW. Sham 
operated rats had no difficulties performing acceptable runs and were tested as described 
above. DA depleted animals had difficulties of different degrees to cross the walkway because 
of the AIMs. After 3 unsuccessful attempts or crossings that were obviously influenced by AIMs 
(like stopping for licking and gnawing or sideway walking while attempting to turn around) the 
rat was returned to its homecage for further timing and rating of the stereotypies until this 
AIM inducing effect of the L-DOPA had worn off. Typically animals turned to their food bowls 
then and started eating undisturbedly.  
5. Histological procedures 
5.1. Perfusions 
At the end of behavioural testing the rats were given a lethal intra-peritoneal injection of 200 
mg/ml sodium pentobarbitone (0.6 – 0.8 ml/rat Euthatal, Merial Animal Health Ltd., Harlow, 
UK). Once deeply anaesthetised they were perfused transcardially with 0.1% phosphate 
buffered saline followed by a fixative (4% paraformaldehyde in 0.1M phosphate buffer) until 
fixed (approximately 350ml). Brains were left to post-fix in situ for at least 60 min before 
removal and subsequent storage in 20% sucrose solution in 0.1 M PB) at approximately 4: C.   
5.2. Sectioning 
Coronal 30 µm sections were cut in a series of 1:6 on a freezing microtome and separated into 
striatum, SN and PPTg before being transferred into a cryoprotectant (ethylene glycol and 
sucrose solution) for storage at - 20 C.  
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5.3. Immunohistochemical staining 
5.3.1. Stains performed  
Three different stains were performed in order to assess the regions of interest: (1) Choline 
Acetyltransferase (ChAT): Sections taken from the upper brainstem containing the PPTg were 
stained for ChAT, an enzyme expressed in nuclei and terminals of cholinergic neurons 
responsible for the synthesis of acetylcholine (ACh), to assess the number of surviving 
cholinergic neurons in this structure in case of PPTg lesioned animals and to aid the 
determination of electrode placement in brains of rats from the DBS studies. (2) Neuronal 
nuclei (NeuN): PPTg sections were furthermore stained with NeuN, a nuclear antigen that 
binds to neuron-specific nuclear protein in neuronal nuclei and to a lesser extent the 
cytoplasm of neuronal cells and is therefore commonly used to non-selectively mark neurons. 
Here, NeuN stains were used to assess the extent of ibotenic acid lesions in the PPTg and 
placement and track lesion sizes of implanted electrodes where applicable. (3) Tyrosine 
hydroxylase/ CalbindinD28k (TH/Cb): On midbrain sections containing the SN a double stain was 
performed staining for TH, an enzyme responsible for the synthesis of the DA precursor L-
DOPA, in order to mark DA containing neurons and the calcium binding protein Cb. Within the 
midbrain dopaminergic cell groups Cb is heterogeneously distributed and is not expressed in 
DA containing neurons in the SNc. However, neurons in the SNm, SNl, and most importantly 
the VTA, including the parabrachial pigmented nucleus (PBP) and paranigral nucleus (PN), and 
the neuropil of the SNr stain positively for anti-calbindinD28k (McRitchie et al., 1996). This 
differentiated staining helps to distinguish between DA neurons of the SNc and VTA/ PBP/ PN.  
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5.3.2. Protocols 
Chat 
Immunohistochemistry was performed on free floating sections at room temperature. Rinsing 
and incubation was aided by careful agitation on a horizontal shaker. The sections were 
removed from the cryoprotectant and washed 3 times for 3 min in phosphate buffered saline 
solution (PBS). They were then incubated for 45 min in blocking solution (79.9 % PBS; 20 % 
rabbit serum; 0.1% of 10% Trition X-100 [diluted in distilled water]) and subsequently rinsed in 
PBS for 3 min before being incubated with the primary antibody overnight (approximately 
16h). The goat derived polyclonal anti-ChAT (Merck Millipore, Billerica, MA, USA) was diluted 
in an antibody diluting solution (ADS) consisting of 98.9% PBS, 1% rabbit serum and 0.1% 
Triton x-100 at a concentration of 1:5000. For incubation with the secondary antibody sections 
were first rinsed (5 times for 3 min) and then transferred to a biotinylated secondary antibody 
solution (anti-goat IgG, 1:200 in ADS) and incubated for 90 min. After further washing (as 
before) they were incubated in avidin-biotin complex (ABC solution; each, avidin and 
biotinylated horseradish peroxidase reagent, diluted 1:50 in ADS) for 45 min. IgG, avidin and 
biotinylated horseradish peroxidase reagent derived from the Vector Labs Elite ABC kit (Vector 
Laboratories, Peterborough, UK). Finally, after washing, the sections were stained with 3,3 
diaminobenzidine tetrahydrochloride (Sigma Fast DAB; Sigma-Aldrich, Gillingham, UK) for 
approximately 12 min and then washed thoroughly. ChAT stained sections were then mounted 
on glass microscope slides, cleared in Xylene and coverslipped using DPX mounting medium 
(Sigma-Aldrich, Gillingham, UK).  
NeuN/Cresyl protocol 
The protocol for NeuN stains is consistent with the protocol described above. The serum used 
for blocking solution and antibody diluent was normal goat serum and the monoclonal 
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antibody was mouse derived (Merck Millipore, Billerica, MA, USA) and diluted in ADS to a 
concentration of 1:20000. The secondary antibody anti-mouse IgG was taken from the 
corresponding Vector Labs Elite ABC kit (Vector Laboratories, Peterborough, UK). Sections 
were mounted on gelatine coated glass slides and subsequently counterstained with cresyl-
violet. Before conducting this procedure care was taken to completely dry out the sections by 
leaving the slides in a paraformaldehyde gas bath in a dessicator overnight. The slides were 
then cleared in xylene for 3 min and rehydrated through two changes of graded alcohol (100% 
and 50% in distilled water) to water. They were then placed in cresyl violet stain for 30-60 sec 
(depending on the strength of the stain) and then thoroughly rinsed in running tab water for 5 
min before getting dehydrated through graded alcohol and cleared in xylene. They were then 
coverslipped as described above.  
TH/Cb protocol 
For the TH/Cb double stain the protocol was slightly modified. The Cb stain was performed 
first, following the same protocol as described above for ChAT. The monoclonal anti-
calbindinD28k was mouse derived (Sigma-Aldrich, Gillingham, UK) and diluted to a final 
concentration of 1:800. Blocking solution and ADS contained normal goat serum. Anti-mouse 
IgG and the avidin-biotin complex were made from the Vector Labs Elite ABC kit and the 
sections were finally stained using DAB. After a thorough wash the sections were pre-treated 
with avidin (using a concentration of 1:5 in a blocking solution made with goat serum) for 15 
min followed by biotin (1:5 in ADS made with goat serum) to block remaining biotin sites on 
the avidin. The sections were then ready for the TH stain. Anti-TH was a monoclonal mouse 
derived antibody (Merck Millipore, Billerica, MA, USA) used at a concentration of 1:25000 
diluted in goat serum based ADS with which the sections were incubated overnight. The 
secondary antibody and avidin-biotin complex were made up with the mouse version of the 
Vector Labs Elite ABC kit. Here the incubation times were shorter than before: 30 min for IgG 
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and 30 min for ABC. Finally the sections were stained with a slate gray peroxidise substrate 
(ImmPACT SG, Vector Laboratories, Peterborough, UK) to reveal the TH + cells. The double 
stained sections were then mounted, dried, cleared and coverslipped as described above. 
6. Histological analysis 
6.1. Lesion assessment 
6.1.1. NeuN+ 
The extent of non-selective damage caused by ibotenic acid in and around the PPTg was 
assessed on the NeuN/Cresyl stained sections judged by the lack of stained neuronal nuclei. To 
this purpose sections were examined under a light microscope (Leica DM LB2) connected to a 
desktop computer by a Leica camera (type DF320: Leica Microsystems, Milton Keynes, UK) at a 
magnification of x 1.6. All available sections were inspected under the microscope. The lesion 
outline was then drawn on selected schematics from the Paxinos and Watson rat brain atlas 
(Paxinos and Watson, 2005) representing sections just rostrally to the PPTg (including the SN), 
anterior PPTg, posterior PPTg and sections caudally to the PPTg. Ten schematics were chosen 
taking care to pick a relatively even distribution of sections on the rostro-caudal axis covering 
the area 3.12 mm from IAL to – 0.72 mm from IAL. Those sections that corresponded best to 
the chosen schematics were photographed and the outline of the lesion shown by the stain 
transferred onto the schematic (section choice was based on the shape of the section, 
anatomical landmarks and the distribution of cholinergic neurons on corresponding sections 
on ChAT stained sections). Lesions were rated on a scale from 0 to 4 (0 = no lesion of the PPTg, 
1 = small/ partial lesion of the PPTg, 2 = partial to full lesion of the PPTg, 3 = fully lesioned 
PPTg, 4 = extensive lesion covering the PPTg and surrounding tissue). Animals that had either a 
lack of lesion in the PPTg on at least one side (0; PPTg not hit) or lesions that were so 
extensive, that they damaged SN (4 on both sides) were excluded.  
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6.1.2. Chat+ counting 
Additionally to the lesion extent the number of surviving cholinergic neurons was also 
quantified. Cholinergic neurons have proven to be surprisingly resistant to the excitotoxin 
ibotenic acid so for the study conducted to assess the behavioural effect of full lesions of the 
PPTg it was of interest to assess the number of possibly remaining ChAT+ neurons. In the case 
of the PD models that included partial PPTg lesions the number of remaining and presumably 
functioning cholinergic neurons was required to compare these to the degree of PPTg 
degeneration reported for PD, which in the human neurological literature is usually quantified 
in terms of degeneration of cholinergic cells. For this purpose each ChAT+ stained section was 
photographed with the camera-microscope set up as described above at a total magnification 
of x10. These pictures were then opened in Image-J (U.S. National Institutes of Health, 
Bethesda, Maryland, USA), an analysis programme that assisted the manual counting of ChAT+ 
PPTg neurons. The total number of surviving cholinergic neurons of the anterior, the posterior 
and the PPTg as a whole were expressed as a percentage of the average total cell count taken 
from sham lesioned animals. Here it needs to be pointed out that this cell count cannot be 
considered an exact count of present neurons but rather a representative estimate. In the case 
of brains with track lesions from the implanted electrodes the presented cell count reflects the 
number of surviving cells of the non-targeted part of the PPTg (anterior or posterior 
respectively).  
6.1.3. TH+ counting 
All TH+ neurons within the dorsal and ventral tier of substantia nigra part compacta (SNc; SNcd 
and SNcv respectively), substantia nigra pars medialis (SNm) and substantia nigra pars lateralis 
(SNl) were included into the count. The additional Cb stain was performed in order to 
distinguish DA containing neurons of the SN from VTA (including PBP) neurons. In the case of 
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SNc this technique makes separation relatively easy since the SNc does not contain Cb. When 
in doubt – where neurons are densely packed or interdigitated – the triangular shape of the 
SNc neurons with ventrally directed processes distinguished them from the rather elongated 
neurons of the PBP which have a mediolateral orientation. SNl can also contain Cb, here 
however the distribution and orientation of the neurons at the dorsolateral pole of the SN 
allows a confident classification. SNm also contains Cb which makes a separation from VTA/PN 
neurons more difficult. Here the shape of the SNm cluster, SNm neurons (larger than PN) and 
position had to be determining factors for classification. Identification of these subsections 
was aided by the chemoarchitectonic atlas of the rat brain (Paxinos et al., 2009). Counting was 
performed at a 20 x magnification using a handheld cell counter starting with the first 
appearance of TH+ cells caudally from the STN in control groups and non-DA-depleted animals 
and with corresponding sections in the PD models [approximately at - 4.56 mm from Bregma 
(Paxinos and Watson, 2005)], counting through to the last sections showing DA neurons at 
around - 6.60 mm from Bregma. Cell counts of all sections were added and the total expressed 
as a percentage of the average total cell count of sham operated rats.  
Please note: Due to time constraints no TH staining was conducted to assess the density of 
striatal DA, nor NeuN staining to check for non-dopaminergic damage. This had been done 
previously (Gut, 2009) and it had been shown that the track damage of the injecting cannulae 
was negligible or non-existant, that there was no non-dopaminergic damage in the striatum 
and that profound loss DA terminal density was focused on but not restricted to the 
dorsolateral striatum. 
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6.2. Electrode placement 
Electrode tip location in the DBS experiments was determined by examining electrode track 
evidence on ChAT+ stained and counterchecked on NeuN/Cresyl stained sections where there 
were not enough ChAT+ neurons visible to make a judgement. 
7. Behavioural data analysis 
All statistical analysis was performed using SPSS version 21 (IBM Corp., Armon, NY, USA). 
Details of specific tests performed on the according data are given in each chapter. All effects 
were considered statistically significant when p ≤ 0.05. 
7.1. CW data labelling 
Using the CatWalk 7.1 all paw prints had to be labelled manually. For this purpose the first 3 
runs that fulfilled the above criteria of all runs recorded of any particular day of each animal 
were chosen for further processing. Under normal conditions the video clips start with the 
animal already in full motion (start of recording triggered by the rat passing a pre-determined 
“start box” on the walkway) and gets stopped automatically at the end of the runway (ideally 
before the animal slows down the run). However, occasionally those clear start and endpoints 
were not given – for example when the red LEDs of the stimulation device triggered the 
recording before the rat started to cross the walkway or when the rats (mostly parkinsonian 
rats) stopped a few centimetres before the end of the glass plate (i.e. having crossed the 
“finish line” but not being far enough out of the pre-determined “finish box” to trigger the 
automated stop of the recording). In those cases the video clips were cut manually. Some DA 
depleted rats showed occasional to severe slowing down or freezing. Runs were included 
when movement, however slow, was still detectable on the video clip. When rats froze 
completely during the run the data from the run was discarded and the trial repeated. 
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7.2. CW data analysis 
Please refer to the individual chapters for details on the statistical tests used. In general the 
data were explored by performing mixed, univariate and/or repeated measures ANOVAs with 
Tukey HSD corrected post hoc tests where appropriate. Where the data were heterogeneous 
the Huynh-Feldt correction was applied when epsilon > 0.75 and Greenhouse-Geisser 
correction when epsilon < 0.75. 
7.3. FOG 
The occurrence of FOG was expressed as a frequency count and presented as the percentage 
of the number of tests run in each experimental group per condition (number of rats x days of 
testing). To test for a significant association between group affiliation and occurrence of 
freezing chi-squared tests were performed for each experimental condition. 
7.4. Dyskinesias/Stereotypies 
The severity of L-DOPA induced dyskinesias was assessed by determining the time for which 
the rats displayed AIMs in form of L-DOPA induced stereotypies of each level according to the 
modified Creese-Iversen scale as described above and presented in minutes. Mixed ANOVAs 
were performed on these data and further investigated by testing the simple main effects for 
groups (univariate ANOVA) and mixed ANOVAs for individual scores with condition (L-DOPA 
administration with or without DBS) as within and group as between factor. 
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  Chapter 3 The effect of full lesions of the PPTg on gait 
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1. Introduction 
As discussed in Chapter 1 the question regarding the role of the PPTg in the generation of 
locomotion is an important one in light of the continued attempts to target this structure with 
DBS in order to alleviate parkinsonian symptoms [see, among others, (Ballanger et al., 2009; 
Mazzone et al., 2005; Pahapill and Lozano, 2000; Plaha and Gill, 2005; Stefani et al., 2007). The 
literature offers differing views on this question stretching from the finding that an intact PPTg 
is not necessary to generate normal locomotor behaviour (Alderson et al., 2003; Homs-Ormo 
et al., 2003; Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 1994; Steiniger and Kretschmer, 
2004; Winn, 2006) to the notion that the PPTg can be considered a movement generator 
(Garcia-Rill, 1991; Pahapill and Lozano, 2000). Anatomically the PPTg is in a strategic position 
for an involvement in aspects of motor control. It is reciprocally connected with the BG and 
has descending projections that mainly target lower brainstem structures and targets the 
medulla and spinal cord (Martinez-Gonzalez et al., 2011; Mena-Segovia et al., 2004). Early 
experiments in decerebrate cats and rats showed that stimulation of the PPTg induced motor 
responses in form of stepping on a treadmill, consistent with descending influence/control 
over motor regions (Garcia-Rill et al., 1987; Skinner, Kinjo, Henderson, et al., 1990). However, 
stimulating other structures in the brainstem produces the same effect (Garcia-Rill, 1991). A 
further argument for questioning an essential role in motor production is the fact that rats 
with PPTg lesions do not show deficits in spontaneous locomotor behaviour. When tested in 
photocell cages or in the open field they do not behave differently to control rats; in operant 
chambers they make just as fast or frequent lever presses, however incorrectly; and in mazes 
they do not show reduced speed when moving about (Alderson et al., 2003; Dellu et al., 1991; 
Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 1994; Keating and Winn, 2002; Olmstead and 
Franklin, 1994; Steiniger and Kretschmer, 2004; Swerdlow and Koob, 1987; Taylor et al., 2004; 
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D. I. Wilson et al., 2009). It is unquestionable: the PPTg is not necessary for spontaneous co-
ordinated locomotion. There are changes in the locomotor response to psychomotor 
stimulants after PPTg lesions (Alderson et al., 2003) but this reflects its relation to 
corticostriatal circuitry. For example, repeated administration of d-amphetamine results in a 
progressive increase in locomotor activity. Lesions of the PPTg did not change the effect of the 
drug on the first day, but attenuated sensitisation, probably as a result of loss of ascending 
projections of the PPTg to midbrain DA neurons in VTA and SN. By contrast, experimental work 
on non-human primates has shown that bilateral PPTg lesions caused akinesia and hypertonia 
(Kojima et al., 1997; Munro-Davies et al., 1999). However, the use of kainic acid in those 
studies most likely caused very big lesions comprising many more structures than just the PPTg 
(Winn, 2008). Furthermore behavioural testing took place during the immediate post-surgical 
recovery period so that surgery related deficits cannot be excluded (Peterson and Moore, 
1980; Winn, 2006).   
To date the effect of PPTg lesions on motor activity in rodents has focused primarily on 
spontaneous and general locomotor behaviour measured as beam breaks and rearing activity 
in locomotor boxes, latencies to run down an arm in a maze or to collect pellets in an operant 
box. If the PPTg is to be a target for DBS in patients it is necessary to take a more refined 
approach and to examine individual gait parameters in animals.  
To this purpose the gait of rats with bilateral lesions of anterior and posterior PPTg were 
tested the same way as the gait of PD rodents. The same gait parameters that have shown 
deficits in PD models (Gut, 2009) were examined for similar deficits in rats bearing lesions of 
the whole PPTg.  
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2. Methods 
2.1. Subjects 
Twenty adult male Lister-Hooded rats (Harlan Olac Ltd, Bicester, UK) were used. At the start of 
CW training their mean weight was 333g (range 312 – 349g). All animals were put on food 
control at that point as described in the General Methods. All animals reached the target 
weight of 330g for the first surgery (mean weight 336g; range 331 – 350g). The mean weight 
during pre-surgical baseline testing was 336g (range 325 – 342g) and a stable mean weight of 
335g with a small range of 320 – 341g could be maintained over the entire period of the 
experiment. For further details on housing please refer to the General Methods. 
2.2. Experimental protocol 
The experiment followed the timeline presented in Figure 3.1. In brief, the rats were trained 
on the CW for 10 days. All rats were proficient at that point to deliver acceptable runs on the 
CW. Over the following 4 days their pre-surgical performance was recorded. They then 
underwent 2 consecutive surgeries, separated by a week, during which they received unilateral 
PPTg lesions. After a week of recovery the rats were then re-exposed to the CW on the first 
day and then tested daily for 7 days. 
 
 Figure 3.1. Experimental design. At the start of the experiment all animals were trained for 10 days on 
the Noldus CatWalk. They were then tested for 4 days to obtain a pre-surgical baseline. Rats then 
underwent PPTg lesion surgeries. Seven days after the last surgery they were then re-tested on the CW. 
For more details please refer to the text. 
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2.3. Bilateral lesions of anterior and posterior PPTg 
Surgery followed the protocol as described in the General Methods. In 2 separate surgeries the 
PPTg was bilaterally lesioned by microinfusions of ibotenic acid into the anterior and posterior 
PPTg at the following coordinates (in mm): anterior PPTg: + 0.6 from IAL, ± 2.0 from midline 
and - 7.0 from dura; posterior PPTg: - 0.8 from IAL, ± 1.9 from midline and - 6.5 from dura. 
Infusions were always made anterior first but the order of infusions regarding the choice of 
side was counterbalanced. Initially rats were infused with 180 nl of 0.12M ibotenic acid per 
infusion site. Since five out of the first six rats receiving this concentration of the toxin did not 
survive the recovery period the concentration was then dropped to 0.1M (at 180 nl) – 1 out of 
2 rats survived – and then to 0.09M maintaining the same volume, which proved to be a 
concentration with a better survival rate. Control rats received infusions of vehicle only (here: 
PB) into the same sites. At the end of surgery rats were treated with 1-1.5 ml of Hartmann’s 
solution (i.p.) to account for the lack of fluid intake during the time of surgery. Furthermore, 
they also received an i.p. injection of 0.2 ml Diazepam to reduce the risk of injury due to the 
immediate effect of the excitotoxin acting on the targeted brain stem sites.  
2.4. Immediate post-surgery recovery period 
Ibotenic acid has agonist activity at NMDA receptors (Zinkand et al., 1992) causing 
excitotoxicity by increasing the entry of calcium ions into neurons which will ultimately lead to 
the neuronal death. Initially, however, it causes hyperactivity resulting in a problematic post-
surgery recovery that may lead to injuries of the animals or fatalities. If rats survive the initial 6 
to 12h (mainly depending on the concentration of the toxin) they show no signs of a 
compromised long-term recovery such as pain or discomfort and appear rather normal-
behaving. In the short term recovering rats show in general fit-like tremors that last several 
seconds followed by whole body rotation (“barrel rolling”). The lesions affect respiratory 
control in the brainstem. During those tremors the animals stop breathing which is then 
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followed by continuous hyperventilation. This seems to cause a build-up of fluids in the lungs 
which ultimately is often the reason for death during the subsequent stage of recovery, during 
which the fits cease and the animal’s breathing becomes very flat. Several measures have been 
taken to reduce injuries and fatalities: The recovery cages were padded with “bubble wrap 
paper”. This not only prevented injuries but also appeared to decrease the number of fits. Also 
the rats were held with the head elevated to prevent significant fluid build-up in the lungs. 
When the breathing rate became alarmingly low breathing was tried to be stimulated by giving 
short whiffs of CO2 to stimulate the breathing reflex. If this did not help and breathing did not 
improve the rat was given an intramuscular injection of doxapram hydrochloride (Dopram, 
0.5ml/1 kg), a respiratory stimulant. All these measures were approved or instructed by the 
named vet. Ultimately, the reduction of toxin concentration was the most effective measure to 
increase the likelihood of survival.  
2.5. Training and testing on the CW 
Rats were trained for 10 days prior to baseline testing and surgery and tested as described in 
the General Methods. The order of rats trained and tested was randomised.  
2.6. Gait parameters 
The following gait parameters were examined: BOS, swing speed, stride length and duty cycle 
of both front and hind legs, print position of ipsilateral paws and the support formula of 
diagonal pairs of paws and three paws. For details on the gait parameters please see the 
General Methods. 
2.7. Lesion assessment 
The area of the PPTg was histologically assessed for overall neuronal damage and cholinergic 
cell loss following the methods as described in the General Methods. In brief, at the end of 
behavioural testing rats were transcardially perfused with a fixative, the brains removed and 
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stored in sucrose solution until they sank. A series of 1:6 coronal 30 µm sections was cut on a 
freezing microtome and immunohistochemically stained for NeuN and ChAT, mounted on glass 
slides and examined under a light microscope. Overall neuronal damage was assessed visually 
on the NeuN/Cresyl stained sections and rated on a scale from 0 (no lesion) to 4 (extensive 
lesion). Lesions were accepted and rats included into the analysis when at least one side was 
rated a 3 (PPTg fully lesioned) and the other side not less than a 2 (partially to fully lesioned). 
Cholinergic cell survival was assessed by software assisted counts of ChAT+ neurons.  
2.8. CW data analysis 
In order to test the behavioural data for an effect of PPTg lesions on normal gait, differences 
between the lesion and sham group were explored performing mixed ANOVAs across 
condition (pre and post-surgery condition, within subject factor) and between groups (PPTg 
lesion and sham, between subjects factor) and further examined for a simple main effect on 
the post-surgery data performing an univariate ANOVA between groups. Preceding this, the 
data were assessed for pre-existing differences (univariate ANOVA between groups) and for 
differences between all 7 post-surgery testing days (repeated measures ANOVA across days) in 
order to rule out a time effect and pool the data. Normality of the data was identified by the 
Shapiro-Wilk test and homogeneity of variance by the Leven’s test. The handling of violations 
of these assumptions is reported in the results section when they occurred. All tests were 
conducted using SPSS version 21 (IBM Corp., Armon, NY, USA) and results were considered 
statistically significant when p ≤ 0.05.  
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3. Results 
3.1. Recovery 
In the past the same concentration of toxin purchased from the same supplier, prepared 
following the same protocol and injected using the same or very similar coordinates produced 
a mortality rate that was substantial but within an acceptable margin. Here, the toxin was 
associated with a considerably worse survival rate. As described above during the immediate 
recovery period the animals showed fits, barrel rolling, hyperventilation which was presumably 
causing a build-up of fluid which lead to death in 8 cases. Of the several measures taken to 
reduce the fatality rate the most effective (apart from lowering the concentration of the toxin) 
was to keep the animals as quiet as possible, which included holding them during the critical 
period where the fitting occurred (starting approximately 60 min after surgery lasting for up to 
2.5h, but this can be very idiosyncratic). This reduced injuries and also seemed (subjectively) to 
decrease fitting. Close monitoring of the breathing rate and holding them upright to avoid the 
lungs filling up with fluids seemed to help as well. Injections of doxapram hydrochloride were 
not effective, neither was CO2 to stimulate breathing.  
3.2. Histological analysis 
The presented results are obtained from a total of 20 rats, of which 16 underwent surgery for 
bilateral PPTg lesions and 4 received control infusions of vehicle. Due to a suboptimal 
perfusion and a consequently faint stain one rat of the control group was not included in the 
histological analysis; however the behavioural data was considered for the other analyses.    
As noted above the first used concentration of ibotenic acid proved to be too high to 
guarantee an acceptable survival rate. Accordingly, a total of 7 rats did not survive the first 
unilateral infusion of ibotenate (n = 5 died after a concentration of 0.12 M, n = 1 after 0.1 M 
ibotenate and n = 1 after 0.09M ibotenate) and a further animal died after the second 
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unilateral infusion of 0.09M ibotenate. Hence, n = 8 rats constituted the final group of 
bilaterally PPTg lesioned rats (n = 1: 0.12M [first side] + 0.09M [second side];   n = 1: 0.1M [first 
side] + 0.09M [second side] and n = 6:  0.09M both sides) and n = 4 rats were in the sham 
group. 
After histological analysis 2 rats were excluded from all analysis due to very extensive lesions 
not only covering the PPTg area but also the surrounding tissue, most importantly damaging 
the SN (n = 1; rat that survived the high concentration of 0.12M ibotenate) and due to an 
infusion having been placed too laterally and therefore missing the PPTg (n = 1). The remaining 
6 brains therefore were all (bar one side) lesioned with a concentration of 0.09M  and showed 
at least on one side a lesion that covered the PPTg fully along the rostro-caudal axis and the 
second side was at a minimum partially to fully lesioned Figure 3.2.). The single side lesioned 
with 0.10M ibotenate was not distinguishable from the others.  
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Figure 3.2. Lesion size for each rat of the PPTg lesion group rated based on NeuN+/Cresyl stained brain 
sections. Lesions were rated on a scale from 0 to 4 (0 = no lesion of the PPTg, 1 = small/ partial lesion of 
the PPTg, 2 = partial to full lesion of the PPTg, 3 = fully lesioned PPTg, 4 = extensive lesion covering the 
PPTg and surrounding tissue). For rat 3 LHS and RHS both scored a 4 (square covering diamond).  
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Figure 3.3. Representation of lesion extension along the rostro-caudal axis after ibotenic acid infusion 
on a selection of NeuN+/Cresyl stained sections. The position of the schematics (adapted from Paxinos 
and Watson, 2005) on the rostro-caudal axis is represented as the distance from the interaural line (IAL; 
mm). Sections IAL + 2.88 mm through to IAL + 1.68 mm were identified as sections containing anterior 
PPTg neurons (identified by PPTg cholinergic neurons in shams and partially lesioned rats) and those 
from IAL + 1.08 mm to IAL + 0.36 mm represent sections containing posterior PPTg. 
anterior  
PPTg 
posterior  
PPTg 
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Figure 3.4. Representative histological photomicrographs of lesions in anterior and posterior PPTg of 
rats bearing full lesions (C,D,G,H) and sham controls (A,B,E,F). A-D: NeuN/Cresyl stained; E-H: ChAT 
stained. 
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Of the remaining group of n = 6 rats with bilateral PPTg lesions a mean of 69% of ChAT+ PPTg 
neurons were destroyed (range 50% to 93%). Of those rats 1 unilateral lesion was caused by 
0.1M ibotenate (instead of the 0.09M ibotenate used for all other rats) but the second side of 
the same animal by 0.09M ibotenate. Despite this difference the rat was included into the 
behavioural analysis because histological analysis of the lesion size and ChAT+ count does not 
allow to differentiate this brain from the others (mean overall ChAT+ neuron loss = 70%; 
ChAT+ neuron loss on the side that received the differing toxin concentration = 78%). The 
percentage of surviving cholinergic PPTg neurons is shown in Figure 3.5.  
 
 
 
 
Univariate ANOVAs of the raw cell count of surviving ChAT+ neurons confirm that the lesion 
group had significantly fewer ChAT+ neurons than sham controls on the left-hand side (F1,8 = 
65.939 p < 0.001; ƞ2p = 0.892), right-hand side (F1,8 = 42.393 p < 0.001; ƞ2p = 0.841) and 
accordingly when combining both sides to give an overall ChAT+ count (F1,8 = 71.670 p < 0.001; 
ƞ2p = 0.900). 
Figure 3.5. PPTg ChAT+ count as the percentage of the mean count in sham lesioned rats.                
*** indicates a significant difference between PPTg lesion group and shams with p ≤ 0.001; LHS = 
left-hand side; RHS = right-hand side; brain = overall cell count left and right combined. 
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3.3. Behavioural results 
 
Based on the debate about whether or not PPTg lesions can cause motor problems as 
described in the introduction to this experiment, the focus here was on a possible deficit on 
individual gait parameters after PPTg lesions. In a long series of experiments no general 
locomotor deficits could be shown in rodents bearing PPTg lesions. However, effects such as 
hypo- and akinetic states and postural disturbances after PPTg lesions were described 
elsewhere. Consequently, the question here is whether deficits are detectable in PPTg lesioned 
rats on a more detailed level such as in individual gait parameters. In order to assess different 
aspects of gait – gait stability, speed, stride and coordination – the data were analysed 
individually and presented as such in the following. Normality (as examined with the Shapiro-
Wilk test) was given on most of the test days. On rare occasions the data did not follow a 
normal distribution. Given this infrequence these seldom violations were tolerated in the 
analyses reported below. For all analysed parameters a pre-existing difference between groups 
could be ruled out (see Supplementary Table 3.1. for details). Repeated measures of the post-
surgery data for the lesion group and the sham group showed in general no day effect. On 
those few occasions where there was a significant effect of day Bonferroni corrected planned 
pairwise comparisons did not reveal any significant differences between the individual testing 
Figure 3.6. Illustration of a rat’s footfall on the CW during pre-surgical baseline testing. The animal is 
crossing the walkway from the right to the left-hand side. Paws of the right-hand side are in green, paws 
of the left-hand side in red. Darker shades depict the hindpaws.   
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days. Because there was no clear effect of day, it was regarded as acceptable to pool data over 
days.  (Data not shown)  
3.3.1. Gait stability 
BOS – The mean values of BOS (and other parameters) are presented in Figure 3.7. This is the 
only parameter where a mixed ANOVA showed a significant interaction of condition (pre vs 
post surgery) and group (F1,8 = 15.262 p = 0.005; ƞ2p = 0.656) and a significant effect of surgery 
(F1,8 = 10.258 p = 0.013; ƞ2p = 0.562) on BOS of the front limbs but no effect of group (F1,8 = 
0.299 p = 0.600). Exploring the simple main effect of group on the post-surgery data confirms 
the absence of a group difference (F1,8 = 2.224 p = 0.174). The effect of surgery lies in the sham 
group. Their stance was significantly narrower after surgery (F1,3 = 13.98 p = 0.033; ƞ2p = 0.823), 
a training effect which the lesion group did not show (F1,5 = 0.445 p = 0.534). A narrower 
stance, shorter duty cycles, increased swing speed and longer strides were observed in shams 
on several occasions during this project (and in the preceding Master’s project  (Gut, 2009) ) 
after a prolonged period of time when the rats had a lot of exposure to the CW. These changes 
are opposite to deficits displayed by parkinsonian rats and are therefore considered 
improvements. Regarding the hind limbs both groups showed a significantly narrower BOS 
after surgery (lesion group: F1,5 = 32.148 p = 0.002; ƞ2p = 0.865; sham group F1,3 = 364.079 p < 
0.001; ƞ2p = 0.992); the groups did not differ from each other (F1,8 = 0.144 p = 0.714).  
Duty Cycle – a repeated measures ANOVA of the duty cycle of the hind limbs in the lesion 
group revealed a significant effect, showing that the duration of contact with the walkway 
decreased after surgery, representing an adaptation to the task rather than an effect of the 
lesion (F1,5 = 9.099 p = 0.030; ƞ2p = 0.645). However, there were no differences between the 
groups regarding neither the duty cycle of the front limbs (F1,8 = 4.782 p = 0.060) nor the hind 
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limbs (F1,8 = 0.223 p = 0.650). The post-surgery data of the lesion group of the hind limb data 
was not normally distributed (p = 0.019).  
Support – The majority of the rats’ runs were supported by 2 legs at any given time. This 
percentage of diagonal support was decreased in the lesion group after surgery (F1,5 = 15.231 p 
= 0.011; ƞ2p = 0.753), but the two groups did not differ significantly from each other (F1,8 = 
0.003 p = 0.955). Similarly, the percentage of moments during a run when the rat was 
supported by 3 legs simultaneously was the same in both groups (F1,8 = 1.870 p = 0.209) and in 
neither of the groups was this affected by surgery (lesion group: F1,5 = 4.544 p = 0.086; sham 
group: F1,3 = 2.704 p = 0.199). An additional analysis of the use of 4 paws for support shows 
that the change observed in the lesion group regarding the diagonal support did not mean a 
worsening of gait – that is an increased need of support using more than 2 legs. Here, likewise, 
the groups did not differ from each other (F1,8 = 0.640 p = 0.447) nor were any of the groups 
affected by surgery (lesion group: F1,5 = 1.960 p = 0.220). 
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Figure 3.7. Performance on the CW – Parameters reflecting gait stability. Graphs show group means ± 
SEM of selected gait parameters; *** indicates a significant difference compared to pre surgery baseline 
with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. The changes in gait in both, lesion and 
sham group, indicate an improvement rather than a worsening of gait as the changes were opposite to 
what is observed in parkinsonian rats. Please refer to the text for details.  
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3.3.2. Speed 
Swing Speed – Repeated measures ANOVAs of the Swing Speed of front and hind limbs 
confirmed a slight reduction of the velocity of the legs during the swing phase in the lesion 
group (front: F1,5 = 6.707 p = 0.049; ƞ2p = 0.573; hind: F1,5 = 6.660 p = 0.049; ƞ2p = 0.571). 
However, this reduction was not enough to cause the groups to differ significantly from each 
other (front: F1,8 = 2.938 p = 0.125; hind: F1,8 = 2.745 p = 0.136).  
 
 
 
 
 
3.3.3. Stride 
Stride Length – Both groups showed an inceased stride length after surgery, another training 
effect, which, however, was only significant in the front limb data of the lesion group (F1,5 =  
7.476 p = 0.041; ƞ2p = 0.599). But most importantly lesion group and sham group did not 
significantly differ from each other (front: F1,8 = 3.606 p = 0.094; hind: F1,8 = 2.233 p = 0.173). 
 
Figure 3.8. Performance on the CW – Swing Speed. Graphs show group means ± SEM of selected gait 
parameters; * indicates a significant difference compared to pre surgery baseline with p ≤ 0.05. Please 
refer to the text for details.  
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3.3.4. Coordination 
Print position – The negative values of print position show that pre as well as post surgery, the 
rats placed their hind paws in front of the front paws during their runs. This distance between 
ipsilateral front and hind paws was further increased after surgery. Accordingly, repeated 
measures ANOVAs showed significant differences between pre and post surgery data of the 
left Print Position in the lesion and sham group (lesion group: F1,5 = 11.701 p = 0.019; ƞ2p = 
0.701; sham group: F1,3 = 11.260 p = 0.044; ƞ2p = 0.790)  and in the lesion group on the right 
hand side – the change in the sham group did not reach significance (lesion group: F1,5 = 10.911 
p = 0.021; 0.686; sham group: F1,3 = 5.687 p = 0.097). Given the similar development of the 
Print Position in both groups post surgery the groups did not differ from each other on either 
side (left: F1,8 = 4.619 p = 0.064; right: F1,8 = 0.226 p = 0.648). 
  
Figure 3.9. Performance on the CW – Stride Length. Graphs show group means ± SEM of selected gait 
parameters; * indicates a significant difference compared to pre surgery baseline with p ≤ 0.05. Please 
refer to the text for details. 
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4. Discussion 
In accordance with the experience of this and other labs the results show that complete and 
near-to-complete lesions of the PPTg do not cause gait deficits. So far it had been shown that 
similar lesions have no effect on more general motor behaviour as observed in the homecage, 
in locomotor test boxes or when performing tasks in the radial maze or operant boxes. Here it 
has been shown that this extends to individual gait parameters. It is important to make this 
addition given the association made by severals of gait deficits in PD and the PPTg.  
The animals’ gait did not differ in the individual parameters reflecting stability, speed, stride 
and coordination compared to sham lesioned animals. In some parameters changes could be 
observed compared to the pre surgery gait. These changes however do not reflect gait deficits 
as would be expected in parkinsonian animals or in fact PD patients (shortened stride, slower 
movement, increased stand) (Rodriguez-Oroz et al., 2009). On the contrary, they show 
improvement in those parameters. This needs to be interpreted as a training effect that the 
animals show when becoming more familiar with the CW. The same effect had already been 
Figure 3.10. Performance on the CW – Parameter reflecting coordination. Graphs show group means ± 
SEM of selected gait parameters; * indicates a significant difference compared to pre surgery baseline 
with   p ≤ 0.05. Please refer to the text for details. 
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observed previously in sham operated rats and even in parkinsonian rats when tested on the 
CW for more than 5 weeks (Gut, 2009). An extensive training before the first data collection 
before surgery and a re-training day after surgery were scheduled to counteract against this 
training effect, but it is clearly still apparent. Where this effect occurred it did so in both groups 
however, and on some occasions did not reach significance. However, on these occasions this 
was not indicative of group differences: in fact, the groups did not differ significantly from each 
other in any of the tested parameters.  
In all animals the lesions were extensive. Additional damage was found anterior to the PPTg 
extending into SN and/or posterior to the last section of the PPTg, invading the area in and 
around the lateral and medial parabrachial nucleus. Nevertheless these extensive lesions did 
not have an effect on the quantitative metrics of gait – contrary to the view that the PPTg is a 
critical  componant of locomotor circuitry and  in contrast to the reported effect of extensive 
lesions of the PPTg and surrounding areas in monkeys.  
In the General Introduction plausible explanations have been given to explain the notable 
differences between PPTg lesion studies in non-human primates and rodents in relation to 
motor behaviour. In a more recent paper the authors present data from PPTg lesioned 
macaques (without dopaminergic depletion) which displayed gait deficits in form of decreased 
step length and speed, postural changes, as well as rigidity in the extremities without affecting 
the global motor behaviour as observed in the home cage (Karachi et al., 2010). The authors 
describe those PPTg lesions as cholinergic lesions because they used the selective urotensin II 
– conjugated diphtheria toxin (Clark et al., 2007). However, the same concentration that has 
been used successfully in this lab to produce selective cholinergic lesions of the PPTg in 
rodents had no effect on gait in the macaque study. Only a concentration ten times stronger 
than that produced the reported effects. It is therefore very likely that the lesions made with 
this concentration were not selective but also destroyed other cell types in the PPTg and 
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surrounding area (as was observed in rodents with increasing concentrations of this toxin). 
Non-selective lesions would however be more comparable to the lesions produced in this 
rodent experiment. It is being argued that the organisation of the PPTg and its projections is 
different in rats compared to primates, one argument being the difference between the 
quadrupedal locomotion of rodents compared to the bipedal gait of monkeys (Alam et al., 
2011). Given the remarkable preservation of the PPTg through evolution with very similar 
structure and pattern of connections in all studied species from teleost fish to human [for 
reviews see (Martinez-Gonzalez et al., 2011; Winn, 2008) this argument does not appear 
strong enough to explain such fundamental differences. However, despite a well preserved 
anatomical structure, interspecies differences have been pointed out with respect to the 
connectivity between the PPTg and different BG nuclei (Alam et al., 2011). In this regard the 
rat PPTg receives mostly BG output from SN (Steininger et al., 1992) whereas in monkeys the 
PPTg receives most afferents from the GPm (DeVito and Anderson, 1982). Entopeduncular 
efferents in the rat only target a smaller area of the PPTg, if at all (Steininger et al., 1992). 
Afferent and efferent projections of SNr in return are more differentiated in the monkey than 
in the rat (Beckstead and Frankfurter, 1982). Nevertheless it remains unknown whether these 
differences can account for the apparently conflicting results found in lesion studies in rats and 
monkeys.  
The PPTg clearly has motor properties but these are not separable from its sensory and 
attentional properties and its role in reinforcement processes, which the literature has shown 
(i) anatomically and (ii) functionally: (i) The functional heterogeneity is reflected in its 
anatomical/neurochemical, electrophysiological heterogeneity and its widespread connectivity 
with a great variety of structures [see General Introduction and (Alderson et al., 2008; Ros et 
al., 2010)]. Martinez-Gonzalez et al have shown that ascending and descending motor 
connections of the PPTg arise largely from separate, though intermingled, neurons of different 
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neurochemical compositions (Martinez-Gonzalez et al., 2013). Given the different target sites 
of PPTg projections from individual cell groups within the PPTg and their possibility to 
contribute to the activation of different pathways, PPTg motor output has to be considered as 
highly differential making it inadvisable to speak about its gross effect in terms of activation or 
inhibition. This is in line with different degrees of change in the activity of the PPTg in PD 
models (Aravamuthan et al., 2008; Breit et al., 2001; Carlson et al., 1999; Mitchell et al., 1989; 
Orieux et al., 2000). And this can potentially provide a further explanation why different lesion 
studies of the PPTg show different behavioural results. In none of the studies the lesion 
techniques cause a 100% depletion of all cell types of the PPTg, nor are the proportions of 
surviving neuronal types identical across those different experiments. In this experiment an 
average of 29.4% of cholinergic neurons remained intact. Even though the exact degree of 
depletion of the other cell types has not been established, the NeuN stain suggests a much 
higher degree of cell death compared to cholinergic neurons. In the study conducted by 
Karachi and colleagues they report a survival of cholinergic neurons of 61% (Karachi et al., 
2010). It is not implausible that the survival of different cell groups and types might contribute 
to the different results observed. In an earlier study by Dunbar and colleagues (Dunbar et al., 
1992) the use of two different excitotoxins, ibotenic acid and quinolinate, caused different 
lesions in respect to the cholinergic and non-cholinergic parts of the PPTg in rats, resulting in 
functional differences on behavioural level as well.  
(ii) Functionally, and in further support of the findings of this experiment, electrophysiological 
data relate PPTg firing patterns to conditioned responses and reward related processes rather 
than to movement [cat: (Dormont et al., 1998); primate: (Kobayashi and Okada, 2007; Okada 
et al., 2009)], which fits very well with findings on the behavioural level showing the role of the 
PPTg in the process of learning [for example (Alderson et al., 2002; Inglis, Allen, et al., 1994; 
Inglis, Dunbar, et al., 1994; Keating et al., 2002; Keating and Winn, 2002)] specifically in 
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establishing of associations between actions and outcomes (Maclaren et al., 2013; Thompson 
and Felsen, 2013; D. I. G. Wilson et al., 2009). Kobayashi and colleagues have shown 
repeatedly in primates that patterns and rates of PPTg neuron firing are not just related to 
movements the macaques had to perform (visual saccades) in a reward task. Different 
populations of PPTg neurons responded to reward predicting stimuli and their delivery, 
mirroring further the expected reward value (Kobayashi and Okada, 2007; Okada et al., 2009). 
Tonic increase and decrease during the task execution correlated with their response 
magnitude to larger or smaller reward cues (Okada and Kobayashi, 2013). Likewise when mice 
had to make a left or right-orientating movement following an odour cue in order to receive a 
reward, PPTg neuron activity was related to the direction selection and there were also 
overlapping populations firing in relation to movement direction and reward outcome 
(Thompson and Felsen, 2013). PPTg neurons have the ability to pass information onto systems 
more directly involved in the selection of actions by providing midbrain DA neurons with rapid 
information about incoming sensory stimuli. This happens fast enough [sensory response 
latencies between 4 – 80ms (Dormont et al., 1998; Pan and Hyland, 2005)] to assume that it 
informs DA neurons about external sensory events [which have a response latency of 70-100 
ms after stimulus presentation (Redgrave et al., 2008)]. By influencing midbrain DA neurons 
and activity in corticostriatal pathways it assumes a role in the construction of goal-directed 
actions/movements. The BG have been proposed to be the seat of the ancient problem of 
selecting an action among behavioural alternatives (Redgrave et al., 1999) and the PPTg needs 
to be understood as a part of this action selection process at a different, lower,  level of the 
neuroaxis, interacting with the BG to make a decision on a specific movement. This highlights 
that the PPTg is not proposed to be non-involved in movement, but it stresses the nature of 
the involvement in movement – one that involves the process of selection. For general 
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locomotor behaviour, exploration, grooming, feeding, walking down the CW, the PPTg is not 
necessary. Chapter 5 discusses the differential role of anterior and posterior PPTg. 
In conclusion, the data provide evidence that extensive PPTg lesions in rats do not cause gait 
deficits which agrees with the lack of locomotor deficits in earlier PPTg lesion studies but is 
difficult to reconcile with some lesion studies conducted in primates. When investigating the 
role of the PPTg in PD it needs to be understood within its strategic position and close relation 
with the BG, thalamus and cortex and equally with the rest of the brainstem and spinal cord. It 
needs to be taken into account that the functional relations between these structures change 
in the absence of normal DA availability in PD, that the firing activity of the PPTg itself changes 
as a consequence and that in addition the PPTg is also affected from degeneration of its 
neuronal population. For this reason the next step was to add partial PPTg lesions to the 
existing PD rodent model and investigate the effect of such lesions on gait. 
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  Chapter 4 Development and examination of a refined 
model of Parkinson’s disease 
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1. Introduction 
1.1. A role of the PPTg in PD 
Parkinson’s disease has a broad spectrum of symptoms. Not all of these are motor symptoms 
and of those motor symptoms, not all respond well to DA replacement therapy. In more 
advanced stages, some PD patients show akinesia, gait deficits and postural impairments that 
are refractory to DA medication (Chastan et al., 2009).  Degeneration of PPTg neurons in PD  –  
and in other pathological conditions that lead to parkinsonian-like symptoms; changes of PPTg 
functioning in PD models and PD patients; the anatomical position of PPTg and its involvement 
in BG functioning; as well as data from animal studies suggesting a role of PPTg in posture and 
gait (for more details please refer to the General Introduction) – all these facts strongly 
indicate an involvement of the PPTg in PD (Pahapill and Lozano, 2000). 
1.2. Identification of the extent of PPTg degeneration 
Loss of PPTg cholinergic neurons was shown many years ago (Hirsch et al., 1987; Jellinger, 
1988; Zweig et al., 1989). Rinne and colleagues (Rinne et al., 2008) specified in their study an 
average loss of cholinergic neurons similar to that reported by Zweig and colleagues (36%). 
Rinne and colleagues showed that in addition to cholinergic cell loss, non-cholinergic neuron 
number was also reduced by 23% and the overall reduction in the numbers of all neurons in 
the PPTg along the rostrocaudal axis was reported to be 27%. Cell degeneration and atrophy 
was found in surviving neurons, showing a 14% (all neurons) to 26% (cholinergic neurons only) 
decrease in cell size. In Parkinsonism the DA loss leads to an overactive inhibitory output from 
the BG output nuclei SNr and GPi onto the thalamus and PPTg. Increased metabolic activity in 
the PPTg has been interpreted as an indicator for this inhibitory input in primates and rats 
(Carlson et al., 1999; Mitchell et al., 1989). More apparently decreased cytochrome oxidase in 
MPTP treated monkeys (Gomez-Gallego et al., 2007), decreased fluoro-2-DG in a rodent PET 
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study (Jang et al., 2012) and decreased firing activity in parkinsonian rats (Florio et al., 2007) 
indicate hypoactivity in the PPTg. On the other hand PPTg hyperactivity has been shown as 
well using extracellular recordings (Breit et al., 2001; Breit et al., 2005; Zhang et al., 2008) and 
expression of cytochrome oxidase messenger RNA (Orieux et al., 2000) in parkinsonian rats, a 
possible consequence of an overactive STN projecting onto the PPTg. Since different neuronal 
populations within the PPTg receive different afferents (Martinez-Gonzalez et al., 2011) it is 
plausible to think that these populations can show different activities.  
1.3. Need for a refinement of the existing model of PD 
Lesion studies in rodents have consistently shown that the PPTg is not necessary for the 
generation of locomotion and the previous chapter has proven that this is also true for the 
generation of gait. Nevertheless, in particular the literature on PPTg-DBS in PD patients 
hypothesises that the functional disturbance and degeneration of the PPTg plays a role in the 
development of gait and postural dysfunctions in, especially those symptoms refractory to DA 
medication. While animal models bearing extensive PPTg lesions were described to show 
akinetic symptoms, Karachi and colleagues showed gait and postural deficits in macaques 
bearing DTx-UII-induced lesions in the PPTg. This group very recently described that additional 
PPTg lesions to MPTP-induced DA depletion caused an increase of gait deficits which did not 
respond to DA medication, in contrast to the hypokinetic symptoms that were observed 
before. This is the only study that investigates the effect of a combination of DA depletion and 
PPTg lesion on motor symptoms. In an earlier study DA depletion was induced by MPTP after 
lesioning of the PPTg, with the effect that hardly any parkinsonian symptoms developed 
(Matsumura and Kojima, 2001). Apart from this study, PPTg lesions were only added to nigral 
DA cell loss to study the electrophysiological effect on the BG circuit in rats (Breit et al., 2006; 
Yan et al., 2008). Given the clear indications for PPTg involvement in PD and especially in the 
search for a treatment option that puts the PPTg at the centre of attention, an animal model is 
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required that mimics closer the pathophysiological state found in PD patients by taking into 
account PPTg degeneration.  
1.4. Decision on the model 
An ideal model for PD needs to prove face validity – similarities in symptoms and underlying 
pathophysiology – and ideally a high degree of construct validity – similarities in the 
pathogenesis of the disease.  
The most common animal models of PD are achieved by intracerebral injections of 6-OHDA, a 
catecholamine cell-specific neurotoxin, in rats and systemic administration of MPTP in 
primates and mice (Burns et al., 1983; Sundstrom et al., 1990; Ungerstedt, 1968). The 6-OHDA 
model shows considerable construct validity: while the exact mechanisms of DA neuron 
degeneration caused by this toxin are still being investigated it is known that 6-OHDA initiates 
degeneration through a combination of oxidative stress, mitochondrial respiratory dysfunction 
by acting on complex I and IV of the mitochondrial respiratory chain causing respiratory 
inhibition, and inflammation [for more details please refer to (Duty and Jenner, 2011)]. For this 
study face validity is of great importance. In rats, nigrostriatal lesions made by infusions of 6-
OHDA, cause akinesia, rigidity and catalepsy, impairments in skilled paw use such as reaching 
and compensatory stepping (Jeyasingham et al., 2001; Klein et al., 2007; Lee et al., 1996). 
Depending on the dose and injection site, moderate to severe degrees of DA neuron loss in the 
SN can be achieved, which remain higher to DA cell loss in the neighbouring VTA, with 
associated striatal DA depletion. Further similarities include changes in neuronal activities in 
the BG and related structures, such as an increased firing of the STN (Benazzouz et al., 2002; 
Breit et al., 2006) and overactive BG nuclei [GPi and SNr (Blandini et al., 2000; Mitchell et al., 
1989)]. However, the use of 6-OHDA alone does not cause other pathological changes outside 
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the nigrostriatal system, which makes a refinement of the model necessary to include further 
pathological features, such as PPTg degeneration.  
The choice of the optimal technique for the creation of the 6-OHDA model, which serves as a 
basis for the new model, is crucial. This model shows marked variability in the size of lesion 
and behavioural effects depending on the use of the toxin. 
The literature shows that in order to achieve consistent and visible behavioural outcomes of 6-
OHDA lesions it requires a substantial depletion of DA neurons. Partial lesions have proven to 
be less reliable. Thus, with lesions of below 80% destruction, animals did not show robust 
deficits in the cylinder-reaching test (Hefti et al., 1980). It needs close to complete lesions for 
PD models to display deficits in adjusted stepping tests, forelimb placement tests (Kirik et al., 
1998; Olsson et al., 1995). Paw preference in the cylinder-rearing test occurs in rats with about 
90% lesions (Schallert et al., 2000). This translate to PD gait deficits: in a previous experiment 
(Gut, 2009) it was shown that rats which received a high dose of 6-OHDA showed more robust 
and longer lasting deficits as measured on the CW than rats which received a lower dose of the 
same toxin (injected into the same striatal sites). Apart from the dose, Kirik and colleagues 
have shown that functional effects further depend on the site of infusion (Kirik et al., 1998). 
Infusions can be made (a) into the SN directly, though this adds mechanical damage to the 
tissue caused by the infusion cannula and further increases the risk of a higher DA cell loss in 
the neighbouring VTA; or (b) into the MFB, which causes a rapid and complete lesion in the 
nigrostriatal pathway, but also the mesoaccumbens pathway; or (c) into the striatum, which 
causes a more progressive retrograde damage to the SN, the extent of which can be controlled 
by infusion technique and dose. While the dorsomedial parts of the striatum are reported to 
have more general effects on locomotion, the lateral parts have more pronounced effects on 
movement initiation, sensorimotor orientation, and skilled motor behaviour (Kirik et al., 1998). 
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It is the lateral part of the caudate-putamen complex in rodents which corresponds to the 
human putamen, the striatal subregion with the most profound DA depletion in PD patients. 
Assessing the effect of 1, 2, 3 and 4 injection sites Kirik and colleagues found that rats that 
received 6-OHDA injections distributed over 4 sites of the lateral striatum along the rostro-
caudal axis showed more pronounced deficits in forelimb stepping and skilled paw use than 
rats that received the same amount of toxin into fewer injection sites. 
Many 6-OHDA-induced PD models are hemiparkinsonian, which allows for various tests of 
lateralised function including rotation in response to amphetamine or apomorphine (Cenci and 
Bjorklund, 1993; Metz et al., 2005) or the cylinder paw preference test. Bilateral nigrostriatal 
lesions result in marked adipsia and aphagia, making increased care in the form of hand-
feeding and monitoring water intake and body weight necessary (Sakai and Gash, 1994). In PD, 
degeneration of brain structures is not limited to one side, although the degeneration is not 
necessarily equally distributed (Brooks, 2010). For this reason, and especially when aiming to 
assess deficits that effect the whole body and not just one side, for this study it was necessary 
to use a bilateral model. Further, Roedter and colleagues have shown that the same amount of 
toxin injected bilaterally instead of unilaterally causes additional behavioural deficits in general 
locomotor activity and explorative behaviour, and also skilled forelimb use, indicating 
compensatory mechanisms of the unlesioned side, which is lost with bilateral lesions (Roedter 
et al., 2001). A pilot study testing two unilaterally lesioned rats (using the same surgical 
techniques, toxin and dose as described below in the methods for the main experiment) on the 
CW confirmed the need for a bilateral model: the gait of those hemiparkinsonian rats did not 
differ from sham lesioned rats (see Table 4.1.).  
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1.5. Aim of this experiment 
With the intention to subsequently test the effect of PPTg stimulation on gait parameters, this 
experiment aimed to refine the existing traditional 6-OHDA model and examine the 
differences in gait of parkinsonian rats with and without partial PPTg lesions. Based on the 
literature reviewed above it was decided to use a bilateral 6-OHDA model made by infusion of 
the toxin at four striatal sites in order to create a stable lesion of sufficient magnitude to cause 
a robust behavioural phenotype with consistent and long-lasting deficits. Partial PPTg lesions 
were planned to be made by microinfusions of ibotenic acid into 2 sites of the PPTg, as has 
been done routinely before (Bortolanza et al., 2010; Walker and Winn, 2007; D. I. Wilson et al., 
2009). This, however, required a reduction of the toxin concentration, because the previous 
purpose of ibotenic acid infusion was to cause complete lesions of the PPTg. The concentration 
of the toxin was determined in pilot surgeries preceding the main experiment. 
Table 4.1. Summary of the effect of unilateral 6-OHDA lesions in comparison to sham lesion rats. 
Data show group means. Please note that the data derive from a pilot study using just two 
hemiparkinsonian rats. Hence, no SEM are presented. Data from sham lesion rats derive from the 
experiment described below.  
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Furthermore, in accordance with the hypothesis that a lack or reduction of afferent stimulation 
of nigral DA neurons due to PPTg degeneration might contribute to DA degeneration, DA cell 
counts were examined in animals bearing partial PPTg lesions. Moreover, it is also 
hypothesised that a lack of functioning target neurons and altered afferent input from the BG 
might contribute to PPTg cell damage. Hence, cholinergic PPTg neuron counts in 6-OHDA 
treated rats were compared to sham operated animals. 
2. Pilot 1: Determination of ibotenic acid concentration for partial 
lesions 
2.1. Methods 
Eight male Lister-Hooded rats (Harlan Olac Ltd, Bicester, UK) with a mean pre-surgery weight 
of 346g (range 336g – 362g) underwent bilateral surgeries for partial PPTg lesions following the 
protocol described in the General Methods and below in the description of the main 
experiment. Four rats received 200 nl of ibotenic acid per infusion site (two per side) of a 
concentration of 0.04M and 4 the same volume of 0.06M. After the second surgery, the rats 
were perfused, coronal 30 µm sections were cut in a series of 1:4 of the PPTg area and stained 
for ChAT and NeuN (counterstained with cresyl violet) and assessed under a light microscope. 
2.2. Characterisation of lesions 
One rat died during recovery after the first ibotenate infusion. Hence, n = 3 rats constituted 
the final group lesioned with 0.06M ibotenic acid, n = 4 rats were lesioned with 0.04M ibotenic 
acid. 
Figure 4.1. shows representative photomicrographs of lesions after 0.04M and 0.06M in 
anterior and posterior PPTg. Cell counts of ChAT+ neurons of the PPTg (of 6 brains; 1 brain of 
the 0.04M groups had to be excluded from cell counts because the sections were damaged) – 
averaged per section – are presented and compared in Figure 4.2. Univariate ANOVA of the 
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averaged cell count per section of surviving ChAT+ neurons revealed that the groups did not 
differ from each other (F1,4 = 0.082 p = 0.789). 
 
 
  
Figure 4.1. Example sections of a PPTg lesion caused by 0.04M ibotenic acid (A and B) and of a PPTg 
lesion cause by 0.06M ibotenic acid (C and D). Photomicrographs show NeuN/Cresyl stained sections of 
anterior and posterior PPTg. 
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2.3. Conclusion  
After visually inspecting the extent of lesions on the NeuN/Cresyl stain, and given the fact that 
the use of the slightly higher concentration of ibotenic acid did not cause a higher loss of 
cholinergic neurons, the decision was made to use a concentration of 0.06M of ibotenic acid in 
future experiments to create partial lesions that were to be added to DA depletion of SN. 
Lesions caused by 0.04M were smaller, to an extent that the risk was higher to miss the PPTg 
or not cause a big enough lesion that would have functional effect. In view of the complexity of 
the refined PD model it was intended to create – involving three surgeries per animal – and the 
risk that the toxin itself poses to the survival of the rat, it appeared advisable to minimise the 
risk of having to exclude rats from analysis due to unsatisfactory histological results. 
  
Figure 4.2. PPTg ChAT+ count averaged per section. Graph shows group means ± SEM. 0.04M and 0.06M 
group did not differ significantly from each other. LHS = left-hand side; RHS = right-hand side; brain = 
overall cell count left and right combined. 
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3. Main experiment 
3.1. Methods 
3.1.1. Subjects 
Forty-six adult male Lister-Hooded rats (Harlan Olac Ltd, Bicester, UK) were used. Due to the 
time consuming care which those bilateral PD models require the experiment was split into 2 
sets with 26 animals in the first set and 20 in the second. At the start of CW training the mean 
weight of the animals of the first set was 270g (range 247 – 289g) and of the second set 334g 
(range 310 – 363g). The animals were put on food control once they reached their target 
weight (described in the General Methods). All animals reached the target weight of 330g for 
the first surgery (1st set: mean weight 348g; range 335 – 359g; 2nd set: mean weight 335g; 
range 331 – 342g). The mean weights during pre-surgical baseline testing were 338g (range 
280 – 352g) and 327g (range 319 – 336g) and a stable mean weight of 329g with a small range 
of 317 – 343g and 335g (range 329 – 343g) was maintained over the entire period of the 
experiment. For further details on housing please refer to the General Methods. 
3.1.2. Experimental protocol 
The experiment followed the timeline presented in Figure 4.3. In brief, the rats were trained 
on the CW for 10 days. All rats were proficient at that point to deliver acceptable runs on the 
CW. Over the following 4 days their pre-surgical performance was recorded. They then 
underwent 1, 2 or 3 consecutive surgeries, separated by a week, depending on the 
experimental group they belonged to. After a week of recovery the rats were then re-exposed 
to the CW and then tested for 7 days. 
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3.1.3. Surgical procedures 
Surgery followed the protocol as described in the General Methods. In brief: 
Bilateral partial PPTg lesions 
In two separate surgeries the PPTg was bilaterally lesioned by microinfusions of ibotenic acid 
into the anterior and posterior PPTg at the following coordinates (in mm): anterior PPTg: + 0.6 
from IAL, ± 2.0 from midline and - 7.0 from dura; posterior PPTg: - 0.8 from IAL, ± 1.9 from 
midline and - 6.5 from dura. Infusions were always made anterior first but the order of 
infusions regarding the choice of side was counterbalanced. Rats were infused with 200 nl of 
0.06M ibotenic acid per infusion site. Control rats received infusions of vehicle only (here: PB) 
into the same sites. At the end of surgery rats were treated with 1-1.5 ml of Hartmann’s 
solution (i.p.) to account for the lack of fluid intake during the time of surgery. Furthermore, 
Figure 4.3. Experimental design. At the start of the experiment all animals were trained for 10 days on 
the Noldus CatWalk. They were then tested for 4 days to obtain a pre-surgical baseline. In order to 
comparing the traditional 6-OHDA model of Parkinson’s disease to a refined model consisting of the 
same nigral DA depletion plus partial lesions of the PPTg, rats with partial PPTg lesions only and the 
corresponding sham controls, rats underwent 2 or 3 successive surgeries with 7 days in recovery in 
between. Seven days after the last surgery they were then re-trained. Post-surgical testing was 
performed every other day over 14 days. 
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they also received an i.p. injection of 0.2 ml Diazepam to reduce the risk of injury due to the 
immediate effect of the excitotoxin acting on the targeted brain stem sites.  
Bilateral DA depletion of the SNc 
Seven µg (free base weight) of 6-OHDA-hydrobromide dissolved in 2 µl of 0.1% L-ascorbic acid 
/0.9% saline were delivered at 4 sites into the striatum of both sides ot the brain at the 
following coordinates (in mm): (1) AP: + 1.3 (measured from Bregma), ML: ± 2.6 (measured 
from midline at the skull surface), DV: - 5.0 (measured from Dura); (2) AP: + 0.4,  ML: ± 3.0 mm, 
DV:  - 5.0; (3) AP: - 0.4, ML: ± 4.2, DV: - 5.0; (4) AP: - 1.3, ML: ± 4.5, DV: -5.0. Infusions were 
controlled by a Harvard microdrive pump. Control rats received infusions of vehicle only (here: 
0.1% L-ascorbic acid /0.9% saline solution) into the same sites. Before being placed into a 
heated recovery cage rats were treated with 2-2.5 ml of Hartmann’s solution (i.p.). 
Combined lesions 
Rats that received a combination of DA depletion and partial bilateral PPTg lesions underwent 
3 separate surgeries. During the first 2 bilateral partial PPTg lesions were created as described 
above. Following a further 7 days of recovery the DA depleting procedure was performed. 
3.1.4. Training and testing on the CW 
Rats were trained for 10 days prior to baseline testing and surgery and tested as described in 
the General Methods. During the execution of the first set of the experiment inconsistencies of 
CW data during baseline testing required re-adjustments of software and hardware settings 
which delayed the data collection by a week. During this time the rats continued to be exposed 
daily to the CW. The order of rats trained and tested was randomised.  
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Gait parameters 
The following gait parameters were examined: BOS, swing speed, stride length and duty cycle 
of both front and hind legs, print position of ipsilateral paws and the support formula of 
diagonal pairs of paws and three paws. For details on the gait parameters please see the 
General Methods. 
3.1.5. Lesion assessment 
The area of the PPTg and the SN were histologically assessed for overall neuronal damage and 
cholinergic cell loss and loss of dopaminergic neurons respectively following the methods as 
described in the General Methods. In brief, at the end of behavioural testing rats were 
transcardially perfused with a fixative, the brains removed and stored in sucrose solution until 
they sank. A series of 1:6 coronal 30 µm sections was cut on a freezing microtome. 
PPTg 
For PPTg assessment the corresponding sections were immunohistochemically stained for 
NeuN and ChAT, mounted on glass slides and examined under a light microscope. Overall 
neuronal damage was assessed visually on the NeuN/Cresyl stained sections and rated on a 
scale from 0 (no lesion) to 4 (extensive lesion). Lesions were accepted and rats included into 
the analysis when they received a rating of at least a 1 (small/partial lesion). Animals were 
excluded when both sides received a 4 (extensive lesion). Cholinergic cell survival was assessed 
by software assisted counts of ChAT+ neurons.  
SNc 
Sections corresponding to the SN were immunohistochemically double-stained for TH and Cb 
and similarly examined under a light microscope. All TH+ neurons within the dorsal and ventral 
tier of substantia nigra part compacta (SNc; SNcd and SNcv respectively), substantia nigra pars 
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medialis (SNm) and substantia nigra pars lateralis (SNl) were counted using a handheld cell 
counter. 
3.1.6. CatWalk data analysis 
In order to test the CW data for an effect of DA depletion on normal gait and to explore 
potential differences between the traditional and an refined model of PD mixed ANOVAs were 
performed across post-surgery testing days (within subject factor) and between groups (PPTg 
lesion group, combined lesion group, 6-OHDA group and sham controls, between subjects 
factor) and further examined for a simple main effect performing repeated measures ANOVAs 
for individual groups to compare the groups for an effect – or lack of it – of day on their 
performances. Preceding this, the data were assessed for pre-existing differences (mixed 
ANOVAs within pre surgical testing days and between groups). Normality of pre and post-
surgery data was identified by the Shapiro-Wilk test and homogeneity of variance by Leven’s 
test. The handling of violations of these assumptions is reported in the results section when 
they occurred. All tests were conducted using SPSS version 21 (IBM Corp., Armon, NY, USA) 
and results were considered statistically significant when p ≤ 0.05.  
3.2. Results 
3.2.1. Histological analysis 
The presented results were obtained from a total of 46 rats, of which 12 underwent surgery 
for bilateral partial PPTg lesions, 7 infusions of 6-OHDA, 17 underwent the 3 surgeries 
necessary for the combination of both lesion types and 8 received control infusions of vehicles 
in surgeries for either bilateral PPTg infusions (n = 3), infusions into the striatum (n = 2) and 
both (n = 3). Two animals were excluded before surgeries because they failed consistently to 
deliver acceptable runs on the CW by the time of baseline testing. One animal injured its paw 
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during the recovery stage after ibotenate infusion and had to be excluded as well. Due to a 
failed perfusion the resulting brain sections were too fragile to obtain a complete set of 
sections to analyse and one rat of the control group was not included in the histological 
analysis; however the available sections were inspected visually and no lesions were 
observable; therefore the behavioural data was considered for the other analyses 
A total of 11 rats did not survive the recovery phase after infusion of ibotenate. After the loss 
of 4 rats in a row conducting the 2nd set of the experiment a new batch of toxin was used to 
exclude the possibility of problems with the toxin. Hence, n=7 rats constituted the final group 
of bilaterally PPTg lesioned rats, n = 7 rats were in 6-OHDA group (DA depleted rats), n = 7 rats 
formed the combined lesion group and n = 8 rats were in the control group. Figure 4.4. shows 
the lesions size ratings made on NeuN/Cresyl stained sections. 
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Figure 4.4. Lesion size for each rat of the PPTg lesion group (A) and combined lesion group (B) rated 
based on NeuN+ stained brain sections. Lesions were rated on a scale from 0 to 4 (0 = no lesion of the 
PPTg, 1 = small/ partial lesion of the PPTg, 2 = partial to full lesion of the PPTg, 3 = fully lesioned PPTg,    
4 = extensive lesion covering the PPTg and surrounding tissue; square covering diamond). 
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Figure 4.5. Representation of lesion extension along the rostro-caudal axis after ibotenic acid infusion 
on a selection of NeuN+ stained sections. The position of the schematics (adapted from Paxinos and 
Watson, 2005) on the rostro-caudal axis is represented as the distance from the interaural line (IAL; 
mm). Sections IAL + 2.88 mm through to IAL + 1.68 mm were identified as sections containing anterior 
PPTg neurons (identified by PPTg cholinergic neurons in shams and partially lesioned rats) and those 
from IAL + 1.08 mm to IAL + 0.36 mm represent sections containing posterior PPTg. Lesion damage is 
represented in coloured shading: blue for lesions in the PPTg lesion groups and red for lesions in the 
combined lesion groups. 
PPTg lesion group Combined lesion group 
anterior  
PPTg 
posterior  
PPTg 
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Figure 4.6. Representative histological photomicrographs of lesions in anterior and posterior PPTg of 
rats bearing partial lesions (A and B: NeuN stained; C and D: ChAT stained; E and F: ChAT stained 
sections of sham lesioned rat).  
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The PPTg lesion group showed a ChAT+ PPTg cell loss of 56% (range 33% to 73%) and in the 
combined lesion group 73% of cholinergic neurons were destroyed (range 56% to 96%). The 6-
OHDA group, which did not receive any lesion inducing toxin infused into the PPTg showed a 
PPTg cholinergic cell survival of 97% (range 84% to 108%) when expressed as a percentage 
from the average sham cell count. The percentage of surviving cholinergic PPTg neurons is 
shown in Figure 4.7.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7. PPTg ChAT+ count as the percentage of the mean count in sham lesioned rats. Graph shows 
group means ± SEM. *** indicates a significant difference between PPTg lesion/ combined lesion group 
and shams with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. PPTg and combined lesion 
groups did not differ from each other (p = 0.095) and neither did 6-OHDA and sham lesion groups (p = 
0.979). LHS = left-hand side; RHS = right-hand side; brain = overall cell count left and right combined. 
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Univariate ANOVA of the raw cell count of surviving ChAT+ neurons confirm a significant 
difference between groups (F3,24 = 56.235 p < 0.001; ƞ2p = 0.875). Tukey corrected post hoc 
tests reveal that both groups, PPTg lesion group and combined lesion group had a significantly 
lower ChAT+ cell count in the PPTg compared to sham controls (PPTg lesion p < 0.001; 
combined lesion: p < 0.001). Furthermore, PPTg lesion group and combined lesion group did 
not differ from each other (p = 0.095), and neither did the 6-OHDA caused any observable 
destruction of cholinergic neurons in the PPTg: 6-OHDA group and sham controls did not differ 
from each other (p = 0.979). 
TH+ cell count in SN 
Both groups which received 6-OHDA infusions into the striatum showed a marked DA 
degeneration: TH+ count in the 6-OHDA group was reduced by 91% (range 88% to 96%; of 
average sham count) and in the combined lesion group by 93%. (range 92% to 95%). In the 
PPTg lesion group an average 90% of the TH+ neurons in SN were counted (range 69% to 
112%). Statistically, as revealed by univariate ANOVA, the groups differed significantly from 
each other in their remaining nigral TH+ cell count. (F3,24 = 238.817 p < 0.001; ƞ2p = 0.968). Post 
hoc tests (Tukey corrected) showed that the differences between the sham controls and both 
6-OHDA treated groups were significant (6-OHDA group: p < 0.001; combined group: p < 
0.001). Both DA depleted groups did not differ from each other (p = 1.000). Likewise, there was 
no statistical difference with the PPTg lesion group and sham controls (p = 0.230) (see Figure 
4.9). 
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Figure 4.9. SN TH+ count as the percentage of the mean count in sham lesioned rats. Graph shows 
group means ± SEM. *** indicates a significant difference compared to shams with p ≤ 0.001; LHS = left-
hand side; RHS = right-hand side; brain = overall cell count left and right combined; 6-OHDA and 
combined lesion groups did not differ from each other (p = 1.000) and neither did PPTg and sham lesion 
group (p = 0.230). 
 
Figure 4.8. Representative histological photomicrographs of SN. Panels A and B show sections from a 
sham lesion rat; C and D show dopamine depletion after 6-OHDA infusions. 
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3.2.2. Behavioural results 
PPTg lesions on their own – at least in rodents – do not cause locomotor deficits or gait or 
postural deficits, as described in the previous chapter. Given its degeneration in PD and the 
fact that specific symptoms, such as gait and postural impairments, do not respond to DA 
medication this experiment aimed to assess whether additional partial PPTg lesions create a 
PD model whose deficits compared to sham operated rats are different to the traditional PD 
rodent model involving only DA depletion. This and the general feasibility of creating a refined 
model of PD by combining DA depletion and partial PPTg lesions were important questions to 
answer before pursuing to assess the effect of PPTg-DBS on gait and posture. The same 
aspects of gait – gait stability, speed, stride and coordination – were explored by analysing the 
data individually and presented as such in the following. Before any analysis, the data deriving 
from both individual sets of the experiment were inspected for differences. Great care had 
been taken to keep the experimental conditions as similar as possible so no differences due to 
confounding variables were expected. Given the small numbers in the groups, when taken 
separately for each set, the group means and ranges of each parameter were inspected for 
differences. On no occasion, neither in pre nor post-surgery performance, did the behavioural 
data allow identification of which set the data were derived from (Supplementary Table 4.1.). 
Normality as examined with the Shapiro-Wilk test was given on most of the test days. On rare 
occasions, the data did not follow a normal distribution. Given this infrequency these seldom 
violations were tolerated in the analysis, but reported below. Pre-surgery data was assessed 
for pre-existing differences, which could be ruled out for each analysed parameter 
(Supplementary Table 4.2.).  
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Traditional and refined model in comparison with sham controls 
The main focus here was on the question of whether the PD model refined by additional PPTg 
lesions would be different than the traditional PD model when compared to sham controls.  
 Gait stability 
BOS – The mean values of BOS (and other parameters) are presented in Figure 4.10. Mixed 
ANOVAs of front and hind limbs showed no interaction of post-surgery testing days and groups 
(front: F18,150 = 1.394 p = 0.142; hind: F18,150 = 1.619 p = 0.062) nor an effect of day in the front 
limbs, though this was present in the hindlimbs (front: F6,150 = 1.776 p = 0.108; hind: F6,150 = 
5.260 p < 0.001; ƞ2p = 0.174). Repeated ANOVAs for each group showed that this day effect 
was only in the PPTg lesion group and the sham controls (PPTg lesion group: F6,36 = 5.652 p < 
0.001; ƞ2p = 0.485; sham group: F6,42 = 5.052 p = 0.010 Greenhouse-Geisser corrected; ƞ2p = 
0.419) but not in the DA depleted models (combined group: F6,36 = 0.603 p = 0.726; 6-OHDA 
group: F6,36 = 0.985 p = 0.449). The PD models therefore failed to further decrease their BOS as 
both non-DA depleted groups did. There was a significant effect of group (front: F3,25 = 27.154 p 
< 0.001; ƞ2p = 0.765; hind: F3,25 =  20.219 p < 0.001; ƞ2p = 0.708). Post hoc tests specified that 
both, combined group and 6-OHDA group showed a significantly bigger BOS (front: combined 
group: p < 0.001; 6-OHDA group: p < 0.001; hind: combined group: p < 0.001; 6-OHDA group: p 
< 0.001). However, there was no significant difference between both PD models (p = 0.683). 
Duty Cycle – A significant interaction of testing days and groups in the front limb data (F18,150 = 
2.334 p = 0.003; ƞ2p = 0.219) stems from day effects in PPTg lesion group (F6,36 = 3.911 p = 
0.004; ƞ2p = 0.395) and 6-OHDA group (F6,36 = 3.172 p = 0.013; ƞ2p = 0.346). However, as post 
hoc tests reveal, this did not translate to significant differences between individual testing days 
in the 6-OHDA group and only the last of the testing days of the PPTg group reaching a 
significant decrease of stance duration, which can be attributed to a training effect as 
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explained before. More importantly there was no significant effect of group in this parameter 
(front: F3,25 = 1.517 p = 0.235; hind: F3,25 = 2466 p = 0.086). Post-surgery data of Duty Cycle hind 
were not normally distributed but this violation was tolerated.  
Support – There was a group difference regarding the percentage of diagonal two-legged 
support during the animals’ gait cycle (F3,25 = 7.991 p = 0.001; ƞ2p = 0.490). Post hoc tests found 
that only the 6-OHDA group used significantly less diagonal support compared to sham 
controls (p = 0.004). Despite the observable decrease of diagonal support in the combined 
lesion group, 6-OHDA group and combined lesion group were not significantly different (p = 
0.097); this change was not big enough to lead to a significant difference between the 
combined group and sham controls (p = 0.583). A decrease of two-legged support is usually 
compensated by an increase of three or more legged support. Indeed, the significant effect of 
group (F3,25 = 5.536 p = 0.005; ƞ2p = 0.399) and further post hoc tests found that the three-
legged support in the 6-OHDA group was significantly increased compared to sham controls (p 
= 0.014). The combined group showed the same trend as described for diagonal support: 
three-legged support seemed increased – and there was no significant difference between 
combined lesion group and 6-OHDA group (p = 0.750) – but not sufficiently to lead to a 
significant difference when compared to sham controls (p = 0.132). Post-surgery data of 
Support 3 were not normally distributed but this violation was not further accounted for in the 
analysis. 
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Figure 4.10. Performance on the CW – Parameters reflecting gait stability. Graphs show group means ± 
SEM of selected gait parameters; *** indicates a significant difference compared to Sham lesion group 
with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. Despite the changes in the distribution of 
support in the combined lesion group failing to reach significance, in none of the selected parameters 
the combined and the 6-OHDA lesion groups differ from each other significantly. Neither did PPTg and 
sham lesion groups show significant differences. Please refer to the text for details.  
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Speed 
Swing Speed – No day x group interaction nor any day effect was found by mixed ANOVAs of 
Swing Speed front and hind, but there were significant effects of group (front: F3,25 = 26.540     
p < 0.001; ƞ2p = 0.761; hind: F3,25 = 66.856 p < 0.001; ƞ2p = 0.889). Both PD groups differed 
significantly from sham controls, showing a significantly reduced swing speed (both combined 
lesion group and 6-OHDA group compared to sham: p < 0.001 for front and hind limbs). Post-
surgery data of the hind limbs was not normally distributed; this was tolerated in the analysis. 
 
 
 
 
 
 
  
Figure 4.11. Performance on the CW – Swing Speed. Graphs show group means ± SEM of selected gait 
parameters; *** indicates a significant difference compared to Sham lesion group with p ≤ 0.001; ** 
indicates p ≤ 0.005 and * indicates  p ≤ 0.05. The combined and the 6-OHDA lesion groups did not differ 
from each other significantly. Neither did PPTg and sham lesion groups show significant differences. 
Please refer to the text for details.  
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Stride 
Stride Length – Mixed ANOVAs on Stride Length of front and hind limbs found significant day x 
group interactions (front: F18,150 = 2.038 p = 0.026, Greenhouse-Geisser corrected; ƞ2p = 0.196; 
hind: F18,150 = 1.873 p = 0.046, Greenhouse-Geisser corrected; ƞ2p = 0.184) which, followed up 
by repeated measures ANOVAs for each group, meant that sham controls and PPTg lesioned 
rats changed across the testing days (front: PPTg lesion group: F6,36 = 4.975 p = 0.001; ƞ2p = 
0.453; sham control group: F6,42 = 2.470 p = 0.039; ƞ2p = 0.261; hind: PPTg lesion group: F6,36 = 
6.170 p <0.001; ƞ2p = 0.507; sham control group not reaching significance: F6,42 = 2.147 p = 
0.068) but not the DA depleted animals of both PD groups (front: combined lesion group: F6,36 
= 0.420 p = 0.861; 6-OHDA group: F3,36 = 1.358 p = 0.258; hind: combined lesion group: F6,36 = 
0.400 p = 0.874; 6-OHDA group: F6,36 = 1.068 p = 0.400). Most importantly there were 
significant effects of group (front: F3,25 = 13.795 p < 0.001; ƞ2p = 0.623; hind: F3,25 = 11.156 p < 
0.001; ƞ2p = 0.572). The front limbs of rats from the combined lesion and the 6-OHDA group 
made significantly shorter steps (combined lesion group: p = 0.021; 6-OHDA group: p < 0.001). 
The shortened steps of hind paws in the combined lesion group did not reach significance (p = 
0.068), the steps of 6-OHDA rats were significantly shorter than sham controls (p < 0.001); 
however there was no significant difference between 6-OHDA group and combined lesion 
group in the hind limbs data either (p = 0.134). 
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Coordination 
Print position – Mixed ANOVAs found no day x group interactions (RHS: F18,150 = 1.588 p = 
0.129, Greenhouse-Geisser corrected; LHS: F18,150 = 1.189 p = 0.277) or effects of day (RHS: 
F6,150 = 0.605 p = 0.623, Greenhouse-Geisser corrected; LHS: F6,150 = 1.316 p = 0.253) or group 
(RHS: F3,25 = 0.873 p = 0.468; LHS: F3,25 = 1.057 p = 0.385) in the Print Position data. This 
parameter was unaffected by DA manipulation. 
 
 
  
Figure 4.13. Performance on the CW – Parameter reflecting coordination. Graphs show group means          
± SEM of selected gait parameters. Please refer to the text for details. 
 
Figure 4.12. Performance on the CW – Stride Length. Graphs show group means ± SEM of selected gait 
parameters; *** indicates a significant difference compared to Sham lesion group with p ≤ 0.001; ** 
indicates p ≤ 0.005 and * indicates  p ≤ 0.05. Despite the decrease in stride length of the hind limbs in 
the combined lesion group failing to reach significance, the combined and the 6-OHDA lesion groups did 
not differ from each other significantly. Neither did PPTg and sham lesion groups show significant 
differences. Please refer to the text for details. 
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The effect of partial PPTg lesions 
In none of the analysed parameters, bar Swing Speed of the hind limbs,  did the PPTg lesion 
group bearing bilateral partial PPTg lesions differ significantly from the sham controls (please 
refer to Table 4.2. for details). 
 
 
  
Table 4.2. Summary of the effect of partial PPTg lesions, 6-OHDA lesions and combined lesions on 
CW gait parameters. The data show group means ± SEM. There was no significant difference 
between combined lesion group and  6-OHDA lesion group and no significant difference between 
PPTg lesion group and sham lesion group. * p < 0.001 versus sham lesion group. † p < 0.005; ‡ p < 
0.05. 
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3.3. Discussion  
  
Different to sham? 
 
Different to 
pre-surgery? 
  
PPTg combined 6-OHDA 
 
sham 
BOS 
front No bigger bigger 
 
no  
hind No bigger bigger 
 
no 
Swing 
Speed 
front No slower slower 
 
no 
hind 
slower (but 
significantly 
faster than other 
groups) 
slower slower 
 
no 
Stride 
Length 
front No shorter shorter 
 
no 
hind No No shorter 
 
no 
Duty 
Cycle 
front No No No 
 
no 
hind No No No 
 
no 
Print 
Position 
right No No No 
 
further 
left No No No 
 
no 
Support 
di
ag
on
al
 
No No less 
 
no 
three No No more 
 
no 
 
 
 
Table 4.3. Summary of analysed parameters. Post-surgery data of rats bearing partial PPTg lesions, combined 
lesion group and 6-OHDA lesion group compared to sham lesion group. Further the table shows the results of 
pre- to post-surgery data comparison of the sham lesion group. Cells shaded in red show differences 
compared to the sham lesion group that reflect a deficit of the performance. Green shading reflects 
improvements. Blue frames reflect the absence of significant differences. 
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The experiment presented in the previous chapter showed that the PPTg itself is not a crucial 
structure for the generation of normal gait. Rats bearing complete and near-to-complete 
lesions of the PPTg did not present differences in the analysed gait parameters reflecting 
stability, speed, stride and coordination compared to sham lesion rats. This is also true for 
partial PPTg lesions. Only the swing speed of the hind legs was slower than in the control 
group, but significantly faster than both parkinsonian models of this experiment.  Furthermore, 
the addition of a partial PPTg lesion did not cause any of the analysed gait parameters to differ 
significantly from the traditional Parkinson’s model – but in comparison with the sham lesion 
control group the deficits in stride length of the hind limbs and in the distribution of support of 
the combined lesion group were not significantly different. Potentially this could mean that the 
additional PPTg lesion might have attenuated the effect of the DA depletion on specific gait 
parameters. Two explanations could be plausible: a) In PD (models) the STN is hyperactive  
(Bergman et al., 1994; Breit et al., 2007; Hassani et al., 1996; Remple et al., 2011): a partial 
PPTg lesion might cause a decrease of excitatory input to the STN. Or b) caused by the loss of a 
part of its neuronal population compensatory mechanisms within the PPTg could have led to 
an compensatory increase of activity in those remaining PPTg neurons which are under over-
inhibitory control from the BG. Whatever mechanism might be involved, it could have partially 
re-established a balance within the BG circuit.  
Parkinson’s patients who suffer more frequently from falls than others (“fallers”) were 
reported to show a higher cell loss in the PPTg (Karachi et al., 2010) and a decreased thalamic 
innervation of cholinergic afferents (Bohnen et al., 2009) than non-fallers. Falls can be caused 
by postural deficits and impaired balance, as well as being the consequence of progressively 
decreased step length and occurrences of FOG (Schaafsma et al., 2003). In this context, it 
seems surprising that the additional PPTg lesions in this study did not lead to further 
impairments in comparison to the traditional 6-OHDA model. One reason might be that the 
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induced destruction of a part of the PPTg spared enough neurons to maintain the same level of 
impairment as caused by DA depletion alone. This is however unlikely, comparing the average 
cell loss of 73% of cholinergic neurons (range 56% to 96%) in this experiment to the degree of 
PPTg degeneration in PD patients described in the literature. Another reason might be the 
nature of deficits that might be expected with additional PPTg lesions: if the main effect is to 
be expected in balance rather than gait per se, the CatWalk might not be the most direct 
means to measure it. Balance deficits and consequently falls can be the result of impaired 
sensorimotor integration – including deficits in proprioceptive processing, inability to switch 
between sensory modalities, impaired interlimb coordination and asymmetries (Boonstra et 
al., 2008; Lewis and Byblow, 2002; Vaugoyeau et al., 2011). To test if postural adjustments can 
be processed adequately or quickly enough in the response to changed postural demands, a 
more adequate test could be the rotarod test. The beam walking test might be a good 
alternative for assessing motor coordination deficits (Stanley et al., 2005).  
The results presented here are discordant with the only other study that examines the 
behavioural effect of a combination of PPTg lesions and DA degeneration in the SN. The Paris 
group describe a MPTP-model which, as they describe, showed worsening of DOPA-
unresponsive gait and balance disorders after the addition of bilateral PPTg lesions. Bilateral 
lesions were made either by the excitotoxin ibotenic acid or Dtx-UII, which, injected into the 
upper brainstem, is selective for cholinergic neurons if given in the right concentration (Clark 
et al., 2007). The authors reported a slight increase in balance deficits (an increase from 0 to 1 
on a semi-quantitative scale from 0 to3) and adverse postural changes such as an increased 
knee angle and elevated pelvis, which however were marginal and not significant. In fact, 
examining the data as presented in the paper (Table 1; Grabli 2013), the only significant effect 
of the additional PPTg lesion is an improvement of global activity, step speed and rigidity 
compared to the MPTP-induced state pre-PPTg lesion, which does not reach baseline 
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performance. Unfortunately, the authors do not offer data for the ibotenic acid and DTx-UII 
groups individually, but offer graphs that show a more severe effect after ibotenic acid. The 
histological data do not offer either a differentiation of the effect of both toxins: the 
cholinergic cell loss is only given averaged for both groups. Surprisingly, the loss of non-
cholinergic neurons in both groups did not differ significantly from each other: the DTx-UII 
group showed a loss of 6% and the ibotenic acid group 10%. One last difficulty regarding the 
interpretation of this study lies in the fact that no timescale of the experimental design is 
offered. It is unclear when and how quickly after surgeries the animals were tested. It is 
surprising that the monkey that showed slight balance deficits after PPTg lesion surgery 
showed improved balance scores after a subsequent further dose of MPTP. It seems that the 
actual results – reflecting no further deficits after additional PPTg lesions – do not differ much 
from the results presented in this chapter. However, given the issues described above this 
interpretation has to remain cautious. 
As described in the General Introduction there is no agreement if there is a relationship 
between DA loss in SN and PPTg degeneration. According to Braak the degeneration in both 
structures occurs around the same stage of the disease (Braak et al., 2003); the literature 
offers support for a destructive influence of a defective PPTg onto SN neurons, others have 
shown PPTg degeneration after MPTP-induced DA cell death in aged monkeys (Karachi et al., 
2010), and there is evidence for no influence at all (Heise et al., 2005). Very recently, Pienaar 
and colleagues (Pienaar and van de Berg, 2013) have shown that the destruction of SN DA 
neurons in the unilateral 6-ODHA model caused no decrease in the total number of ChAT+ 
neurons in the PPTg, confirming the results of Heise and colleagues. This goes in line with the 
findings here. However, by means of further stereological analysis of NeuN+ neurons of that 
unilateral PD model the authors could reveal a significant loss of non-cholinergic neurons. 
Since quantitative histological analysis in this study was restricted to the cell count of ChAT+ 
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neurons in PPTg it cannot be excluded that other techniques might lead to similar findings. In a 
similar way to this ‘dying-back’-theory (Pienaar and van de Berg, 2013) of PPTg neurons, others 
argue that nigral DA neurons might degenerate due to altered input from the PPTg, given that 
DA neurons have been shown to need to be stimulated in order to survive (Michel et al., 
2013). Here, however, partial PPTg lesions similar to the degree of degeneration in PD patients 
did not cause an decrease of TH+ neurons in SN compared to sham lesioned rats.  
In pilot surgeries preceding the experiments lesions caused by 0.04M ibotenic acid produced 
small lesions. The risk of not causing enough damage was considered high with this 
concentration and the decision was made to use a concentration of 0.06M. Examining the 
extent of lesions in NeuN/Cresyl stained brain sections in this experiment showed that it might 
be advisable to reduce not the concentration, but the volume of the toxin to decrease spread 
of toxin in the tissue and constrain the affected area more. 
Apart from the effect of additional PPTg lesions on gait parameters in the rodent PD model 
and the effect of partial PPTg lesions on nigral DA neurons and vice versa, this experiment 
aimed to assess the feasibility of a combined lesion model in view of subsequent experiments 
that were aiming to assess the effect of PPTg-DBS in a rodent model that mimics the 
physiological state of PD closer than the traditional model. It was important to ascertain that 
rats bearing combined lesions could survive three surgeries and would be able to complete the 
behavioural tests. Further, it was important to assess the degree of care – especially feeding – 
those rats would require, in order to plan the next experiments. Given that they tolerated the 
surgeries well (once recovered from the ibotenic acid infusions) and required the same 
amount of care as the traditional bilateral 6-OHDA model, this refined model could be taken 
forward to the stimulation studies. 
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  Chapter 5 The effect of anterior and posterior PPTg-DBS on gait and L-DOPA induced dyskinesias   
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1. Chapter Introduction 
Since 2005 DBS of the PPTg has constituted an experimental treatment option in attempts to 
address axial symptoms of Parkinsonism. The hope was to find an alternative to the 
established target sites for DBS, which fail (or lose efficacy with disease progression) to 
address symptoms refractory to DA medication – gait and postural disturbances, FOG – and to 
offer an option to patients not considered good candidates for STN-DBS. Despite initial reports 
of beneficial effects of PPTg-DBS (Mazzone et al., 2009; Mazzone et al., 2005; Moro et al., 
2010; Plaha and Gill, 2005; Stefani et al., 2007) the results of subsequent studies have been at 
best only modest (Ferraye et al., 2010; Snijders et al., 2008). In addition, the focus has moved 
from axial symptoms to other domains: cognition (Alessandro et al., 2010; Costa et al., 2010; 
Stefani et al., 2010; Zanini et al., 2009), sleep (Lim et al., 2009; Romigi et al., 2008; 
Thevathasan et al., 2010) and physiological functions (Aviles-Olmos et al., 2011; Xiang et al., 
2011). To date, the PPTg is not a safe or standard option in clinical settings (Potter-Nerger and 
Volkmann, 2013).  
1.1. Hypothetical basis for the consideration of the PPTg as a target for DBS 
The hypothesis that successful correction of the axial symptoms of PD could be achieved with 
PPTg-DBS stems from two assumptions: (i) dysfunction in the output nuclei of the BG has a 
pathological impact on the PPTg that might be corrected by local low frequency stimulation 
(LFS); and (ii) the PPTg is a locomotor control structure, a main component of the MLR (Munro-
Davies et al., 1999; Nandi et al., 2002; Pahapill and Lozano, 2000). This second assumption has 
been discussed in Chapter 3 and it has been shown that in accordance with evidence from the 
literature, the PPTg is not a motor controlling structure: full – or partial – lesions of the PPTg 
did not lead to changes in rats’ gait.  
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There is clear evidence for changed neuronal activity of the PPTg in PD models and it is 
plausible that altered input from the BG output nuclei plays an important role. However, 
limiting the BG-PPTg relationship in PD to an over-inhibitory input resulting in reduced 
glutamatergic output to the spinal cord would present an over-simplified understanding of the 
role of the PPTg in PD and further the role of the PPTg as a target of DBS. 
1.2. Precise target site within a heterogeneous structure 
The PPTg contains a diverse population of cholinergic, GABAergic and glutamatergic neurons, 
each distributed differently (Martinez-Gonzalez et al., 2011; Ros et al., 2010). The pattern of 
afferent and efferent connections differs: BG output is directed predominantly to anterior 
parts (the pars dissipatus) and sensory input to posterior parts (pars compactus) (Winn, 2008).  
Consequently, there are clear functional differences between anterior and posterior PPTg 
(Alderson et al., 2008). This raises questions whether the consequences of PPTg-DBS are 
dependent on location within the PPTg, as well about the nature of effects that might be 
expected. Clarity about this is an essential precursor to decisions about which patients might 
be considered best candidate for PPTg-DBS and to which PPTg sites DBS should be targeted.   
1.3. L-DOPA induced dyskinesias 
After chronic treatment with L-DOPA, motor complications develop which can interfere with 
normal behaviour and can be more debilitating than the PD symptoms themselves.  
Dyskinesias include different types of movement disorders such as chorea-ballism, dystonia, 
myoclonus, tics and tremor (Guridi et al., 2012). L-DOPA induced dyskinesias (LID) are defined 
as involuntary, purposeless, irregular but potentially repetitive movements, which are mainly 
choreic in nature (Voon et al., 2009). They generally coincide with peak L-DOPA plasma 
concentrations [‘on’ period dyskinesias (Guridi et al., 2012)] but also appear as diphasic 
dyskinesias occurring both before the onset of L-DOPA benefit and as the effect is wearing off 
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(Obeso et al., 2000). The pathogenetic mechanisms are not completely agreed on (Winkler et 
al., 2002) but the degree of nigrostriatal damage and the use of L-DOPA – chronic, pulsatile 
and overall duration – are known to be determining factors. This non-physiological, 
intermittent stimulation of denervated DA receptors is thought to cause processes of striatal 
plasticity that change striatal synaptic functions and hence the excitability of the striatum, 
introducing changes in striatopallidal circuits such as a reduction in main firing frequencies in 
GPi and STN (causing an increase in thalamocortical drive leading to dyskinesias) (Guridi et al., 
2012; Thanvi and Lo, 2004). Given the complexity and interconnectivity of the BG with other 
structures it is likely that not only changes in striatal response to L-DOPA are involved in LIDs. A 
recent study showed that outside the BG there was a response to LIDs, measured by 
immediate-early gene expression, suggesting a possible involvement of structures such as the 
motor cortex, the dorsal hippocampus, the cuneiform nucleus and the PPTg (Bastide et al., 
2014). FosB expression was also noted in pedunculopontine and zona incerta of dyskinetic PD 
mice models (Ding et al., 2007). What is the nature of the effect of degeneration of those 
structures on LIDs? There is a vast literature employing rodent models of LIDs [for a review see 
(Duty and Jenner, 2011; Iderberg et al., 2012)] eliciting abnormal involuntary movements 
(AIMs) as a rodent manifestation of dyskinesias and examining the mechanisms responsible for 
treatment related dyskinesias in PD. However, there is no assessment of LIDs in PD models 
that include extranigral degeneration. There is evidence of what might be considered as 
dyskinesias in rats with PPTg damage. For example, PPTg lesioned rats showed enhanced 
stereotypic orofacial movements in response to either systemic or intra-ventrolateral striatal 
injections of d-amphetamine compared to sham operated animals (Inglis, Allen, et al., 1994) 
(Allen and Winn, 1995). Further, if the degeneration of the PPTg influences the motor 
performance of PD patients it is likely that it also has an effect on motor symptoms induced by 
L-DOPA.  Could stimulation of the PPTg correct LIDs? Chronic DBS of the EPN and Pf improved 
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dyskinesia scores in hemiparkinsonian rats that showed LIDs after chronic administration of L-
DOPA (Alam et al., 2014), while STN stimulation has been shown to be pro-dyskinetic (Jouve et 
al., 2010). 
1.4. Deep brain stimulation in clinical practice 
DBS stimulation in patients is – apart from the risk that the surgery involves – much more 
complex than treating the symptoms with medication. The most important factor for a 
beneficial outcome is patient selection. The decision for implantation of DBS electrodes has to 
be made carefully and to withstand a critical cost-benefit analysis. This evaluation in regards to 
a treatment of the cardinal features of PD, essential tremor and dystonia by targeting STN, 
thalamus and the GPi can nowadays be based on many years (and patients) of experience. For 
STN stimulation a patient has the best chance of a positive effect if the diagnosis is idiopathic 
PD with symptoms of bradykinesia, rigidity and/or tremor and if these symptoms are L-DOPA 
responsive. In this case, debilitating dyskinesias and severe motor fluctuations can be the 
reason for consideration of DBS and can be improved. Contraindications are a high age (>70), 
cognitive deficits (because these might be indicative of an atypical PD syndrome), axial L-
DOPA-resistant symptoms such as speech difficulties, FOG, psychiatric symptoms and general 
surgical contraindications like cardiovascular or respiratory problems. The main objective 
should be to achieve an increase of quality of life and therefore the real life situation of the 
patient and the expectations should be guidance in the decision. Consequently, extensive 
behavioural assessment of the symptoms, the psychiatric state, the response and possible 
dependence of DA medication (Ardouin et al., 2009; Thobois et al., 2010), cognitive 
assessment, often L-DOPA challenges and brain scans all have to precede the decision for the 
DBS surgery. This requires an extensive interprofessional team of neurologists, neurosurgeons, 
neuropsychologists and internists (Bronstein et al., 2011). Post-operative management can be 
complex and time consuming as well. It often takes several months until the optimal settings 
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are found and they require close monitoring to be able to respond to changes due to disease 
progression (Castrioto et al., 2013).  
Several companies offer stimulation systems which are becoming increasingly sophisticated. A 
major improvement was the development of devices carrying rechargeable batteries. New 
advances will include closed-loop modulation systems, which allow adjustments of stimulation 
parameters based on a feedback system – these have so far been used in DBS for epilepsy 
(Smith et al., 2010). Implantation techniques depend on training and experience of the 
surgeon and the capacities of the hospital. Different brain navigation systems exists (whether 
frame-based or frameless) and pre-operative assessment for the determination of target 
coordinates and calculation of the trajectory are based on different techniques including MRI 
and CT scanning, ventriculography, and intraoperative neurophysiological monitoring. 
Surgeons also differ in the use of general or just local anaesthesia. Confirmatory MRI scans 
after implantation in the operating theatre can detect problems of misplaced electrodes or 
haemorrhages immediately which ideally can be addressed during the same procedure 
(though not all centres can offer this). Bilateral electrodes are implanted during one or two 
procedures and the extension cables and pulse generators can be implanted the same day or 
any time after this (Benabid et al., 2009).  
Programming is intricate because the available range of frequency, pulse width and amplitude 
allows a large number of possible combinations. In addition, the electrodes are often 
quadrupolar, offering a variety of contact configurations as well.  The main aim should be to 
achieve an optimal clinical benefit, avoiding adverse side effects. Since the use of re-
chargeable devices, current consumption is not a very important factor to consider anymore.  
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1.5. DBS in behaving rodent models 
The rat brain is of course considerably smaller than the human brain and in a laboratory 
setting the surgical equipment generally does not include possibilities of in vivo scanning and 
intraoperative confirmation of electrode placement. Neither can stimulation settings be 
adjusted until an optimal benefit is achieved; on the contrary, an experiment requires strategic 
and consistent decisions on independent variables and maximal control of possible 
confounding variables. Therefore, many technical considerations have to be taken into account 
when deciding on materials and techniques. In the literature, most DBS studies in behaving 
rats are acute (Benazzouz et al., 2000; Gubellini et al., 2009; Schulte et al., 2006; Spieles-
Engemann et al., 2010). For stimulation, the rats are mostly implanted with electrodes which 
are then connected to a pulse generator. An interposed swivel prevents twisting of the 
connecting cables and allows relatively free movement of the rat. Using this technique, rats in 
an STN-DBS study were tested for PPI of startle (Lindemann et al., 2012) or during PPTg-DBS, 
rats were tested in different tasks including the cylinder test, adhesive removal test and open 
field exploration (Rauch et al., 2010). Other solutions are implantable devices (Paulat et al., 
2011), encapsulated in silicon rubber and sterilized before implantation. However, this 
technique poses a greater risk for infections and in case of device failure there is no direct 
access to it. Others have developed devices that can be carried by the rat in a backpack 
(Nowak et al., 2011). This, however, limits the rat’s mobility and can increase stress and 
anxiety. Forni and colleagues developed a microstimulator that can be attached and detached 
to a support base on the skull, which is connected to the implanted electrodes (Forni et al., 
2012). This solution appears to be the most elegant, because it gives the rat completely free 
movement as long as the device is well balanced and not too heavy. It is constantly accessible 
for control and maintenance, the battery can be changed (which allows chronic stimulation 
over a long period of time), it decreases the risk of inflammation and mechanical irritation of 
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subcutaneous tissue and, in the case of device failure, it can be repaired or exchanged. For 
these reasons, the decision in the present study was to create a headstage for the stimulation 
device. The microstimulator was designed by a colleague of the Strathclyde Institute of 
Pharmacy and Biomedical Sciences Richard Pinnell. (For more details please see below.)  
For this study, first a series of methodological aims needed to be achieved before the 
experimental questions could be addressed:  
Methodological aims: 
(i) In order to accommodate a headstage on the skull of the rats that would be able to hold the 
DBS device securely in place for chronic stimulation, the size of the rats needed to be 
increased. Hence, the well-established PPTg coordinates for smaller rats required verification 
and, if necessary, adjustments. (ii) Small electrodes and a headstage offering secure fixture of 
the device but also quick release of it had to be developed and surgical techniques established. 
(iii) The stimulation system – electrodes, headstage, device, battery – had to be tested for its 
effect on normal behaviour of the rats and its overall durability in a long experimental 
protocol. 
Experimental Aims:  
The experimental aim of this study was to define more accurately what the potential for PPTg-
DBS might be in order to make predictions about what effects might be expected from chronic 
stimulation of particular parts of the PPTg. Taking forward the refined PD model described in 
the previous chapter two experiments are presented here that describe the effects of DBS of 
different sites within the PPTg – namely the anterior and the posterior part of the structure - 
on gait and L-DOPA induced side effects. Before, methodological considerations and the 
respective pilot studies are summarised. 
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2. Pilot 2: Coordinates pilot 
2.1.  Introduction 
The coordinates for lesions of anterior and posterior PPTg as used in the previous experiments 
have been employed in this lab for many years and the rate of successful toxin infusions into 
the correct site was high. However, in order to increase the stability of the headstage in this 
experiment the decision was made to use bigger animals than before (minimum of 
approximately 380g instead of 330g) to have a bigger surface to work on and a thicker skull to 
hold the weight of the stimulation device. Changing the animals’ weight required verifying the 
accuracy of the coordinates. 
2.2. Methods and procedure  
A total of eight rats at a mean weight of 385g (range 379g – 393g) were used to test and 
correct the coordinates for ibotenic acid infusions into anterior and posterior PPTg in two sets 
of two rats and one set of four.  
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1) n = 2 rats received unilateral lesions using 200 nl of 0.06M ibotenic acid into the previously 
used target sites with the following coordinates (in mm): anterior PPTg: + 0.6 from IAL, ± 2.0 
from midline and - 7.0 from dura; posterior PPTg: - 0.8 from IAL, ± 1.9 from midline and - 6.5 
from dura. 
 
  
 
 
After perfusion, 2 days after surgery, the brains were sectioned and stained for NeuN/Cresyl to 
determine the lesion placement (see Figure 5.1.). Based on the findings, the decision was 
made to move the anterior coordinate backwards by 1 mm and the posterior electrode 2 mm 
more ventrally. Given that the surgery is performed at an angle with the nose of the rat 
elevated, going “deeper” also means going further caudally. 
 
 
Figure 5.1. Representative histological photomicrographs of lesions in anterior and posterior PPTg after 
infusion of 200nl of 0.06M ibotenic acid per site at previously used coordinates (see text for details). 
Sections are all NeuN/Cresyl stained. (A) The lesion covers the very rostral part of the PPTg and reaches 
probably into SN; (B) The medial-lateral and dorsal-ventral position in anterior PPTg looks good. (C) The 
posterior lesion sits too high. The brown patch is surprising but appears repeatedly in these pilots, 
however have hardly ever been seen – or only in very extensive, full lesions – in previous (and later) 
experiments. The reason can be that these rats were perfused only 2 days after the surgery, whereas 
usually there is a longer period of time between lesion and perfusion. The dark stain is likely the product 
of an immediate but transient inflammatory response to the injection. 
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2) n = 2 rats therefore received unilateral lesions using 200 nl of 0.06M ibotenic acid using the 
following coordinates (in mm): anterior PPTg: + 0.5 from IAL, ± 2.0 from midline and - 7.0 from 
dura; posterior PPTg: - 0.8 from IAL, ± 1.9 from midline and - 6.7 from dura. 
 
 
 
 
 
 
The placement of the lesions of the posterior infusion appeared to be reaching too far caudally 
of the end of the PPTg. In addition, especially one lesion was more extensive than expected 
and in comparison to others. This obviously could have been due to an inexact volume of the 
toxin and therefore creating a bigger lesion. Nevertheless, two more changes were piloted 
based on these observations: 
 
 
 
Figure 5.2. Representative histological photomicrographs of lesions in anterior and posterior PPTg after 
infusion of 200nl of 0.06M ibotenic acid per site at adjusted coordinates which brought the anterior 
infusion further caudal and the posterior lesion more ventral/caudal (see text for details). Sections are 
all NeuN/Cresyl stained. (D) Lesion placement is good, the lesion size however is on the large side. (E) 
The dorsal-ventral position is much better. (F) The posterior lesion reaches into several sections caudal 
of the PPTg).  
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3) n = 2 rats received infusions of 200 nl ibotenic acid into the same (changed) coordinates 
used in 2) however at a lower concentration of 0.04M. In n = 2 rats 200 nl of 0.06M ibotenic 
acid were infused, moving the posterior coordinate 1 mm further rostrally, keeping the 
previously changed deeper dorsal-ventral measurement. 
 
 
 
 
 
 
The purpose of reducing the toxin concentration was to avoid creating a large lesion that went 
much further caudal than the PPTg. This was successfully done with 0.04M of ibotenic acid, but 
the overall lesion size was considered too small. The coordinates as adjusted and used with 
0.06M ibotenic acid produced satisfactory lesion placements, though still slightly caudal. 
Figure 5.3. Representative histological photomicrographs of lesions in anterior and posterior PPTg after 
infusion of 200nl of 0.06M ibotenic acid per site at further adjusted coordinates which brought the 
posterior infusion further rostral (G – I; see text for details);and after infusion of 200nl of 0.04M ibotenic 
acid at coordinates used in (ii). Sections are all NeuN/Cresyl stained. (G) Lesion placement is good. (H) 
Lesion reaches a bit too far ventral. (I) The posterior lesion still reaches into several sections caudal of 
the PPTg. (J) Position is good, lesion size is small. (K) Good placement, too small. (L) No further lesion 
behind the caudal end of the PPTg.  
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Nevertheless, the decision was made to use these coordinates, because moving the posterior 
infusion further rostral would have carried the risk of overlapping lesions of anterior and 
posterior infusions. 
The final coordinates therefore were (in mm): anterior PPTg: + 0.5 from IAL, ± 2.0 from midline 
and - 7.0 from dura; posterior PPTg: - 0.7 from IAL, ± 1.9 from midline and - 6.7 from dura. 
3. Pilots 3 – 5: Development and pilots of the DBS system (pulse 
generating device, headstage and electrodes)  
3.1. Introduction 
3.1.1. Device 
As described above critical features in the pulse generating device were the possibility to easily 
detach the device for maintenance and battery exchange, a wireless operation of the device, 
and a size and weight which allowed to place the device onto the rats’ head rather than 
implanting it subcutaneously. Richard Pinnell, a PhD student under the supervision of 
Professor Judith Pratt, was developing a wireless DBS device in the course of his studies. 
Together we developed a head mountable fixture for the device, which was small enough to fit 
on the rats’ skull offering enough stability to hold the device. 
Further, specific decisions had to be made regarding the configurations and technical features 
of the device. (i) Constant-voltage or constant-current: Constant-voltage (or voltage control) 
stimulators maintain a constant voltage emission, and if the stimulus wave form is a 
rectangular voltage pulse, the actual current pulse does not have a rectangular shape and will 
vary. The fluctuations in resistance due to different and changing compositions of brain tissue 
can have an important effect on the actual current. Constant-voltage devices consume less 
battery power. Constant-current (or current control) stimulators: the amplitude of the current 
pulse is independent of the electrode-tissue impedance, because the voltage curve will be 
154 
 
constantly adjusted to create a consistent current flow. (ii) Mono-phasic vs biphasic: Mono-
phasic pulses result in a charge build-up at the electrode/tissue interface, which causes 
damage to the tissue. An alternative are biphasic pulses with a second pulse going in the other 
direction (anodic pulse) of the same size to achieve a charge balance at the electrode poles 
(Butson and McIntyre, 2007; Hanson et al., 2008). In the clinical setting, the stimulators deliver 
pulses followed by a repolarising pulse of smaller amplitude. (iii) Channels: the original device 
was designed to record from one channel (corresponding to two electrodes) and stimulate 
through a second one. By eliminating the option for electrophysiological recording space was 
freed on the central processing unit for further control over stimulation settings (pulse shape, 
frequency, pulse width, intensity) without having to increase the size of the device. 
Furthermore, it offered a second channel for possible simultaneous stimulation of two brain 
structures; an option also discussed in the literature (Ferraye et al., 2011; Stefani et al., 2007). 
(iv) Ranges: the device needed to offer programmability of stimulation parameters covering at 
least 20 – 130 Hz for the stimulation frequency, 60 – 500 µs for the pulse width and 30 (or as 
low as possible) – 400 µA stimulation amplitude. (v) Safety: the original device very cleverly 
offered the possibility to change stimulation parameter wirelessly, without having to detach 
the device from the animal’s head. However, for safety reasons (for complete control over a 
continuous and stable stimulation without changes to the settings over the entire time of 
chronic stimulation) the default code of the device’s CPU needed to be easily programmable to 
ensure that no change of stimulation settings would occur in the case of a device failure and 
consequential reset. Further, the device required a switch, which would offer a quick 
interruption of the stimulation activity.  
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3.1.2. Electrodes 
The choice of the electrode design needed to reflect the need for a small electrode that causes 
the least amount of mechanical damage as possible. Furthermore it had to deliver current to 
the tissue precisely and the stimulation-induced damage – inflammation, glial scar formation –
kept to a minimum. Electrochemical reactions at the interface of electrode and tissue are 
unavoidable (Gimsa et al., 2005). The risk of damaging tissue depends on the electrode 
properties, stimulation waveform, charge per phase, charge density, and total stimulation time 
(Harnack et al., 2004). The right choice of material can significantly reduce the amount of 
damage. Stainless steel has the advantage of being strong but unfortunately causes significant 
damage to neuronal tissue within a wide region around the tip of the electrode after high 
frequency stimulation (HFS) (Harnack et al., 2004). In fact, stainless steel showed the lowest 
resistance to corrosion (for direct current) in comparison with platinum, platinum/iridium and 
tungsten (Stevenson et al., 2010) and damaged volume induced by Pt/Ir electrodes was 
significantly lower in comparison with stainless-steel electrodes (Gimsa et al., 2005; Harnack et 
al., 2004). Platinum/Iridium alloys in a proportion of 90:10 is a commonly used material with a 
higher biocompatibility. It also evokes tissue responses, though these were described as being 
less than with other materials such as stainless steel, titanium, tungsten (Geddes and Roeder, 
2003).  
No electrodes are available which represent a comparable downscaled version of multi-polar 
electrodes used in human DBS. One option is to use a monopolar electrode, which consists of 
an electrode with one pole (usually the cathode) at the target site in the brain and an 
extracranial anode. This type of electrode might influence a larger area than a bipolar 
electrode. Bipolar electrodes have an increased target specificity compared to the spherical 
field created with a unipolar electrode. A bipolar electrode can either consist of two separate 
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unipolar electrodes with a specific pre-defined distance between which the current travels. A 
further option is a concentric electrode, which is made of a cannula through which a wire is 
threaded. The tip of the cannula and the tip of the wire make the two poles. The limitation of 
the parallel wires is the difficulty in maintaining consistently the same distance between the 
two poles. Concentric electrodes have the lowest stimulus artefact and their biggest advantage 
is that they do not have any directionality – orientation of the electrode while implanting it is 
of no issue.  
Impedance depends on the electrode material, the nature of the tissue, the surface area and 
the stimulation parameter. It decreases with increasing frequency and current density. The 
impedance of the electrode-tissue interface determines the actual charge delivered to the 
tissue, the volume of neural activation (Butson and McIntyre, 2005), the distribution of current 
density on the electrode and therefore consequence like neural excitation, tissue damage and 
electrode corrosion (Wei and Grill, 2009). In vivo impedance quantification of electrode-
electrolyte interface was not possible in this study. However in vitro identification of 
impedance in aCSF was performed to obtain a point of reference for the comparison with 
other electrodes and to test consistency of these homemade electrodes.  
3.2. Establishing materials and methods 
3.2.1. Device  
The microstimulator consisted of two printed circuit boards (PCBs) containing the transceiver 
module, voltage amplifier, constant-current generator and microcontroller. The 
microcontroller could be programmed for the required frequency (range 0.1 Hz – 5 KHz) and 
pulse width (range 10 µs – 500 ms). A variable resistor offered the possibility of manual 
adjustment of the devices intensity output individually for each channel (range 30 µA – 1.5 
mA). It was designed to deliver constant current square waves: with either anodal, cathodal, or 
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biphasic pulses. For system configuration (parameter setting) the programme software IAR 
Embedded Workbench IDE was used by connecting the device to the computer via a debug-
interface module and a custom-built reprogrammer circuit (built by Richard Pinnell). For quick 
interruption of the stimulation circuit a slide-switch was interposed. The final dimensions of 
the device were 1.5 cm x 3 cm x 0.5 cm at a weight of 5g.  
3.2.2. Batteries  
The use of button cell lithium batteries allowed keeping the weight and the size of the pulse 
generator system small, however at the cost of having to replace the batteries regularly for 
chronic stimulation. The choice fell on CR2032 (see Figure 5.4.) because of their flat shape that 
would only add a few millimetres (about 5 mm) to the device’s dimensions. In a series of test 
running the device at different stimulation parameters using this battery I could confirm that 
when running the device at 25 Hz, 160 µs at a biphasic mode with the stimulation intensity set 
relatively high [about 500 µA following the results of (Rauch et al., 2010)] the battery would 
last for a guaranteed 76h before the device’s performance became unstable. At a higher 
frequency of 130 Hz and a pulse width of 400 µs this threshold dropped to 60h. Using two 
channels of the device (which would correspond to four electrodes) a guaranteed stable 
performance lay between 24 and 48h. On the basis of these tests the decision was made to 
change the batteries every other day to avoid irregularities of the chronic stimulation. The 
battery added about 3.5g to the weight of the stimulation device. 
3.2.3. Headstage 
Chronic stimulation was possible with a connector stage mountable to the skull, which 
connects to the implanted electrodes. The home cages were modified to prevent snagging. In 
several pilot surgeries (Pilot 3) the headstage was finalised and adjusted in a further pilot 
during which the wearability was tested over a prolonged period of time. 
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Figure 5.4. (Pilot 3) Photographs illustrating the development of the headstage design. (A) The first 
design was small. However, it did not offer enough support for the device. Especially after decreasing 
the friction between headstage and device: initially the device was sitting too tightly on the pins, which 
made it difficult and stressful for the rat to attach and remove the device without risking to the 
adhesion of the headstage to the skull. (B) Also, because of this, there was a gap between the device 
and the base of the headstage. (C) shows the device and the first prototype of the headstage. (D) The 
second version featured a case for the device to sit in and a screw, which allowed securing the device to 
the headstage (E). The final version of the headstage (F) had an additional second screw on the opposite 
side (not visible here). (F) also shows the final device and the battery. 
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The DBS device had to be well tolerated by the rat in order to assure its well-being; further gait 
parameters should not be affected by simply wearing it (in OFF mode) to not confound the 
results. For this reason in Pilot 4 three rats received implants of electrodes into the PPTg and 
headstages as presented in Figure 5.4.E. The first of these animals was kept for three weeks 
and monitored if the headstage had an effect on the rat’s wellbeing and if it adapted well to 
manipulations of the headstage when attaching and detaching the device. The rat did not 
receive any stimulation. The headstage and device were tolerated well and did not modify the 
spontaneous activities of the animal such as feeding, sleeping and moving and neither did the 
attached device. Figure 5.5. shows how well the rat adapted to extra height on its head when 
sleeping.  
 
 
The other two rats also had implanted electrodes connected to headstages. After a week of 
recovery, the rats were trained on the CW and then tested, first without wearing the device for 
two days and then with the device attached (no stimulation) for another two days. The testing 
protocol followed the CW testing protocols described in the General Methods and the other 
experimental chapters. Figure 5.6. shows that wearing the device itself – without stimulation – 
Figure 5.5. (Pilot 4).The rats adapted well to the device in their basic activities. 
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caused no difference in the rats’ gait measured on the CW. Univariate ANOVAs confirmed the 
absence of any significant difference between the rats carrying the device and not (BOS front: 
F1,6 = 0.847 p = 0.393; BOS hind: F1,6 = 0.173 p = 0.692; Stride Length front: F1,6 = 0.081 p = 
0.786; Stride Length hind: F1,6 = 0.002 p = 0.963; Swing Speed front: F1,6 = 0.249 p = 0.635; 
Swing Speed hind: F1,6 = 3.437 p = 0.113; Regularity Index: F1,6 = 1.000 p = 0.356). Pilot 3 also 
served to refine the surgical techniques (elevated nose for electrode implant to avoid damage 
to the sinus situated right above the PPTg) and determination of the required length of the 
electrode and of the connecting wires. Further, craniotomies were performed above the 
striatum as required for striatal infusion of 6-OHDA to test the skull stability. These extra holes 
in the skull did not seem to have an effect on the stability of the headstage. 
 
Figure 5.6. (Pilot 4). Selected gait parameters of rats without and with the device attached to the 
headstage. Graphs show group means ± SEM. 
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3.2.1. Electrodes 
The electrodes were made in the lab using Teflon coated platinum/iridium (90:10) wire 
(uncoated diameter 50 µm, coated diameter 114 µm; Science Products GmbH, Hofheim, 
Germany) threaded through a 30 ga stainless steel cannula (Plastics One, Roanoke, VA, USA) 
protruding 500 µm. The cannula was insulated with polyolefin 2:1 heat shrink. Both the 
cannula and the wire were bared of the insulation material at the extremity leaving a bared tip 
of 250 µm. The exposed surface area of each pole was therefore approximately 0.041 mm2 for 
the exposed tip of the inner wire and 0.236 mm2 for the exposed end of the cannula. This 
electrode has a total diameter of 300 µm (cannula) + 50 µm (insulation). Short pieces of wire 
connect both, the cannula and the wire, to connector pins, which were to be connected to the 
headstage during implantation surgery. Before use the electrodes were tested fully immersed 
in 0.9% saline solution to check for breakages of the insulation. Before deciding on this very 
thin Pt/Ir wire, which allowed the use of a 30 ga cannula, it was tested, whether it could 
withstand the resistance of brain tissue without bending, by pushing it into clay at the above 
described parameters (500 µm protruding from a 30 ga cannula).  
 
 
 Figure 5.7. Photograph and photomicrograph of concentric electrodes. (A) The electrode is attached to 
a guide cannula by means of dental cement. The green and pink wires connect the cannula and Pt/Ir 
wire respectively to the headstage.   
500 µm 
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To determine the impedance of the electrodes a sample of 6 electrodes were randomly 
selected and measured performing in vitro stimulation with the electrode tip immersed in aCSF 
(148mM NaCl, 2.7mM KCl, 1.2mM CaCl2, 0.85mM MgCl2.6H2O) at room temperature using a 
Solartron 1260 impedance analyser (Solartron Analytical, Farnborough, UK). The electrodes 
were stimulated in constant current mode at stimulation parameters used in the experiment 
at (a) 25 Hz, 160 µs and 50 µA and (b) 25 Hz, 160 µs and 100 µA. The electrode impedance for 
50µA was 22.3 ± 1.6 kΩ and for 100 µA the impedance was 21.2 ± 1.4 kΩ *calculated from the 
measured reactance and resistance using the equation |Z|= sqrt((Z’^2)+(Z’’^2)), with Z’ = 
resistance and Z’’ = reactance].  This impedance is much lower than the impedance tested in 
vitro by Forni and colleagues (2012) who used parallel, bipolar, Pt/Ir electrodes. However, the 
impedance evaluated in vivo - 16.5 ± 1.3 kΩ - was very similar to the impedance measured 
here. Here, aCSF was used for in vitro measurements, whereas Forni and colleagues used a 
0.9% saline solution. The aCSF solution might have a better conductance than the saline 
solution. More importantly, the measurements of the impedance showed, by the small SEM, 
the consistency of the construction of these homemade electrodes.  
A final set of four pilot surgeries (Pilot 5) were conducted to assess the effect of stimulation 
and the feasibility of chronic stimulation. Two rats were implanted with bilateral electrodes 
(here still all stainless steel concentric electrodes) into anterior PPTg using coordinates 
established in Pilot 2. After a minimum of 7 days of recovery, the stimulation-induced side 
effects for each animal were determined at a stimulation of 25 Hz (frequency) and 160 µs 
(pulse width) and the intensity adjusted accordingly. Both rats were stimulated at a final 
amplitude of 96 µA. One of the animals was stimulated over 12 days before it lost its device. In 
the meantime, it had lost the battery once as well. The other rat lost the device after 5 days; 
further, the switch had broken off. This pilot showed that the general behaviour, once a 
stimulation intensity was found that did not cause any side effects, was not affected by the 
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stimulation and the rats were able to feed, drink and groom themselves. The spontaneous 
activity in the homecage did not seem to be altered. Further, it showed the exposure of the 
device to possible damage in the homecage. For this reason the decision was made to wrap 
the device into parafilm (Bemis Company, Inc., Neenah, USA) after setting of parameters was 
completed and the battery attached. This protected the device from water and dust and held 
the battery in place. 
 
 
 
 
The final two rats underwent further pilot surgeries to finalise the electrode design (length of 
the electrode and use of Pt/Ir). Both started chronic stimulation 9 days after surgery at 25 Hz, 
and 160 µs. Unfortunately, one rat lost its headstage after 27 days. The other rat was perfused 
after 43 days. During this time both rats were successfully stimulated for 10 days without 
causing changes in the rat’s general behaviour and wellbeing. During the rest of the time they 
were kept with the device attached to the headstage to assess long-term headstage stability. 
 
Figure 5.8. (Pilot 5). Final design of headstage and stimulation device. The device is wrapped in parafilm 
for protection. The red LEDs indicate ongoing stimulation of bilateral electrodes. 
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3.2.2. Stimulation parameters 
Stimulation parameters for the experiments described in this chapter were: 
(i) Pulse shape: Biphasic square constant current waves to avoid charge build-up at the 
electrode/tissue interface as described above. 
(ii) Frequency: 25 Hz. Based on the literature more beneficial results were achieved with LFS 
rather than HFS in the PPTg (Jenkinson et al., 2004; Mazzone et al., 2005).  
(iii) Pulse width: 160 µs and 500 µs. A crucial question regarding the mechanisms behind DBS is 
the question whether soma or axons are mainly affected by the stimulation. The truth is that 
different factors determine current spread and therefore the effect of DBS: the characteristics 
of the stimulated tissue play a crucial role in current spread: axon diameter, whether axons are 
myelinated, axon orientation with respect to the electrode, and what is closest, soma or axon. 
Chronaxie describes a tissue-excitability parameter and is the determining factor for the choice 
of pulse duration. It is the minimum time required to stimulate an excitable tissue at double 
the strength of the rheobase (minimal current amplitude that is required for depolarisation 
threshold of the cell membrane). Pulse width and amplitude are inversely exponential: With 
higher amplitude the pulse width can be shorter. In addition, the type of neural element 
influence the chronaxie and it was suggested that longer pulse widths influence the cell soma, 
whereas shorter pulse widths mainly affect axons (Kern and Kumar, 2007). For this reason a 
shorter pulse width of 160 µs (with change of direction after 80 µs) was chosen as described by 
Rauch and colleagues (Rauch et al., 2010), and a longer pulse width of 500 µs. 
(iv) Intensity: Individual differences and slight deviations during implantation surgery can 
affect the effect of the stimulation. In PD patients, all parameters are individually set and 
modified until the best clinical benefit is achieved. Here, frequency and pulse width were 
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maintained constant, but the stimulation intensity was set individually according to the 
stimulation induced side effects observable in the rats. (Please refer to the General Methods 
for details.) 
4.  Main experiments: Anterior and posterior PPTg-DBS 
4.1.  Methods 
4.1.1. Subjects 
Forty-two adult male Lister-Hooded rats (Harlan Olac Ltd, Bicester, UK) were used in two 
experiments. The first stimulation experiment targeted the posterior PPTg (pPPTg-DBS); the 
second experiment targeted the anterior PPTg (aPPTg-DBS). At the start of baseline testing the 
mean weight of the animals of the pPPTg-DBS experiment was 385g (range 378 – 390g) and 
380g (range 363 – 390g) of the aPPTg-DBS experiment. The animals were put on food control 
once they had reached their target weight of 380g so all animals maintained their weight for 
the first surgery (pPPTg-DBS: mean weight = 384g; range  380 – 388g; aPPTg-DBS: mean weight 
= 381g; range 367 – 387g). A stable mean weight of 380g with a range of 371 – 389g and 379g 
(range 366 – 396g) was maintained over the entire period of the experiment. For further 
details on housing, please refer to the General Methods. 
4.1.2. Experimental protocol 
In both experiments parkinsonian models (traditional and refined) and sham controls with 
implanted DBS electrodes into anterior or posterior PPTg underwent a series of different 
testing conditions after surgery (represented schematically in Figure 5.9.). After 11 days of CW 
training a post-surgical baseline was taken (3 days), then their response to levodopa was 
observed on 2 consecutive days. After a washout period of 2 days rats were re-tested on the 
CW before DBS was switched on. Stimulation was chronic and lasted 6 days: rats were tested 
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on day 4, 5 and 6 during that period. After a day of rest from stimulation, DBS was switched on 
again, maintaining the same frequency but changing the pulse width. Testing followed the 
same pattern as before. After testing on day 6 of stimulation, the DBS was left on. The 
following 2 days the rats were tested for their reaction to the combination of L-DOPA and DBS. 
DBS was then switched off and the rats given a day of rest before being re-tested for the last 
time. 
 
 
 
 
 
 
4.1.3. Surgical procedures 
Surgery followed the protocol as described in the General Methods. In brief: 
Bilateral DA depletion of the SNc 
7 µg (free base weight) of 6-OHDA-hydrobromide dissolved in 2 µl of 0.1% L-ascorbic acid 
/0.9% saline were delivered to 4 sites in the striatum of both sides at the following coordinates 
(in mm): (1) AP: + 1.3 (measured from Bregma), ML: ± 2.6 (measured from midline at the skull 
Figure 5.9. Experimental design. At the start of the experiment all animals were trained for 11 days on 
the Noldus CatWalk. They were then tested for 3 days to obtain a pre-surgical baseline. Rats then 
underwent 1 or 3 successive surgeries for 6-OHDA infusion, PPTg lesion surgeries and DBS electrodes 
implantation with 7 days in recovery in between procedures. 7 days after the last surgery they were 
then re-tested on the CW under post-surgical baseline condition, after L-DOPA administration, under 
two different chronic DBS-ON conditions and DBS-ON + L-DOPA condition. For more details please refer 
to the text. 
167 
 
surface), DV: - 5.0 (measured from Dura); (2) AP: + 0.4, ML: ± 3.0, DV: - 5.0; (3) AP:  - 0.4, ML: ± 
4.2, DV: - 5.0; (4) AP: - 1.3, ML: ± 4.5, DV: - 5.0. Infusions were controlled by a Harvard 
microdrive pump. Control rats received infusions of vehicle only (here: 0.1% L-ascorbic acid 
/0.9% saline solution) into the same sites. After surgery all rats were placed into a heated 
recovery cage and given 2-2.5 ml of Hartmann’s solution (i.p.). 
Combined lesions 
Rats that received a combination of DA depletion and partial bilateral PPTg lesions underwent 
3 separate surgeries. In 2 surgeries separated by a week the PPTg was bilaterally lesioned by 
microinfusions of ibotenic acid into the anterior or posterior PPTg at the following coordinates 
(in mm): anterior PPTg: + 0.5 from IAL, ± 2.0 from midline and - 7.0 from dura; posterior PPTg:  
- 0.7 from IAL, ± 1.9 from midline and - 6.7 from dura. Infusions were always made anterior 
first but the order of infusions regarding the choice of side was counterbalanced. Rats were 
infused with 200 nl of 0.06M ibotenic acid per infusion site. Control rats received infusions of 
vehicle only (here: PB) into the same sites. At the end of surgery rats were treated with 1-1.5 
ml of Hartmann’s solution (i.p.) to account for the lack of fluid intake during the time of 
surgery. Furthermore, they also received an i.p. injection of 0.2ml Diazepam to reduce the risk 
of injury due to the immediate effect of the excitotoxin. Following a further 7 days of recovery 
the DA depleting procedure was performed as described above. 
Electrode implantation 
Both PD models received implantations of concentric bipolar electrodes into either the 
anterior or posterior PPTg. These procedures were conducted during the same surgery as the 
infusion of 6-OHDA for DA depletion. After the last infusion of 6-OHDA into the striatum the 
skull was cleaned and dried and bone wax (Henry Schein Animal Health, Dumfries, UK) was 
used to close the burr holes above the striatum. Unless burr holes had already been made in 
168 
 
previous procedures they were now drilled above the anterior or posterior PPTg on both sides 
using the same coordinates as stated for the PPTg lesion procedure. Five to 6 stainless steel 
round-head machine screws with sharply cut threads (0-80 x 1/8 and 0-80 x 3/32); Plastics 
One, Roanoke, VA, USA) were screwed into the skull. The first electrode (for details about the 
electrode design and material please see Section 3.2.1. of this chapter) was then carefully 
lowered into place (anterior or posterior PPTg) and fixed onto the skull and neighbouring 
screw using a methyl methacrylate based dental acrylic (Simplex Rapid, Kemdent Works, 
Wiltshire, UK). The electrode was detached from the guiding cannula and the procedure 
repeated for the implantation of the second electrode. Anode and cathode of the electrodes 
were then carefully connected to the headstage (see details about the headstage in Section 
3.2.3 of this chapter) and the headstage was then fixed with more dental cement to the skull. 
Rats were given an i.p. injection of 2.5 ml Hartmann’s solution (Baxter Healthcare Ltd, Norfolk, 
UK) at the end of the procedure. 
4.1.4. Training and testing on the CatWalk 
Rats were trained for 11 days prior to baseline testing and surgery and tested as described in 
the General Methods. Red LEDs on the device corresponding to the connected electrodes 
indicated functioning of the device. This blinking red light often caused the recording of CW-
runs to start before the rat had entered the start box of the glass walkway. On those occasions 
the clips were manually cut to match with the actual start of the run of the rat. 
4.1.5. Gait parameters 
The following gait parameters were examined: BOS, swing speed, stride length and duty cycle 
of both front and hind legs, print position of ipsilateral paws and the support formula of 
diagonal pairs of paws and three paws. For details on the gait parameters please see the 
General Methods. 
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4.1.6. Stimulation protocol  
Details on intensity settings, battery changes and regular checks can be found in the General 
Methods. In brief; DBS devices were programmed and tested on an oscilloscope. The 
stimulation intensity was then manually set to the lowest point possible (~30 µA). Then, the 
threshold for stimulation-induced behavioural side-effects was determined for each rat 
individually in a step-wise procedure. Typical side effects were slowing or an arrest of 
exploratory behaviour up to “freezing” and “staring”, erected whiskers and/or ears. Once one 
or several of these side effects were detected the intensity was reduced by 20% of this side 
effect inducing intensity and re-tested. Once satisfactory stimulation intensity was determined 
the device was securely fixed onto the headstage and switched on. The rat was then returned 
to its homecage. Final average stimulation intensities were in the pPPTg-DBS experiment: 
DBS1: 107 µA (range 72 µA – 136 µA); DBS2: 105 µA (range 72 µA – 152 µA; for both settings 
the intensity was lower for 6-OHDA group than for the other groups); in the aPPTg-DBS 
experiment: DBS1: 78 µA (range 56 µA – 120 µA); DBS2: 61 µA (range 40 µA – 72 µA). The 
devices were checked at least twice a day by inspecting if the red LEDs were indicating ongoing 
stimulation. Every other day the battery of the device was changed.  
4.1.7. L-DOPA injections and L-DOPA induced abnormal involuntary movements 
For assessment of L-DOPA induced AIMs in both PD models rats received injections of L-DOPA 
(12 mg/kg/ml L-3,4 – Dihydroxyphenylalanine methylester [free base weight] plus 15 mg/kg/ml 
Benserazide hydrochloride [free base weight] in sterile 0.9% saline i.p.). Immediately after the 
injection they were returned to their homecage but kept under close observation (with the top 
of the cage removed) to classify and quantify L-DOPA induced AIMs. Ratings of behaviour were 
made using a modified version of the Creese-Iversen scale (Creese and Iversen, 1973) (for 
more details please refer to the General Methods).  
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4.1.8. Histological assessment 
The area of the PPTg and the SN were histologically assessed for overall neuronal damage, 
cholinergic cell loss and loss of dopaminergic neurons respectively, and placement of DBS 
electrodes (following the protocols described in the General Methods). In brief, at the end of 
behavioural testing rats were transcardially perfused with a fixative, the brains removed and 
stored in sucrose solution until they sank. A series of 1:6 coronal 30 µm sections was cut on a 
freezing microtome. 
PPTg lesions 
For PPTg assessment the corresponding sections were immunohistochemically stained for 
NeuN and ChAT, mounted on glass slides and examined under a light microscope. Overall 
neuronal damage was assessed visually on the NeuN/Cresyl stained sections and rated on a 
scale from 0 (no lesion) to 4 (extensive lesion). Lesions were accepted and rats included into 
the analysis when they received a rating of at least a 1 (small/partial lesion). Animals were 
excluded when both sides received a 4 (extensive lesion). Cholinergic cell survival was assessed 
by software assisted counts of ChAT+ neurons. The quantification of ChAT+ neurons of the part 
of the PPTg in which the electrodes were implanted was not possible. Therefore only ChAT+ 
cell loss of the non-implanted portion of the PPTg was analysed. 
SNc lesions 
Sections corresponding to the SN were immunohistochemically double-stained for TH and Cb 
and similarly examined under a light microscope. All TH+ neurons within the dorsal and ventral 
tier of substantia nigra part compacta (SNc; SNcd and SNcv respectively), substantia nigra pars 
medialis (SNm) and substantia nigra pars lateralis (SNl) were counted using a handheld cell 
counter. 
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Electrode placement 
Electrode tip location in the DBS experiments was determined by examining electrode track 
evidence on ChAT+ stained and counterchecked on NeuN/Cresyl stained sections where there 
were not enough ChAT+ neurons visible to make a judgement. 
4.1.9. Data analysis 
FOG 
The occurrence of FOG was analysed by means of the Chi-square test of independence to test 
whether one of the groups that suffered from FOG was more likely to do so than the other.  
CW data 
Preceding any analysis, the data were assessed for pre-existing differences (univariate ANOVA 
between groups) and the effect of the different testing conditions on sham controls was 
assessed (repeated measures ANOVA within conditions). The effect of DA depletion and DA 
depletion plus additional PPTg lesions, as well as the effect of DBS was explored by mixed 
ANOVAs across condition (pre surgery, post-surgery, DBS1 and DBS2, within subject factor) and 
between groups (combined lesion group, 6-OHDA group and sham controls, between subjects 
factor) and further examined for simple main effects performing univariate ANOVAs between 
groups and repeated measures ANOVAs in the case of significant group x condition 
interactions. Normality of the data was identified by the Shapiro-Wilk test and homogeneity of 
variance by the Leven’s test. The handling of violations of these assumptions is reported in the 
results section when they occurred. All tests were conducted using SPSS version 21 (IBM Corp., 
Armon, NY, USA) and results were considered statistically significant when p ≤ 0.05.  
L-DOPA induced AIMs 
Mixed ANOVAs with group as between subject factor and severity scores 1 – 6 as within factor 
were conducted to assess the data for interactions between severity state of dyskinesia and 
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groups. Simple main effects were further tested in the case of a significant interaction. In order 
to directly compare the effect of anterior and posterior PPTg-DBS mixed ANOVAs with group 
as between subject factor and ON vs OFF condition as within subject factor were conducted on 
relevant dyskinesia scores. 
4.2. Results 
4.2.1. Histological analysis 
Electrode placements 
Despite presenting and discussing the results of the 2 experiments together in one chapter 
they will be analysed and illustrated separately in the following.  A total of 42 rats were used, 
21 in the anterior PPTg-DBS experiment and 21 in the posterior PPTg-DBS experiment. In both 
experiments 6 rats each underwent surgeries for the traditional PD model, 9 each underwent 
the 3 surgeries necessary for the refined model (combination of DA depletion and PPTg lesion) 
and 6 each received control infusions of vehicles – 3 striatal infusions and 3 infusions into 
striatum and PPTg. 
The following flow chart summarises the numbers and reasons for exclusion of subjects (Figure 
5.10.)  
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 Anterior PPTg-DBS Posterior PPTg-DBS 
Rats undergoing surgeries   
 
 
 
  
Deaths on surgery table - 2 
Deaths during recovery 3 3 
 
 
 
 
 
  
 
Groups before histology 
 
6-OHDA combined sham 6-OHDA Combined sham 
  
 
 
  
Excluded due to misplacement of electrodes 1 1 1 1 - 2 
Excluded due to extensive tissue damage - - - - 1 - 
 
 
 
 
 
 
 
 
 
 
 
 
FINAL GROUPS  
6-OHDA combined sham 6-OHDA Combined sham 
  
 
 
 
Figure 5.10. Flow chart of excluded subjects.  
 
21 21 
6 6 6 6 6 6 
5 5 5 4 4 4 
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Figure 5.11. Electrode placements. Representative photomicrographs of electrode tracks in anterior 
(A and B) and posterior (C and D) PPTg. NeuN stained sections (A and C) are taken from combined 
lesion group and show cell loss of the PPTg area. ChAT stained sections (B and D) are from 6-OHDA 
lesion group showing cholinergic PPTg neurons. Schematic drawings (adapted from Paxinos and 
Watson, 2005) representing implantation sites of electrode tips in Experiment Three (E) and 
Experiment (F). Note that one rat of the combined lesion group of Experiment Four was not included 
into the DBS testing, and is therefore not included in these schematics. Red triangles represent sites 
of electrode tips in the combined lesion groups, yellow squares of sites in the 6-OHDA lesion groups 
and grey circles of sites in the sham lesion groups.  
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Figure 5.12. Representation of lesion extension along the rostro-caudal axis after ibotenic acid infusion 
on a selection of NeuN+ stained sections. The position of the schematics (adapted from Paxinos and 
Watson, 2005) on the rostro-caudal axis is represented as the distance from the interaural line (IAL; mm). 
Sections IAL + 2.88 mm through to IAL + 1.68 mm were identified as sections containing anterior PPTg 
neurons (identified by PPTg cholinergic neurons in shams and partially lesioned rats) and those from IAL 
+ 1.08 mm to IAL + 0.36 mm represent sections containing posterior PPTg. The column on the left hand 
side represents lesions from the aPPTg-DBS experiments and the one on the right hand side shows lesion 
sizes of the pPPTg-DBS experiment. Lesion damage is represented in red shading. 
Anterior PPTg-DBS 
experiment 
Posterior PPTg-DBS 
experiment 
anterior  
PPTg 
posterior  
PPTg 
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PPTg lesions and ChAT+ cell count  
 Anterior PPTg-DBS experiment 
All of the remaining animals bearing PPTg lesions of the combined lesion group had a 
NeuN/Cresyl lesion rating of at least 1 and no higher than one 3 (see Figure 5.13). 
 
 
 
 
 
 
 
Because of the implanted electrode in anterior PPTg only ChAT+ cell loss of posterior PPTg was 
analysed and is presented here. The loss in the combined lesion group was 56% (range 37% to 
80%). Cholinergic cell survival in posterior PPTg of the 6-OHDA group was 93% (range 78% to 
106%). The percentage of surviving cholinergic PPTg neurons in its posterior part is shown in 
Figure 5.13.  
B A 
Figure 5.13. Lesion size for each rat of the combined lesion group of the aPPTg-DBS experiment 
(A) and pPPTg-DBS experiment (B) rated based on NeuN+ stained brain sections. Lesions were 
rated on a scale from 0 to 4 (0 = no lesion of the PPTg, 1 = small/ partial lesion of the PPTg, 2 = 
partial to full lesion of the PPTg, 3 = fully lesioned PPTg, 4 = extensive lesion covering the PPTg 
and surrounding tissue). Where only one symbol can be seen RHS and LHS received the same 
lesion size rating. 
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Univariate ANOVA of the raw cell count of surviving ChAT+ neurons confirms a significant 
difference between groups (F2,11 = 18.862 p < 0.001; ƞ2p = 0.774). Tukey corrected post hoc 
tests reveal that the combined lesion group had a significantly lower ChAT+ cell count in the 
posterior PPTg compared to sham controls (p < 0.001). Furthermore, the 6-OHDA infusion did 
not cause any loss of cholinergic neurons in the PPTg: 6-OHDA group and sham controls did 
not differ from each other (p = 0.758). 
 Posterior PPTg-DBS experiment 
Four rats formed the combined lesion group and had a NeuN/Cresyl lesion rating of at least 1 
and no more than one side was scoring a 4 (see Figure 13 above). 
Of rats with the electrodes implanted in posterior PPTg only the cell count of anterior PPTg 
was analysed and compared between groups. The average cell loss was 51% (range 35% to 
67%). In the 6-OHDA group the cholinergic cell survival in anterior PPTg was 100% (range 74% 
to 122%) expressed as a percentage from the mean cell survival of sham controls (see Figure 
14 below). 
Univariate ANOVA of the raw cell count of surviving ChAT+ neurons found a significant 
difference between groups (F2,9 = 8.210 p = 0.009; ƞ2p = 0.646). Tukey corrected post hoc tests 
showed that the infusion of ibotenate caused a significant loss of ChAT+ cells in anterior PPTg 
of the combined lesion group (compared to sham controls p = 0.016). The cell count in the 6-
OHDA group did not differ from sham controls (p = 1.000). 
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Figure 5.14. PPTg ChAT+ count as the percentage of the mean count in sham lesioned rats. (A) 
shows cell count of the posterior PPTg (aPPTg-DBS experiment) and (B) shows cell count of the 
anterior PPTg (pPPTg-DBS experiment). Graphs show group means ± SEM. *** indicates a significant 
difference between combined lesion group and shams with p ≤ 0.001; ** indicates p ≤ 0.005 and * 
indicates  p ≤ 0.05. 6-OHDA and sham lesion groups did not differ from each other (aPPTg-DBS: p = 
0.758 and pPPTg-DBS: p = 1.000). LHS = left-hand side; RHS = right-hand side; brain = overall cell 
count left and right combined. 
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TH+ cell count in SN 
 Anterior PPTg-DBS experiment 
6-OHDA infusions into the striatum caused an extensive DA depletion in SN: TH+ count in the 
6-OHDA group was reduced by 94% (range 92% to 96%; of average sham count) and in the 
combined lesion group by 97% (range 95% to 99%; of average sham count). A univariate 
ANOVA found significant differences between groups (F2,11 = 2211.938 p < 0.001; ƞ2p = 0.998). 
The differences between the sham controls and both 6-OHDA treated groups were significant 
(6-OHDA group: p < 0.001; combined group: p < 0.001). Both DA depleted groups did not differ 
from each other (p = 0.248). 
 Posterior PPTg-DBS experiment 
The DA depletion in the posterior PPTg-DBS experiment was similarly extensive in both groups 
which received 6-OHDA infusions into the striatum: TH+ count in the 6-OHDA group was 
reduced by 93% (range 92% to 95%; of average sham count) and in the combined lesion group 
by 94% (range 89% to 96%; of average sham count). The groups differed significantly from 
each other in their remaining nigral TH+ cell count (F2,9 = 311.796 p < 0.001; ƞ2p = 0.986). Post 
hoc tests (Tukey corrected) showed that the differences between the sham controls and both, 
the 6-OHDA group (p < 0.001) and the combined lesion group (p < 0.001) were significant. Both 
DA depleted groups did not differ from each other (p = 0.971).  
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Figure 5.15. SN TH+ count as the percentage of the mean count in sham lesioned rats. (A) shows cell 
count the aPPTg-DBS experiment and (B) from the pPPTg-DBS experiment; Graphs show group 
means ± SEM. *** indicates a significant difference compared to shams with p ≤ 0.001; LHS = left-
hand side; RHS = right-hand side; brain = overall cell count left and right combined; 6-OHDA and 
combined lesion groups did not differ from each other (aPPTg-DBS: p = 0.248; pPPTg-DBS: p = 0.971). 
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4.3. Behavioural results 
4.3.1. Behavioural results - FOG 
 
 
 
 
Testing sessions during which it was notably difficult for the rats to complete acceptable runs 
(for the criteria of acceptable runs, please refer to the General Methods) or where rats did not 
complete all 3 required runs due to severe starting hesitation – FOG – were noted and are 
reported as a percentage of all available testing occasion of each condition respectively (post-
Figure 5.16. Frequency count of FOG episodes that resulted in < 3 runs per session or considerable 
difficulties in CW testing expressed as a percentage of the total number of testing occasions 
(number of testing sessions per condition x number of rats). 
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surgery baseline, DBS1, DBS2, DBS off, Figure 5.16.). Chi-square tests of independence were 
performed to examine the relationship between the occurrence of freezing and experimental 
group. In the anterior PPTg-DBS experiment in each testing condition there was a statistically 
significant association between these variables (post-surgery baseline: χ2(2) = 13.680 p = 0.001; 
V = 0.571; DBS1: χ2(2) = 27.756 p < 0.001; V = 0.823; DBS2: χ2(2) = 24.333 p < 0.001; V = 0.617; 
DBS OFF: χ2(2) = 7.200 p = 0.027; V = 0.775). Rats of the combined lesion group were more 
likely to show freezing in all 4 conditions. In the posterior PPTg-DBS experiment no FOG 
occurred with solely the electrode in place but with the DBS OFF. A statistically significant 
association between group and the occurrence of FOG was only present in the DBS1 condition 
(χ2(2) = 8.649 p = 0.013; V = 0.013); the combined lesion group was more likely to freeze than 
the 6-OHDA group. FOG occurred also in the DBS2 and DBS OFF condition in the combined 
group, but not 6-OHDA group; however these frequencies were not high enough to reach 
statistical significance (DBS2: χ2(2) = 5.677 p = 0.059; DBS OFF: χ2(2) = 2.933 p = 0.231) 
4.3.2. Behavioural results – Gait 
Because the unexpected occurrence of FOG made it difficult in specific testing conditions to 
record sufficient acceptable runs (as defined in the General Methods) a total of 2 instead of 3 
runs was accepted to calculate the mean of the behavioural data for the individual testing 
session if the animal was not capable to perform 3 runs within a reasonable time.  
Pre surgery comparison 
Univariate ANOVAs confirmed that there were no pre-surgery differences in any of the 
observed parameters (please refer to the Supplementary Table 5.1.). Violation of the 
assumption of normality in the sham lesion group of BOS front data and in the combined group 
of BOS hind data were tolerated. 
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Due to the FOG that occurred in the combined lesion group after surgery in the DBS OFF 
condition the group size was reduced to n = 3 at the time of post-surgery baseline testing. 
Confirming previous results: Is the 6-OHDA group different to sham controls?  
 Anterior PPTg-DBS 
Gait parameters in the 6-OHDA group which reflecting gait stability – BOS, Duty Cycle and 
Support – show differences in comparison with sham controls. The BOS was increased after 
surgery, the stance duration longer and less support was distributed over two diagonal paws 
and instead the time of three paws contacting the ground simultaneously was increased. Only 
the Duty Cycle of the hind paws showed the same trend but did not reach significance (BOS 
front: F2,10 = 19.094 p < 0.001; ƞ2p = 0.792; BOS hind: F2,10 = 10.982 p = 0.003; ƞ2p = 0.687; Tukey 
corrected post hoc tests front: p = 0.001; hind: p = 0.012; Duty Cycle front: F2,10 = 10.718 p = 
0.003; ƞ2p = 0.682; Tukey corrected post hoc tests front: p = 0.004; Support diagonal: F2,10 = 
9.456 p = 0.005; ƞ2p = 0.654; Support three: F2,10 = 7.131 p = 0.012; ƞ2p = 0.588; Tukey corrected 
post hoc tests diagonal: p = 0.006; three: p = 0.012). 
 The Swing Speed of the hind limbs was slower in the 6-OHDA (Swing Speed hind: F2,10 = 14.251 
p = 0.001; ƞ2p = 0.740; Tukey corrected post hoc tests hind: p = 0.002 ). The decrease of speed 
of the front paws (compared to pre-surgical baseline: F3,12 = 20.498 p < 0.001; ƞ2p = 0.837, 
Tukey corrected post hoc test: p = 0.014) did not reach significance in comparison with sham 
controls, probably due to the reduction of Swing Speed in shams. The Stride Length in the 6-
OHDA group was significantly shorter than the Stride Length of sham controls (Stride Length 
front: F2,10 = 8.183 p = 0.008; ƞ2p = 0.621; hind: F2,10 = 5.948 p = 0.020; ƞ2p = 0.543; Tukey 
corrected post hoc tests front: p = 0.007; hind: p = 0.021). There was no difference between 
shams and the 6-OHDA regarding the Print Position (F2,10 = 0.211 p = 0.814). 
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 Posterior PPTg-DBS 
The effect of 6-OHDA lesions on gait parameters in the posterior PPTg-DBS experiment was by 
and large similar. BOS of the front limbs, Duty Cycle of the hind limbs, Support, Swing Speed 
and Stride Length showed the same parkinsonian characteristics (BOS front: F2,9 = 24.697 p < 
0.001; ƞ2p = 0.846; Tukey corrected post hoc tests front: p = 0.002; Duty Cycle hind: F2,9 = 8.282 
p = 0.009; ƞ2p = 0.648; Tukey corrected post hoc tests hind: p = 0.012; Support diagonal: F2,9 = 
5.356 p = 0.29; ƞ2p = 0.543; Tukey corrected post hoc tests diagonal: p = 0.025; Support three: 
F2,9 = 7.413 p = 0.013; ƞ2p = 0.622; Tukey corrected post hoc tests three: p = 0.010; Swing Speed 
front: F2,9 = 8.852 p =0.007; ƞ2p = 0.663; hind: F2,9 = 17.080 p = 0.001; ƞ2p = 0.791; Tukey 
corrected post hoc tests front: p = 0.006; hind: p = 0.001; Stride front: F2,9 = 15.700 p = 0.001; 
ƞ2p = 0.777; hind: F2,9 = 14.932 p = 0.001; ƞ2p = 0.768; Tukey corrected post hoc tests front and 
hind: p = 0.001). During post-surgical testing the sham controls showed an increase in distance 
between front and hind paws on both sides (with the hind paw placed in front of the front 
paw) which can be interpreted as an increase in interpaw coordination. The 6-OHDA only 
showed attenuated changes of this distance which resulted in a significant difference on the 
righ-hand side compared to sham controls (Print Position right: F2,9 = 7.856 p = 0.011; ƞ2p = 
0.636; Tukey corrected post hoc test p = 0.009).  
Confirming previous results: Is there a difference between the traditional PD model and the 
refined model (Does the additional PPTg lesion make a difference)?  
 Anterior PPTg-DBS 
None of the gait parameters measured in this experiment were affected by the addition of 
partial PPTg lesions; there were no differences between the 6-OHDA group and the combined 
lesion group (BOS front: p = 0.528; hind: p = 0.500; Support diagonal: p = 0.974; three: p = 
0.827; Swing Speed hind p = 0.952; Stride Length front: p = 0.626; hind: p = 0.920). 
 
185 
 
Posterior PPTg-DBS 
Most of the gait parameters here were not changed by additional PPTg lesions either (BOS 
front: p = 0.216; Support diagonal: p = 0.029; three: p = 0.163; Swing Speed front: p = 0.177; 
hind: 0.285; Print Position right: p = 0.082). Interestingly, in this experiment the group with the 
additional PPTg lesion  showed improvement in  a few gait parameters. The stance duration of 
the hind limbs became shorter and the Stride Length longer, reaching sham control levels 
(Duty Cycle hind: p = 0.024; Stride Length front: p = 0.038; hind: p = 0.05). 
Does the DBS ameliorate the lesion deficits in the combined lesion group and 6-OHDA group? 
Do the stimulation parameters of DBS1 and DBS2 affect the gait differently?  
 Anterior PPTg-DBS 
Conducting repeated measures ANOVAs for both, the 6-OHDA group and the combined lesion 
group, followed up by post hoc tests if appropriate, the data were tested for an effect of DBS 
compared to the post-surgery deficit. As presented above, the combined lesion group suffered 
from severe FOG already in the post-surgery testing condition which increased further during 
the DBS ON conditions. For this reason the group size dropped down to n = 2 and in addition, 
of the 3 testing sessions conducted per DBS condition, several did not lead to usable data, 
reducing the information even in these n = 2 considerably. Therefore the effect of DBS on 
animals of the combined lesion group who did not freeze or froze but still managed to deliver 
acceptable runs cannot be confidently assessed. However, conducting repeated measures 
ANOVAs on the collected data from the combined lesion group showed that there was no 
difference between conditions in any parameter – the stimulation of anterior PPTg had no 
effect on gait in the combined lesion group (BOS: front: F3,3 = 3.711 p = 0.155 hind: F3,3 = 3.337 
p = 0.174; Duty Cycle: front:F3,3 = 0.184 p = 0.901; hind: F3,3 = 2.166 p = 0.271; Support: 
diagonal: F3,3 0.498 p = 0.709; three: F3,3 = 0.294 p = 0.829; Swing Speed: front: F3,3 = 0.682 p = 
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0.682; hind: F3,3 = 1.183 p = 0.447; Stride Length: front: F3,3 = 0.377 p = 0.778; hind: F3,3 = 1.174 
p = 0.449; Print Position: RHS: F3,3 = 6.667 p = 0.077; LHS: F3,3 = 1.376 p = 0.400).  
In the 6-OHDA group anterior PPTg stimulation had a detrimental effect on a number of gait 
parameters, in many cases significant effects were only achieved with the settings of DBS2; 
other parameters  were not affected in any way. The BOS of the front limbs further increased 
compared to the post-surgical baseline deficit with DBS1 and DBS2.  
 
 
 
 
 
 
 
 
Figure 5.17. Anterior PPTg-DBS experiment: BOS. Comparison between combined lesion group, 6-
OHDA group and sham control group of pre and post surgery performance, and performance in DBS 
ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. For statistical 
significances please refer to the text. *** indicates a significant difference compared to post surgery 
data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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The stance duration of the front limbs increased as well; the hind limbs showed the same 
trend but the effect was not significant. The same was observed regarding the Support 
parameter: The Support over diagonal paws decreased and over three paws increased 
significantly with DBS2 while this trend could be observed applying stimulation with DBS1 
settings.  
 
 
 
 
Figure 5.18. Anterior PPTg-DBS experiment: Duty Cycle and Support. Comparison between combined 
lesion group, 6-OHDA group and sham control group of pre and post surgery performance, and 
performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. For 
statistical significances please refer to the text. *** indicates a significant difference compared to 
post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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The Stride Length of the hind limbs was significantly shortened with DBS2 stimulation. DBS2 
but not DBS1 stimulation slowed the Swing Speed and the shortened the Stride Length of the 
front limbs observably, without however reaching significance.  
 
 
 
 
 
 
Figure 5.19. Anterior PPTg-DBS experiment: Swing Speed and Stride Length. Comparison between 
combined lesion group, 6-OHDA group and sham control group of pre and post surgery performance, 
and performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. 
For statistical significances please refer to the text. *** indicates a significant difference compared to 
post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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The stimulation of anterior PPTg did not change the Print Position significantly.  
 
 
 
 
 
(BOS front: F3,12 = 148.367 p < 0.001; ƞ2p = 0.974; DBS1: p = 0.004; DBS2: p = 0.046; Duty Cycle 
front: F3,12 = 14.322 p < 0.001; ƞ2p = 0.782; hind: F3,12 = 6.931 p = 0.018 Greenhouse-Geisser 
corrected; ƞ2p = 0.634; front: DBS2: p = 0.010; Support diagonal: F3,12 = 18.557 p < 0.001; ƞ2p = 
0.823; three: F3,12 = 20.694 p < 0.001; ƞ2p = 0.838; diagonal: DBS2: p = 0.039; three: DBS2: p = 
0.001; Stride Length hind: F3,12 = 8.039 p = 0.003; ƞ2p = 0.668; hind: DBS2: p = 0.040). 
 
 
 
 
 
Figure 5.20. Anterior PPTg-DBS experiment: Print Position. Comparison between combined lesion 
group, 6-OHDA group and sham control group of pre and post surgery performance, and 
performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. For 
statistical significances please refer to the text. *** indicates a significant difference compared to 
post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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Posterior PPTg-DBS 
FOG in the posterior PPTg-DBS experiment was less severe and did not lead to a severe loss of 
data regarding the animals’ gait as in the anterior PPTg-DBS experiment. In the combined 
lesion group the group size was reduced to n = 3 due to the loss of one animal before the start 
of DBS ON. The freezing that occurred allowed in all bar one rat of one testing day the 
collection of sufficient data. 
Neither stimulation with a short (DBS1) nor with a long pulse width (DBS2) had an effect on 
any of the measured gait parameters in the combined lesion group. The 6-OHDA group, 
however, could benefit from stimulation of posterior PPTg. In most of the cases stimulation 
with DBS1 showed improvements which did not constitute significant changes in comparison 
with the post-surgical baseline deficit (the effect did not withstand post hoc corrections). 
Stimulation of the same gait parameters during the DBS2 condition then had a significant 
beneficial effect: The stance duration of the hind paws decreased, the Support with three paws 
decreased and the two-legged diagonal Support increased (almost reaching significance), and 
the Stride Length became longer.  
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Figure 5.21. Posterior PPTg-DBS experiment: Duty Cycle, Support and Stride Length. Comparison 
between combined lesion group, 6-OHDA group and sham control group of pre and post surgery 
performance, and performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group 
means ± SEM. For statistical significances please refer to the text. *** indicates a significant 
difference compared to post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 
0.05. 
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In contrast, the Swing Speed increased with stimulation with DBS1 but not DBS2 stimulation 
settings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22. Posterior PPTg-DBS experiment: Swing Speed. Comparison between combined lesion 
group, 6-OHDA group and sham control group of pre and post surgery performance, and 
performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. For 
statistical significances please refer to the text. *** indicates a significant difference compared to 
post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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An increased inter-paw coordination judged by an increase of distance between ipsilateral 
paws with the hind paw placed behind the front paw could be observed with DBS2, which, 
however, did not reach significance. Stimulation of posterior PPTg had no effect on BOS. 
 
 
 
 
 
 
 
 (Duty Cycle hind: F3,9 = 8.380 p = 0.006; ƞ2p = 0.736; DBS2: p = 0.020; Support diagonal: F3,9 = 
4.951 p = 0.027; ƞ2p = 0.623; three: F3,9 = 7.505 p = 0.008; ƞ2p = 0.714; diagonal: DBS2: p = 
Figure 5.23. Posterior PPTg-DBS experiment: BOS and Print Position. Comparison between combined 
lesion group, 6-OHDA group and sham control group of pre and post surgery performance, and 
performance in DBS ON conditions DBS1 and DBS1 on the CW. Displayed are group means ± SEM. For 
statistical significances please refer to the text. *** indicates a significant difference compared to 
post surgery data with p ≤ 0.001; ** indicates p ≤ 0.005 and * indicates  p ≤ 0.05. 
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0.061; three: DBS2: p = 0.021; Stride Length front: F3,9 = 13.555 p = 0.001; ƞ2p = 0.819; hind: F3,9 
= 9.957 p = 0.003; ƞ2p = 0.768; front: DBS2: p = 0.045; hind: DBS2: p = 0.044; Swing Speed front: 
F3,9 = 10.633 p = 0.003; ƞ2p = 0.780; hind: F3,9 = 16.220 p = 0.001; ƞ2p = 0.844; front: DBS1: p = 
0.027). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Summary of the data discussed above. The table answers the following questions: Is 
the 6-OHDA group different to sham controls? Is there a difference between the traditional PD 
model and the refined model (Does the additional PPTg lesion make a difference?)? Does the DBS 
ameliorate the lesion deficit? Are there differences between DBS1 and DBS2? Red indicates a 
deficit and/or worsening of gait parameters; green indicates improvements. Lighter shades 
represent trends, which are not statistically significant. 
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Anterior PPTg 
DBS 
Is the 6-OHDA group different to shams? Does the additional PPTg lesion make a difference? (combined vs 6-OHDA?) 
Does DBS ameliorate the lesion deficit?                                        
(DBS compared to post surgery deficit) Does DBS1 differ from DBS2? 
Post surgery DBS1 DBS2 Post surgery DBS1 less data 
DBS2 less 
data 
combined      
DBS1                
(less data) 
combined 
DBS2               
(less data) 
6-OHDA 
DBS1 
6-OHDA 
DBS2 combined 6-OHDA 
BOS 
f
r
o
n
t
 
bigger  bigger  bigger  No No No No No bigger  bigger No No 
h
i
n
d
 
bigger  bigger  bigger  No No No No No No No No No 
Duty 
Cycle 
f
r
o
n
t
 
longer 
contact  
longer 
contact  
longer 
contact  No No No No No 
longer 
contact 
longer 
contact No No 
h
i
n
d
 
trend: longer 
contact 
longer 
contact  
longer 
contact  No 
shorter contact 
because of DBS 
effect on 6-OHDA 
shorter contact 
because of DBS 
effect on 6-OHDA 
No No trend: longer contact 
trend: longer 
contact No No 
Support d
i
a
g
o
n
a
l
 
less  less  less  No No No  No No trend:   less less No No 
t
h
r
e
e
 
more  more  more  No No less No No trend: more more No No 
Swing 
Speed 
f
r
o
n
t
 
trend: slower slower  slower  No  
faster because of 
DBS effect on 6-
OHDA 
faster because of 
DBS effect on 6-
OHDA 
No No No trend: slower  No No 
h
i
n
d
 
slower  slower  slower  No 
faster because of 
DBS effect on 6-
OHDA 
faster because of 
DBS effect on 6-
OHDA 
No No No trend: slower  No No 
Stride 
Length 
f
r
o
n
t
 
shorter  shorter  shorter  No 
longer because of 
DBS effect on 6-
OHDA 
longer because of 
DBS effect on 6-
OHDA 
No No No trend: shorter  No No 
h
i
n
d
 
shorter  shorter  shorter  No 
longer because of 
DBS effect on 6-
OHDA 
longer because of 
DBS effect on 6-
OHDA 
No No No shorter No No 
Print 
Position 
r
i
g
h
t
 
No No  No No No No No No No No No No 
l
e
f
t
 
No No No No No No No No No No No No 
196 
 
Posterior PPTg 
DBS 
Is the 6-OHDA group different to shams? Does the additional PPTg lesion make a difference? (combined vs 6-OHDA?) 
Does DBS ameliorate the lesion deficit?                                  
(DBS compared to post surgery deficit) Does DBS1 differ from DBS2? 
Post surgery DBS1 DBS2 Post surgery DBS1 DBS2 combined DBS 1 
combined 
DBS2 
6-OHDA 
DBS1 
6-OHDA 
DBS2 combined 6-OHDA 
BOS 
fr
on
t 
bigger  bigger  bigger  No No No No  No No  No No No 
hi
nd
 
trend: bigger bigger bigger  No No No No No No No No 
narrow (but 
not different 
to post) 
Duty 
Cycle 
fr
on
t 
No No No No No  No No No No No No No 
hi
nd
 
longer 
contact  No No 
less contact 
(=shams) No No No No 
trend: less 
contact less contact No No 
Support 
di
ag
on
al
 
less No No No  No No No No trend: further 
trend: 
further No No 
th
re
e 
more No No No No No No No trend: further less No No 
Swing 
Speed 
fr
on
t 
slower  slower  slower  No  No No No No faster No (but same as DBS1) No No 
hi
nd
 
slower  slower  slower  No No No No No trend: faster No (but same as DBS1) No No 
Stride 
Length 
fr
on
t 
shorter  No No Longer (=shams) No No No No trend: longer longer No No 
hi
nd
 
shorter  No No Longer (=shams) No No No No trend: longer longer No No 
Print 
Position 
rig
ht
 
shorter  shorter shorter No No No No No No trend: further No No 
le
ft
 
No No No No  No No No No No trend: further No No 
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4.3.3. L-DOPA induced abnormal involuntary movements 
 
 
 
 
At an average time of 11.8 min (range 7 min to 20.8 min) after the administration of L-DOPA 
the parkinsonian rats showed the first AIMs which then developed into more severe 
dyskinesias over time. Sham controls did not show any signs of dyskinesias. The rate of 
progression and therefore the time the animals exhibited dyskinesias of different severity as 
categorised according to the Creese-Iversen scale (refer to the General Methods for details) 
differed between groups and testing condition. The total amount of time the animals showed 
AIMs however did not differ between groups in any of the 4 conditions (anterior DBS OFF: F1,7 
= 3.506 p = 0.103; DBS ON: F1,6 = 3.241 p = 0.122; posterior DBS OFF: F1,6 = 4.057 p = 0.091; DBS 
ON: F1,5 = 0.086 p = 0.781) – it was the quality of dyskinesias that changed.  
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Figure 5.24. Comparison of the total duration of L-Dopa induced dyskinesias in combined lesion 
group and 6-OHDA group in DBS OFF and DBS ON condition with either anterior or posterior PPTg 
DBS electrodes. Displayed are group means ± SEM. For statistical significances, please refer to the 
text. 
198 
 
 
 
 
 
Figure 5.25. shows the time for which rats in the different groups and conditions were 
dyskinetic. Both parkinsonian groups showed AIMs after i.p. L-DOPA injections. The group with 
combined DA depletion and PPTg lesions showed more severe AIMs and mostly of a different 
quality (panels A and B) – irrespectively of the position of the stimulation electrode [licking and 
biting (scores 5-6) rather than stereotyped head and body movements (scores 2-4)] than the 6-
OHDA group (electrode in anterior PPTg: score 6: F1,7 = 7.151 p = 0.032; score 4: F1,7 = 15.890 p 
= 0.005; electrode in posterior PPTg: score 6: F1,6 = 9.220 p = 0.023; score 2: F1,6 = 7.377 p = 
0.035; score 3: F1,6 = 8.828 p = 0.025; score 5: F1,6 = 7.573 p = 0.033).  
Figure 5.25. Comparison of the severity of L-Dopa induced dyskinesias in combined lesion group and 
6-OHDA group. The duration of dyskinesias of each severity level were recorded in minutes. Panels A-
B graphs compare the effect of L-Dopa in DBS OFF condition and Panels C-D show results of the DBS 
ON condition with either anterior or posterior PPTg DBS electrodes. Displayed are group means ± 
SEM. For statistical significances please refer to the text. 
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Focussing on these differences (dyskinesias scores 4 and 6) the analyses showed an 
amelioration of the severe AIMs in the combined lesion group with posterior DBS (panel D), 
but not with anterior DBS (panel C): Posterior PPTg-DBS (ON) caused a shift of the L-DOPA 
induced AIMs. The appearance of continuous licking and biting was reduced, dyskinesias 
instead taking the form of stereotyped up and down head movements, and crossing and lifting 
of the forelegs [anterior PPTg-DBS experiment: no interaction of group and DBS condition (ON 
/OFF): score 4: F1,6 = 4.591 p = 0.076; score 6: F1,6 = 0.005 p = 0.944; no effect of condition: 
score 4: F1,6 = 0.000 p = 1.000; score 6: F1,6 = 1.212 p = 0.313; posterior PPTg-DBS experiment: 
significant effect of condition: score 4: F1,5 = 9.791 p = 0.026; score 6: significant interaction of 
group and DBS condition: F1,5 = 8.504 p = 0.033]. 
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4.4. Discussion 
4.4.1. Summary 
These two experiments aimed to answer a series of questions. The reason for the integration 
of many assessments into this experimental design is the innate complexity of the animal 
model and the need to have as many questions answered as possible. In the first place, 
materials and methods needed to be developed and tested to create a model of PPTg-DBS in a 
free-moving and refined rodent model of PD.  The pilot surgeries and tests described above 
helped to refine coordinates, surgical techniques and the development of a headstage that 
allowed attaching the DBS device to the rats’ head – a solution that was well tolerated by the 
animals and did not interfere with their behaviour. The work in this chapter was conducted to 
assess the effect of anterior and posterior PPTg LFS on gait deficits in parkinsonian rats – PD 
models that did (combined lesion model) or did not (traditional bilateral 6-OHDA model) 
include partial lesions of the PPTg.  
Replicating the findings presented in the previous chapter, striatal infusions of 6-OHDA caused 
significant and consistent gait deficits which are by and large very similar. The only differences 
were in the Duty Cycle of the front limbs of the 6-OHDA group in the anterior PPTg-DBS 
experiment and the hind limbs in the posterior PPTg-DBS experiment, as well as in the Print 
Position of the right hand side of the same group showing deficits in comparison with sham 
control rats, which reached significance. Similar trends were observed in the combined lesion 
experiment (Chapter 4) but these did not reach significance. Further, as described in the 
combined lesion experiment, the additional PPTg lesion did not change the gait deficits already 
observed after DA depletion in the anterior PPTg-DBS experiment. Interestingly, in the 
posterior PPTg-DBS experiment the stride length of both front and hind limbs of the rats 
bearing lesions in SN and PPTg, was not only longer, but also did not differ from sham 
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operated rats – an effect that was also observed before. The absence of additional deficit with 
additional partial PPTg lesions is discussed in Chapter 4, as well as possible explanations for the 
differences in stride length between both PD models. Notably, this correction of stride length 
only occurs in the experiment where the PPTg lesion of the posterior portion was enlarged by 
the presence of electrodes, not with anterior PPTg electrodes. With regard to the proposed 
explanations in the literature, this might support the assumption of a decreased excitatory 
input to the hyperactive STN in the DA depleted BG circuit.  
Interestingly, a significant and important effect just of the implantation of DBS electrodes 
differentiated rats implanted with anterior PPTg electrodes from groups with posterior PPTg 
electrode. In the DBS-OFF condition, rats of the combined lesion group with electrodes in 
anterior PPTg suffered from severe freezing episodes in form of start hesitation when they 
were sat into the CW for gait assessment. In some occasions, they were able to overcome it 
and initiate the run but the majority of these runs were not completed, because the rats’ run 
down the glass walkway came to a halt when they approached the end of the CW – and they 
froze again (data not scored). Electrodes in the posterior part of the PPTg did not have this 
effect and neither did the 6-OHDA group suffer from significant freezing episodes, no matter 
where the electrode was implanted. Switching the DBS of anterior PPTg electrodes on, further 
increased the total occurrence of FOG in the combined lesion group (by increasing the 
occurrence of freezing episodes and/or decreasing the ability to overcome start hesitation). 
Stimulation of the posterior PPTg electrodes did cause FOG as well in this group; given the 
strong relation between anterior PPTg and FOG in the OFF-condition it is plausible to assume 
that this can be caused by a current spread from the posterior location of the electrode to the 
anterior portion. It was the effect of DBS on parkinsonian gait deficits that was of main interest 
conducting this work: Double blind studies and follow ups of PPTg-DBS studies in PD patients 
could not maintain the positive results reported after the first PPTg electrode implantations or 
202 
 
even show a decline of the transient gait amelioration (Moreau et al., 2009; Moro et al., 2010; 
Peppe et al., 2010). The experiments presented here showed a clear differential effect of 
anterior and posterior PPTg-DBS: Anterior PPTg LFS worsened almost all gait parameter in the 
6-OHDA group. The post-surgery deficit was enhanced with stimulation: observable trends in 
the DBS1 condition reached significance (compared to the post-surgery testing sessions) in the 
DBS2 condition (stimulation at a higher pulse duration). The increased pulse duration might be 
the cause for this effect, but the possibility of reaching significance at that point because of the 
overall duration of chronic stimulation cannot be excluded – the experiment did not offer the 
possibility of a counterbalanced order of testing conditions. (This will be discussed further 
below.) The combined lesion group did not benefit from the stimulation of anterior PPTg. 
However, this effect on gait could only be tested in very few occasions of very few animals, 
because, as described above, many times the rats were not able to complete the CW task due 
to the severe FOG episodes. The data describing the gait of the combined lesion group under 
PPTg-DBS is therefore very scarce and needs to be interpreted cautiously. The effect of 
posterior PPTg DSB was directly opposite: In the 6-OHDA group all gait parameters bar BOS 
improved in comparison with the deficit observed after the surgeries. In contrast to the 
worsening effect of anterior stimulation, amelioration with posterior LFS already appeared 
with DBS 1 settings (shorter pulse width) in some gait parameters, others only showed a trend 
which reached significance with DBS 2 stimulation. The parkinsonian group that had additional 
partial PPTg lesions did not benefit from stimulation of posterior PPTg.  
In summary, the results suggest that the loss of PPTg neurons did further contribute to the 
chronic inhibition of the PPTg caused by the 6-OHDA lesion, which was not sufficient to induce 
FOG. The addition of the anterior, but not posterior, DBS electrode added further to the lesion 
and precipitated FOG already in the DBS OFF condition. Turning anterior PPTg-DBS on 
disrupted the remaining functioning structures further and made the FOG even worse. The 
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increase in freezing after posterior PPTg could be speculated to be due to current spread. In 
the 6-OHDA group stimulating anterior PPTg caused disruption of the BG circuitry leading to 
further impairment of gait and postural parameters; the stimulation of posterior PPTg however 
showed therapeutic potential. 
4.4.2. Severe FOG after additional track lesions in anterior PPTg 
The lesion caused by the anterior PPTg electrode was not big enough to cause FOG – the 6-
OHDA group did not have difficulties. Neither was the partial lesion of anterior (in combination 
with posterior) PPTg caused by ibotenic acid big enough for eliciting FOG. However, the 
combination of both – anterior PPTg electrode in the combined lesion group – added to the 
dysfunction of the anterior PPTg group possibly caused by a dysfunctional BG circuitry in the 
parkinsonian DA depleted state.  
Dysfunctional inhibitory afferents coming from the BG output nuclei GPi/SNr (Breit et al., 2001; 
Carlson et al., 1999; Mitchell et al., 1989; Orieux et al., 2000) target the anterior portion of the 
PPTg. It is plausible that this decreases PPTg activity and hinders adequate relay of BG 
information to downstream brainstem motor nuclei (or recurrent feedback into BG or 
thalamus) causing hypokinesia and the gait deficits observed in PD patients. The degeneration, 
mimicked here by partial PPTg lesions, might not have been sufficient to alter the already 
severe deficits observed in the rats of the 6-OHDA group – but further track damage might 
have augmented this problem of an “over-inhibited” PPTg.  One observation, however, raises 
the question if this explanation is sufficient or, in fact, correct: The manipulation of anterior 
PPTg by LFS in the 6-OHDA group also causes deficits – not FOG but specific gait disturbances. 
This comparison would mean assuming that LFS causes a lesion-like effect on anterior PPTg. 
The possible mechanisms of the stimulation in the area will be discussed in Section 4.4.3. of 
this chapter. As discussed in the General Introduction, FOG constitutes a gait disturbance of its 
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own category – an observation supported by the extensive literature dedicated to this 
phenomenon. As in PD patients, FOG observed here was clearly contextual and it is likely that 
new sensory input, such as narrow walls of the CW and the approaching end of the glass 
walkway, might have triggered the FOG episodes just as obstacles and narrow doorways do in 
PD patients; that is, increasing task demand (having to judge the width of the walkway, 
distance to the end of the CW) or simply providing additional sensory input. It is also 
conceivable that the crossing of the CW in a way that needs to fulfil certain criteria, which the 
rats were trained to meet, posed some additional cognitive demand to the rats, creating a dual 
task situation – tasks that, in patients, also trigger freezing episodes. This contextuality strongly 
suggests that the PPTg is not just a gait control centre.  
The key to this supposition is the position of the PPTg between the BG and brainstem and its 
ability to provide modulatory influence on BG activity via its strong, often reciprocal 
connections several BG nuclei – SNc, VTA, GPi, SNr, STN – or indirectly via extensive afferents 
into the thalamus. The PPTg receives fast polymodal sensory input from sites including the 
superior and inferior colliculi, the lemniscal nuclei, parabrachial nucleus and the trigeminal 
complex at a response latency of under 80 ms, and which can be as short as 4ms (Dormont et 
al., 1998; Pan and Hyland, 2005). This is fast enough to supply DA neurons in the midbrain with 
relevant information about sensory events. It has been shown that these efferents are closely 
related and necessary for the phasic activity of DA neurons. DA neurons are essential for 
generating “reward prediction error” signals, phasic activity in response to reward related 
sensory input, which declines as an association is made with the reward predicting stimuli and 
re-occurs in the absence of a predicted reward (Schultz, 2006). Their response to stimuli is fast 
– too fast to consider the thalamus or cortical projections to be the source for information 
about the stimuli. Cortical responses related to object identification and discrimination do not 
occur before 80 – 160 ms after stimulus onset (Rousselet et al., 2004; Schall, 2003) and 
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responses in extranigral subcortical structures – striatum and STN – also occur too late to be 
providing information before nigral phasic activity [(Matsumura et al., 1992), reviewed in 
(Redgrave et al., 2008)]. This short latency DA response must be dependent on an even shorter 
latency input. The response of the PPTg would be fast enough and anatomically there are 
direct connections to these DA neurons in VTA and SNc. In fact, the absence of nicotinic 
acetylcholine receptor β2 receptor subunit in genetically altered mice abolished the VTA’s 
ability to switch to burst firing (Maskos, 2007; Maskos et al., 2005), the electrical stimulation of 
the PPTg results in increased burst firing activity of midbrain DA neurons (Floresco et al., 2003) 
and striatal DA efflux (Forster and Blaha, 2003). Conde and colleagues have shown that 
inactivation of the PPTg can interfere with processing of sensory information and disrupt 
ongoing conditioned motor performance (Conde et al., 1998; Dormont et al., 1998). DA 
neurons need therefore more information than just about the physical attributes of the 
stimuli. Indeed, the PPTg is able to provide these neurons with information about a stimulus 
regarding its salient aspects – the association of a stimulus with a reward, the prediction of the 
reward value, the reward itself, and the actual value of the reward (Kobayashi and Okada, 
2007; Okada and Kobayashi, 2013; Okada et al., 2009; Thompson and Felsen, 2013).   
Against this background, it is conceivable to assume that the damaged anterior PPTg is unable 
to convey information about incoming sensory stimuli of the environment (“there are walls but 
I fit through”, “there is the edge of the glass, but behind that I find my home cage”) to the SNc. 
At this point the PPTg can normally mediate outflow from the BG output nuclei and assess 
whether to send this forward or if incoming sensory information pose a reason for giving 
preference to a different action (“yes, the way is clear, go ahead” or “no, there are obstacles/ 
danger of falling off the walkway”). The lack of sensory information to the SNc puts a brake on 
the system because the decision on competing actions cannot be made and the rat freezes.  
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4.4.3. The effect of low frequency stimulation 
Before a tentative interpretation of the effect of LFS of anterior and posterior PPTg can be 
made, the possible mechanisms that stimulation of brain structures can have need to be 
considered.  
The ability to ameliorate tremor by means of HFS of the thalamus and thereby producing the 
same effect as thalamotomies (Benabid et al., 1991) and the similarity of motor effects in 
animal models of PD caused by lesions of the STN and the behavioural effects of HFS of the 
STN (Benazzouz et al., 1993; Guridi et al., 1996) has led to the assumption that high frequency-
DBS causes functional inactivation of the structure (by means of a local depolarization block, 
inactivation of voltage-dependent channels, and functional deafferentation) reducing the tonic 
excitatory drive onto the BG output nuclei [reviewed in (Deniau et al., 2010)]. Thanks to a large 
number of studies investigating the mechanisms behind HFS it is now clear that the effects 
cannot be generalized across the structures targeted by stimulation electrodes. The effect 
depends on the stimulation parameters, the distance of the neurons to the electrode contacts, 
the orientation of axons in relation to the electrode, the characteristics of soma and axons 
(type of neurotransmitter, diameter of axons, properties of the synaptic transmission) (Deniau 
et al., 2010; McIntyre et al., 2004; Zhang and Grill, 2010). In fact, STN-HFS evoked synaptic 
effects in other parts of the BG (Benazzouz et al., 2000; Florio et al., 2007; Potter-Nerger et al., 
2008), antidromic activations (Hammond et al., 2008) and changes in neurotransmitter release 
(He et al., 2014; Pazo et al., 2010). Apart from inhibition, HFS therefore clearly also generates 
excitation and antidromic activation and the activations do not only cause changes in firing 
rates but also in firing patterns and oscillatory properties. Garcia and colleagues describe a 
replacement of spontaneous STN spikes by spikes evoked by the HFS and locked to that 
stimulus (Garcia et al., 2003). 
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Whether soma or axons are activated also depends on a row of different factors (see Section 
3.2.2. of this chapter). By using different pulse widths, the intention was to control for one of 
these factors and introduce a possible differential effect of the stimulation. In direct 
comparison, LFS of the PPTg at a shorter and longer pulse width did not cause significantly 
different effects on motor performance. When compared to the post-surgery deficit in some 
parameters the stimulation with 500 µs had a stronger effect (worsening with anterior PPTg 
stimulation and benefitting with posterior PPTg stimulation) compared to stimulation with 
pulses of a length of 160 µs: Where 160 µs caused trends in the same direction, the effect with 
500 µs was significant. However, as mentioned above, the condition with the longer pulse 
width was always second (the order of conditions was not counterbalanced) so it is possible, 
that the effect increased with a longer duration of chronic stimulation.  
The mechanisms behind LFS are not that well studied as HFS. The working hypothesis has been 
that, contrary to a lesion-like effect of HFS, LFS would cause an activation of the PPTg that 
shows decreased activity in the parkinsonian state because of over-inhibition from BG output 
nuclei. PPTg lesions have caused an increased firing rate of STN neurons in normal rats (Breit et 
al., 2005), while lesions in parkinsonian rats have been reported to reduce STN firing (Breit et 
al., 2006). Capozzo and colleagues reported an activating effect on STN neurons in PD rats and 
sham lesioned controls (Capozzo et al., 2009) with acute LFS of the PPTg but an inhibitory 
effect with acute HFS (>50Hz). With chronic stimulation, Alam and colleagues observed a 
reduction of the enhanced activity in the STN of PD models, but no effect in sham lesioned 
controls (Alam et al., 2012). In contrast, a further recent study only found markers for neuronal 
activity (c-fos expression) after LFS of the PPTg at stimulation site and in the central gray. In 
human, imaging studies revealed increased regional cerebral glucose metabolism in a series of 
cortical and subcortical areas (Stefani et al., 2010), changes in regional cerebral blood flow in 
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different subcortical areas, including the thalamus (Ballanger et al., 2009; Strafella et al., 2008)  
and various cortical structures (Ballanger et al., 2009).  
What applies to HFS of the STN is also true for LFS of the PPTg: the actual effect depends on all 
those above-mentioned factors and without further studies assessing the effect of PPTg-DBS 
on its target structures at this point it is only possible to infer the mechanism of the 
stimulation from the behavioural outcome.  
4.4.4. Gait worsening after anterior PPTg stimulation 
Stimulation of the anterior PPTg worsened the already changed gait parameters of the 6-OHDA 
group significantly. Concerning the often-stated hypothetical assumption that PPTg-DBS would 
correct the effect of the over-inhibitory BG outflow in the parkinsonian brain, this seems 
surprising, considering that it is the anterior part of the PPTg that is receiving the efferents 
from SNr and GPi. Two explanations are possible: (i) similarly to the lesion effect of the 
electrodes in the combined lesion group, here the DBS is causing a disruption of sensory 
information transfer from the PPTg to the BG. However, if this was the case, observable 
deficits would be expected in the DBS-OFF condition in the 6-OHDA group as well due to the 
damage caused by the electrode. Further, FOG seems to have different pathological 
mechanisms compared to other gait deficits. These rats of the 6-OHDA group did not suffer 
from any significant FOG episodes, so it is likely that a different mechanism might be causing 
the gait deficits measured on the CW. (ii) It is plausible to believe that the stimulation in 
anterior PPTg is not affecting the neurons of the PPTg, but having an antidromic effect, driving 
the inhibitory afferents from the BG and therefore enhancing the already existing parkinsonian 
deficits. 
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4.4.5. Gait improvement after posterior PPTg stimulation 
Interestingly, posterior PPTg stimulation had the opposite effect and improved several of the 
analysed gait parameters of the rats of the 6-OHDA group. On the assumption that LFS here is 
having an activating effect on the sensory component of the PPTg, two consequences are 
conceivable: (i) increased activity of GABAergic projections to the STN might amend its 
hyperactivity observed in PD (Nandi et al., 2002; Obeso et al., 2008). This modulatory influence 
has been shown before: PPTg lesions reversed hyperactivity in STN (Breit et al., 2006) – likely 
by eliminating cholinergic efferents from the PPTg. This however does not match with the 
suggestion of an activating (rather than lesion) effect of LFS. (ii) Stimulating the sensory 
component of the PPTg might be increasing cholinergic excitatory input to thalamostriatal and 
thalamocortical pathways. The PPTg makes substantial innervations to the thalamus, in 
particular the ventral and intralaminar nuclei (Inglis and Winn, 1995) and cholinergic input has 
shown to have a role in the regulation of thalamic burst firing (McCormick and Prince, 1986). 
Ainge and colleagues have shown increased c-fos expression in thalamic nuclei after the 
stimulation of posterior PPTg (Ainge et al., 2004). In PD patients, self-paced voluntary 
movements changed PPTg activity and functional interactions between the cortices and the 
PPTg (Tsang et al., 2010). There were strong coherences between the PPTg and the cortical 
sensorimotor regions in the theta band on the ipsilateral side. On the basis of the known 
relation between the VT of the thalamus and the sensorimotor cortex by theta band 
coherences, the relations of oscillatory activity between these regions during the pre-
movement period and during execution were interpreted by the authors as a possible 
evidence for a sensorimotor feedback loop: the information from the cortex may drive the 
PPTg during movement preparation while the PPTg is re-entering relevant sensory information 
for the execution of the movement (Tsang et al., 2010). The beneficial effect of the stimulation 
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of posterior PPTg observed in the 6-OHDA group might hence stem from a modulation of this 
thalamicocortical circuit.  
4.4.6. L-DOPA induced AIMs and improvements by PPTg-DBS 
Initially the experimental design included the administration of systemic L-DOPA to both 
parkinsonian groups to be able to compare the therapeutic effect of L-DOPA on gait deficits to 
the effect of DBS. The dose of 12 mg/kg L-DOPA combined with 15 mg/kg Benserazide 
hydrochloride was chosen based on the dosages described in the literature used to induce LID 
in rodent models of PD. The intent was to find a dose that would be high enough for a 
therapeutic benefit but sufficiently low to avoid AIMs. Winkler and colleagues have shown that 
6mg/kg, given chronically over 5 weeks was not enough to improve performance in the 
staircase test (Winkler et al., 2002). Others used injections between 8 – 15 mg/kg twice daily 
over several weeks to induce LIDs (Mahmoudi et al., 2011; Monville et al., 2005; Picconi et al., 
2003). On this basis the dose of 12 mg/kg was chosen, considering that it was only to be given 
on 3 consecutive days (later reduced to 2 days): no severe LIDs were expected. The result was 
a different one. This, however, allowed for the exploration of the effect of PPTg lesions on LID 
and the therapeutic effect of PPTg-DBS on those motor complications. The reason for this 
unexpected reaction might lie in the difference of PD models used. The rats used in the studies 
referred to above were hemiparkinsonian rats caused by different 6-OHDA dosages, injections 
sites and targets. The rats in the experiments of this project presented considerable degrees of 
bilateral DA-degeneration. This degeneration might have been higher than the ones referred 
to which might be constituting the reason for the more readily reaction to L-DOPA with AIMs. 
Time did not permit the establishment of a dose-response-curve.  
With the appearance of AIMs by the PD rats after administration of L-DOPA the intention was 
to take advantage of this effect to compare the severity and nature of AIMs in both 
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parkinsonian groups and assess whether the additional PPTg lesion changed the L-DOPA effect. 
Further, the potential of PPTg-DBS in reducing those side effects was tested. The results 
showed clearly that, in the DBS-OFF condition, the additional PPTg lesion in the combined 
lesion group shifted the severity of the L-DOPA induced AIMs to more severe dyskinetic 
movements, namely dyskinesias scoring a 5 and 6 on the Creese-Iversen scale, which involve 
repetitive orofacial movements: Rats of the combined lesion group showed those severe 
dyskinesias of continuous licking and biting for longer compared to the traditional 6-OHDA 
lesion group. This effect was observed in both, the anterior DBS and posterior DBS experiment.  
Winkler and colleagues pointed out the necessity of having a model for LIDs that better mimics 
the physiological state considering the heterogeneous pattern of DA denervation in patients, 
which affects primarily the putamen and consequently they  chose striatal injections sites over 
injections of 6-OHDA into the MFB (Winkler et al., 2002). These experiments here take this one 
step further by adding extranigral degeneration to the existing model, just as it was done in 
the experiment described in Chapter 4. Abnormal involuntary movements in form of limb, 
trunk and orolingual movements as observed in these rats after L-DOPA injection provide a 
valid rat analogue of human LIDs (Lundblad et al., 2002), especially considering that LIDs in 
patients often involve orofacial movements (Guridi et al., 2008). Those AIMs are often rated by 
frequency counts according to a dyskinesia scale [for example (Cenci et al., 1998)] during pre-
determined monitoring periods of a short interval. By combining severity using a modified 
version of the Creese-Iversen scale and duration recording the total time of AIM exhibition the 
assessment was given a dynamic dimension and allowed for a precise assessment of the L-
DOPA response.   
The difference in the response to L-DOPA between both PD models was observable and 
significant. The PPTg innervates the facial, hypoglossus and the trigeminal motor nucleus (Allen 
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and Winn, 1995; Fay and Norgren, 1997a, 1997b, 1997c), all brainstem nuclei involved in the 
control of facial musculature. The PPTg being in receipt of BG output and directly connected to 
those nuclei may explain the enhanced AIMs in response to L-DOPA administration, in 
particular the increased severity of oromotor movements of licking and biting in the combined 
lesion group compared to the 6-OHDA lesion group. Since L-DOPA had not been given 
chronically the reason for AIMs has most likely been DA receptor supersensitivity in the 
denervated striatum in combination with chronic inhibition of the PPTg (Mitchell et al., 1989). 
The additional PPTg lesion may have caused a further disinhibition of the oral motor nuclei. In 
fact, Allen and colleagues showed a shift in the response to intrastriatal injections of d-
amphetamine in PPTg lesioned rats compared to sham-operated controls to more severe 
stereotypy levels; predominantly with respect to orofacial movements including continuous 
bouts of licking and biting, corresponding to scores 5 and 6 on the Creese-Iversen scale and 
comparable to the observations made in these experiments (Allen and Winn, 1995). D-
amphetamine stimulates DA release and inhibits the reuptake of DA, therefore increasing the 
concentration of DA in the synaptic cleft, prolonging and increasing the effect of DA on 
postsynaptic receptors. This is comparable to the action of L-DOPA, which also increases DA 
concentrations, but by decarboxylation to DA by the lyase enzyme aromatic L-amino acid 
decarboxylase; the stimulant and AIMs inducing effects of d-amphetamine and L-DOPA can 
therefore be considered comparable. 
In the combined lesion group, DBS of the posterior part of the PPTg had a beneficial effect on 
the AIMs, shifting the severity from the highest score to less severe and non-oromotor AIMs. 
There are two possible explanations for it: (i) In PD patients, STN-DBS is a very potent option 
for patients who suffer from LIDs after years of positive response to L-DOPA medication. It 
leads to a significant reduction of LIDs. Since this closely correlates with a reduction of L-DOPA 
dosage for ameliorating the parkinsonian symptoms this is most likely the main cause for the 
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reductions in LIDs. Nevertheless, it is also suggested that the HFS of the STN has anti-dyskinetic 
effects on its own, probably due to an effect on the dorsal border of the STN, reaching the 
lenticularis fasciculus and the zona incerta (Voges et al., 2002). After showing enhanced theta 
band activity in the dorsolateral striatum of hemiparkinsonian rats that displayed LID after L-
DOPA administration in comparison with non-LID hemiparkinsonian rats Alam and colleagues 
suggested that maladaptive synaptic plasticity changes within the BG circuitry after L-DOPA 
treatment lead to enhanced theta band activity in the ‘off’ state which is further pronounced 
in the ‘on’ state (Alam et al., 2014). Enhanced theta band activity had already been shown in 
the SNr of L-DOPA primed PD rats (Meissner et al., 2006) and in the STN of PD patients after L-
DOPA administration (Alonso-Frech et al., 2006). It is possible that DBS of the STN not only 
causes a reduction of LIDs by reducing the L-DOPA dosage necessary for symptomatic relief, 
but also by correcting the abnormal oscillatory activities in the BG circuitry. The effect of 
posterior PPTg-DBS might have similar reasons. Posterior PPTg has cholinergic, GABAergic and 
glutamatergic projections to the STN. By possibly acting on these PPTg efferents by means of 
the LFS altered neuronal activities in the STN and further related nuclei  might be changed and 
relieve the BG circuit from those altered oscillatory activities that have been associated with 
LIDs. (ii) The PPTg has downstream control over cranial nerve nuclei involved in oromotor 
function such as the facial nucleus, the trigeminal motor nucleus and the hypoglossal nucleus. 
The disinhibiting effect on striatal outflow due to the loss of PPTg neurons, which in the 
condition of L-DOPA induced AIMs in rats, may have been partially compensated for by the 
DBS of the posterior PPTg, re-establishing downstream control. 
4.4.7. Methodological considerations 
Naturally, the DBS device could always be improved by miniaturization. However, the pilot 
studies showed that rats tolerate the devices attached to the headstages very well and that 
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carrying the device itself does not interfere with their general behaviour or gait as measured 
on the CW. Nevertheless, a few methodological points could be improved to increase the 
accuracy and ultimately the power of the experiments: (i) The electrodes were as small as they 
could possibly be made with the available means. Compared to the scale of the rat brain the 
track lesions caused by them appeared however very big. Especially considering the effect of 
the lesion caused on the behavioural performance it would be preferable to show that the 
same results would still be reached with smaller sized electrodes. (ii) One concern that arose 
during the first electrode implants was the fact, that using the same burr hole previously 
drilled for microinjections of ibotenic acid meant the absence of an intact dura to measure the 
dorsal-ventral coordinates from. In occasions when the burr hole could not be sufficiently 
cleaned up to then measure from the brain surface and/or estimate the variance caused by the 
loss of dura, the burr hole was extended until a clearer measurement was possible. This, 
however, needed to be avoided to not further compromise the stability of the already heavily 
“used” skull. Given the accuracy of electrode placement confirmed by the histological 
assessment, the concerns were not as serious as previously apprehended. Most of the 
electrodes hit the target well. (iii) In order to increase the power of the results of the 
experiments it would have been ideal to have bigger experimental groups. The care that 
bilateral PD models require and the time it takes to complete the necessary training and 
surgeries limited substantially the possible number of rats used in these experiments. For 
future experiments using the same model, it would require more assistance for the execution 
of the experiment or a re-design of the experimental plan. 
 
215 
 
  Chapter 6 General Discussion 
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1. Aims and summary of results 
There has been increasing interest in the role of the PPTg in PD and the potential for PPTg-DBS, 
but there is no agreement on either of the two questions almost a decade after the first 
implant of electrodes into the PPTg of patients. The first observations were interpreted 
enthusiastically and optimistically (Mazzone et al., 2005; Plaha and Gill, 2005; Stefani et al., 
2007). However, a convincing therapeutic effect has yet to be proven and the stimulation of 
the PPTg in PD patients has failed to follow the same success story as the development of STN-
DBS and other established targets (Ferraye et al., 2010; Moro et al., 2010; Stefani et al., 2013). 
Subjective evaluations of complex symptoms, small numbers of patients and a great variety of 
factors such as patients’ diagnosis, exact target site of the electrode, and stimulation 
parameters contribute to the differences reported in the literature, which shows the clear 
need for objective and controlled experiments.  
The aim of this project was to expand on the existing literature on the role of the PPTg in 
locomotion in general and on movement in PD; specifically by assessing (i) the effect of full 
PPTg lesions on gait and (ii) the effect of the addition of partial PPTg lesions to the widely used 
6-OHDA rodent model of PD. Further, (iii) the core of the project, the effect of PPTg-DBS on 
gait and L-DOPA induced AIMs was examined – more specifically, the effect of stimulation of 
the anterior and posterior PPTg. 
It was shown that the PPTg itself is not a crucial structure for the generation of normal gait. 
Rats bearing partial or full PPTg lesions did not present differences in the individual gait 
parameters reflecting stability, speed, stride and coordination compared to sham lesioned 
rats. In Chapter 3 results were presented which compared the gait of rats that received 
bilateral infusions of ibotenic acid into anterior and posterior PPTg, using a concentration that 
causes a complete or near to complete lesion of the structure. Based on the extensive 
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literature that consistently showed a lack of locomotor deficits in rodents with PPTg lesions the 
hypothesis was, that assessing individual gait parameters would not indicate movement 
disturbances either. The results stand in contrast to PPTg-lesion studies in non-human 
primates the results of which, however, need to be interpreted with caution. This is discussed 
broadly in Chapter 3. The addition of a partial PPTg lesion did not cause any of the analysed 
gait parameters to differ significantly from the traditional Parkinson’s model (using 6-OHDA to 
destroy the dopaminergic innervation of the dorsal striatum) but in comparison with the sham 
lesioned control group one specific difference was shown: The shortened stride length in the 
combined lesion model was not so much shortened as to reach significance in comparison with 
shams. Two possible explanations are discussed in Chapter 4: (i) a decrease of excitatory input 
into the STN might have corrected its hyperactive state in the PD model (ii) or the lesion might 
have caused a compensatory increase of activity in the remaining PPTg neurons counteracting 
the over-inhibitory outflow from the BG. Independently whether upstream or downstream 
alteration caused this selective behavioural change, this shows two things: (i) Additional 
lesions to DA depletion do not change the phenotype of the PD model substantially. Once 
again, this is difficult to reconcile with the assumption that the PPTg operates as a gait control 
centre. However, this subtle difference in stride length makes the close relationship with the 
BG eminent and is hence not surprising. The question is, whether this allows drawing the 
conclusion that the PPTg lesions can cause motor impairment per se, or if changes of 
behaviour can be explained differently. (ii) Secondly, it confirms the necessity of employing a 
PD model that takes into account more of the actual changes in the PD condition. This is most 
strongly confirmed by the results presented in Chapter 5: The effect of DBS of anterior and 
posterior PPTg differs significantly between the two models (6-OHDA lesion model and 
combined lesion model). Stefani and colleagues pointed out themselves “…how is it possible 
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that DBS of a degenerated area is promoting any effect?” [(Stefani et al., 2013) p.7]. In order to 
investigate this, it was crucial to refine the traditional PD model as presented in Chapter 4. 
One striking difference between the groups was in the response to the implanted electrodes. 
Differential effects of anterior and posterior PPTg on FOG were found: FOG was not seen in 
rats with just 6-OHDA lesions but was present in rats with a 6-OHDA lesion plus a partial PPTg 
lesion and an electrode implanted in anterior PPTg even in the ‘OFF’ condition. FOG was then 
further exaggerated when DBS was activated. Posterior electrodes did not cause freezing 
episodes in either of the models and it is conceivable that the occurrence of FOG in the 
combined lesion group after switching the posterior PPTg electrode ‘ON’ is due to current 
spread to the anterior part.  FOG is a symptom that is more prominent in advanced stages of 
PD (Macht et al., 2007) – in this stage it occurs in about 53% of patients (Giladi, 2001) – and 
FOG that occurs during a patient’s ‘ON’-period (on medication) is in general not responsive to 
DA treatment (Bloem et al., 1996; Krause et al., 2004), some PD patients never experience FOG 
and furthermore FOG is also present in other movement disorders (see General Introduction). 
There are, therefore, strong arguments for a cause of FOG lying outside the dopaminergic 
system, which stands confirmed by the results presented in Chapter 5. 
Further, differential effects regarding the effect of PPTg-DBS in both parkinsonian models were 
found: DBS in posterior but not anterior PPTg ameliorated gait deficits in the 6-OHDA lesioned 
rats but not in rats with additional partial PPTg lesions – anterior DBS made gait deficits worse. 
Both, stimulation effects of ascending and descending projections are likely to be involved, as 
well as antidromic activation of afferent fibres. The proposed mechanisms for these effects are 
discussed in Chapter 5. The interpretation of the findings in sight of the role of PPTg in 
movement disorders is summarised below.  
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Finally, it was shown that posterior but not anterior PPTg stimulation attenuated strong AIMs 
which the parkinsonian models showed in response to L-DOPA injections. Rats from the 
combined lesion group developed significantly stronger AIMs than 6-OHDA lesioned rats. PPTg 
lesioned rats exhibited orofacial activities in response to systemic injections of amphetamine 
(Inglis, Allen, et al., 1994); after microinjections of d-amphetamine directly into the 
ventrolateral caudate-putamen rats bearing ibotenate lesions of the PPTg showed more 
stereotypies classified as 5 and 6 on the Creese-Iversen scale compared to control rats – just 
like in this study (Allen and Winn, 1995). The observations presented in Chapter 5 confirm the 
role of the PPTg in mediating striatal outflow and controlling its impact on, here, orofacial 
behaviour, which is disinhibited due to the PPTg lesion. In advanced stages and after chronic 
treatment with L-DOPA parkinsonian patients develop L-DOPA-induced dyskinesias (Obeso et 
al., 2000). Chronic inhibition of the PPTg and PPTg degeneration could be mediating and/or 
worsening those L-DOPA induced oral dyskinesias (Inglis, Allen, et al., 1994). Here, posterior 
PPTg-DBS might have restored some of this control over the oral motor nuclei via its 
descending projections causing an attenuation of the AIMs observed in this study.  
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Various gait parameters 
Full PPTg lesions No deficits 
6-OHDA lesion alone Deficits 
6-OHDA lesion + PPTg lesion Comparable deficits to 6-OHDA alone 
 
      anterior PPTg-DBS posterior PPTg-DBS 
6-OHDA lesion 
alone 
Gait DBS on gait gets worse gait gets better 
FOG 
DBS off no FOG no FOG 
DBS on no FOG no FOG 
L-DOPA  
DBS off L-DOPA induced AIMs 
L-DOPA induced 
AIMs 
DBS on L-DOPA induced AIMs 
L-DOPA induced 
AIMs 
     
   
Anterior PPTg-DBS posterior PPTg-DBS 
6-OHDA lesion 
+ PPTg lesion 
Gait DBS on no effect on gait no effect on gait 
FOG 
DBS off FOG  no FOG 
DBS on FOG +++ FOG 
L-DOPA 
induced 
AIMs 
DBS off More severe AIMs than 6-OHDA group 
More severe AIMs 
than 6-OHDA group 
DBS on More severe AIMs than 6-OHDA group 
Shift to less severe 
scores of AIMs 
 
Table 6.1. Summary of findings presented in this thesis. 
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2. Why did PPTg-DBS not have the expected result?  
The majority of articles published on PPTg-DBS refer to the PPTg as the major component of 
the MLR, a motor controlling structure. The assumption is often made that the excessive 
inhibitory BG output from the SNr and GPi onto the PPTg puts a brake on this motor control 
centre – leading to reduced glutamatergic output to the spinal cord, which could then be 
corrected by LFS of PPTg neurons, assuming LFS drives the inhibited cells. In the General 
Introduction the problems of clinical lesion reports, lesion studies in non-human primates, and 
stimulation studies in decerebrate rats and cats were discussed, naming the major reasons for 
an – at best – cautious  conclusion regarding the role of PPTg in movement control: extensive 
lesions in case of stroke patients and monkeys treated with kainic acid, thermal lesions which 
cannot exclude the possibility of damage to the passing fibres, and post-surgical testing 
regimes that do not allow for sufficient recovery from the operation itself. The most recent 
non-human primate study assessing the role of the PPTg in movement and movement 
disorders – and the only experiment to study the effect of a combination of DA depletion and 
PPTg lesions so far published – does not show significant differences between MPTP lesions 
plus PPTg lesion and non-PPTg-lesioned MPTP-treated macaques (Grabli et al., 2013).  
The rodent literature is unambiguous and more extensive. Bilateral lesions and inactivation of 
PPTg have no effect on general motor behaviour as observed in the homecage, in locomotor 
test boxes or when performing tasks on the radial maze or operant boxes (Alderson et al., 
2003; Dellu et al., 1991; Homs-Ormo et al., 2003; Inglis, Allen, et al., 1994; Inglis, Dunbar, et al., 
1994; Keating and Winn, 2002; Olmstead and Franklin, 1994; Steiniger and Kretschmer, 2004; 
Swerdlow and Koob, 1987; Taylor et al., 2004; D. I. Wilson et al., 2009). The findings presented 
here add to this by showing no gait deficits as measured on the CW after PPTg lesions. 
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Differences between species are at that point often drawn upon to explain the differences 
between the findings resulting from experiments with monkeys and with rodents (Alam et al., 
2011). Reasons for believing that this argument is not sufficient to explain the differences are 
detailed in the General Introduction and it seems rather likely that the above points of 
criticism constitute the main reasons for the differing conclusions regarding the functional role 
of the PPTg.  
3. The role of the PPTg in motor disturbances – separating ‘motor’ and 
‘cognition’? 
The involvement of PPTg in movement disorders is however not negligible and therefore an 
appropriate target in studying motor impairments in PD. But in view of conclusions drawn 
from all animal studies, the PPTg cannot be regarded as a motor structure in the sense of a 
control centre. This raises the question of the nature of movement per se and if it can be 
separated from cognitive processes? 
From an expanding animal literature discussing PPTg functioning we know that the PPTg has a 
significant role in cognitive functions, such as learning and reinforcement processes, the 
updating of action-outcome associations and decision making (Alderson et al., 2004; Alderson 
et al., 2006; Corrigall et al., 2001; Diederich and Koch, 2005; Kobayashi and Okada, 2007; 
Olmstead et al., 1998; Samson and Chappell, 2001; D. I. Wilson et al., 2009). The lack of motor 
impairments after PPTg lesions does not exclude the possibility that motorically expressed 
behaviour can be altered. In a delayed spatial win-shift task PPTg lesioned rats actually entered 
the arms of a maze faster than sham lesioned control rats. This was not due to the direct effect 
of the lesions on movement control, but the rats were impaired in the selection of the 
appropriate arm in order to receive an award and it is likely that the rats’ undirected and 
disorganised completion of the task made them run quickly from arm to arm (Keating and 
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Winn, 2002). So how does the PPTg express its role in motor behaviour and how can the gait 
dysfunctions observed in these experiments be explained? 
4. The differential role of anterior and posterior PPTg 
Cholinergic, GABAergic and glutamatergic neurons within the PPTg are intermingled but 
distributed differentially along a gradient on the rostro-caudal axis (Charara et al., 1996; Lavoie 
and Parent, 1994; Mesulam et al., 1983; Wang and Morales, 2009); their intimate reciprocal 
connections with the BG, important projections to the thalamus, projections to sites of non-
specific cortical input and connections with the medullary reticular formation, cerebellum and 
spinal cord are complex and widespread. Its anatomical/ neurochemical and 
electrophysiological heterogeneity is of great significance because it explains the structure’s 
functional diversity (Martinez-Gonzalez et al., 2013; Martinez-Gonzalez et al., 2012; Ros et al., 
2010). Understanding this diversity is crucial because it suggests that the effect of PPTg-DBS 
will depend on exact location within the PPTg. In fact, of the few cases that reported benefits 
from PPTg-DBS the greatest beneficial effects were achieved with more posterior stimulation 
(Ferraye et al., 2010; Stefani et al., 2013). Finding different activity patterns of anterior and 
posterior PPTg in response to movement in PD patients Thevathasan and colleagues also 
pointed out the probability of differential clinical effects from anterior and posterior PPTg-DBS 
(Thevathasan, Pogosyan, et al., 2012).  
The posterior part of the PPTg receives very fast sensory input and it does not simply relay it: it 
responds to its meaning and value and passes this information on to thalamocortical and 
corticostriatal systems via direct connections with the thalamus and midbrain DA neurons of 
SN and VTA [(Kobayashi and Okada, 2007; Okada and Kobayashi, 2013; Okada et al., 2009; Pan 
and Hyland, 2005), also see (Maskos, 2008; Mena-Segovia, Winn, et al., 2008)]. But at the 
same time the PPTg can influence directly downstream structures such as the reticular 
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formation and spinal cord, initiating action if necessary. Via the anterior PPTg the BG can keep 
a brake on the PPTg controlling it by GABA mediated efferents from BG output nuclei. Anterior 
PPTg has descending connections but also ascending connections to DA neurons, mainly in the 
SN.  Anterior PPTg electrodes (and stimulation) proved in this study to have rather devastating 
results: It caused marked FOG in the combined lesion group. It seems however that the 
damage of neurons caused by electrode implantation added to the ibotenate induced lesion 
causing a loss that led to FOG and was further too big to be corrected by any stimulation (in 
fact stimulation made it even worse).  
The literature that examines FOG in patients with movement disorders clearly demonstrates 
that this is not a pure motor problem. FOG and falls in PD patients correlate with cognitive 
decline, particularly executive dysfunction. As in patients FOG experienced by the rats as 
described in Chapter 5 was clearly contextual: it did not affect homecage behaviour, but on the 
CW, within its confined and narrow space some animals showed pronounced start hesitation. 
FOG can be a sequence effect of gradually decreasing steps, an increased stance phase and an 
increased stride to stride variability and impaired coordination (Chee et al., 2009; Hausdorff, 
Schaafsma, et al., 2003). Given that the type of FOG observed in these rats did not occur 
during on-going gait or in form of destination hesitation (Schaafsma et al., 2003) these type of 
gait changes seem unlikely to have caused the freezing (Plotnik et al., 2008). Freezing episodes 
are largely triggered by external stimuli and when patients need to negotiate tight spaces and 
obstacles (Schaafsma et al., 2003). As discussed in Chapter 5 the narrow walkway on the CW 
bounded by high black walls could be compared to narrow spaces or doorways which often 
trigger FOG in patients. Another possibility is to consider the CW a situation of increased 
cognitive demand for the rats where they have to perform a previously learned task, 
comparable to dual task situations which can also trigger freezing in patients (Hausdorff, 
Schaafsma, et al., 2003).  
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It is conceivable to understand the freezing episodes as an enhanced problem of disrupted 
automatic or habitual control of behavioural output, which has been described as a 
consequence of disrupted normal BG functioning, particularly of the sensorimotor circuitry of 
that system (Redgrave et al., 2010). Many anatomical and behavioural findings allow the 
conclusion that goal-directed and habitual control is mediated independently by two circuits: 
one that connects with the associative and one that connects with the sensorimotor functional 
territories of the striatum: the dorsomedial and the dorsolateral striatum (in humans 
corresponding to anterior caudate and posterior lateral putamen), respectively (Balleine and 
O'Doherty, 2010; Lehericy et al., 2005). In an outcome devaluation task, for example, when the 
subjects’ response during extensive training shifted from goal-directed to habit-based control, 
an increased activation of the dorsolateral posterior putamen in response of the cue was 
measured (Tricomi et al., 2009). In PD patients a greater loss of DA is apparent in the posterior 
putamen (Kish et al., 1988). In rodents, lesions to the dorsolateral striatum blocked stimulus-
response learning (Yin et al., 2004). Instead, inactivation of the dorsolateral striatum enhanced 
the rats’ sensitivity to changes in action-outcome contingencies, while rats without this 
inactivation maintained the same rate of lever presses, not changing to goal-directed 
behaviour after a session of omission contingency (Yin et al., 2006). So it was suggested that 
PD patients replace automatic control by goal-directed processes, which would explain the 
slower execution of movements and the susceptibility to interferences from other goal-
directed tasks (Redgrave et al., 2010) and executive dysfunction. In a dual task situation, when 
goal-directed and habitual control clearly have to act “in concert” (Redgrave et al., 2010), and 
when several tasks compete for goal-directed control, it is likely that a cessation of ongoing 
gait or of the processing of gait initiation can ensue – and FOG occurs.  
Not all PD patients suffer from FOG. Further, it was shown that patients that belong to the 
category of “freezers” show a more marked PPTg degeneration and decreased cholinergic 
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afferents to the thalamus (Bohnen et al., 2009; Karachi et al., 2010). The PPTg degeneration, 
especially damage to the anterior PPTg as observed in the experiment described in Chapter 5, 
might additionally cause two problems: 
(i) Redgrave and colleagues hypothesise that the output from the goal-directed system has to 
overcome distorted, ‘noisy’ output from stimulus-response habitual control circuits at a point 
where those two systems must converge to give rise to one behavioural output (Redgrave et 
al., 2010). Given that the BG outflow targets directly the anterior PPTg, it might be the case 
that the lack of a functioning target structure – the anterior PPTg – further hinders the goal-
directed information to overcome the distorting inhibitory signals. 
(ii) The PPTg is in an ideal position to mediate outflow from the BG output nuclei and assess 
whether to send this forward or if incoming sensory information poses a reason for giving 
preference to a different action. The ability of the PPTg to make such a decision lies in the fact 
that it is able to analyse sensory information about a stimulus regarding its salient aspects – 
the association of a stimulus with a reward, the prediction of the reward value, the reward 
itself, and the actual value of the reward (Kobayashi and Okada, 2007; Okada and Kobayashi, 
2013; Okada et al., 2009; Thompson and Felsen, 2013). PPTg neurons showed task-related 
tonic activity, increasing or decreasing during the task execution period correlated with the 
response magnitude to cues predicting large or small rewards, and reward-related phasic 
responses (Okada and Kobayashi, 2013; Okada et al., 2009). Sensory input into the dorsolateral 
striatum from the anterior PPTg via remaining and functioning midbrain DA neurons of the SNc 
might support the maintaining of some functioning of the sensorimotor circuitry. The lack of 
sensory information due to a lesioned anterior PPTg might increase the chance of the system 
to freeze, especially during a dual task or any other situation that requires goal-directed 
control, so that these resources cannot be used to compensate for lack of habitual control. 
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Improvement in motor performance when guided by sensory stimuli supports this assumption 
(Kadivar et al., 2011; Spaulding et al., 2013): it might cause an increase of sensory output from 
the PPTg, increasing the chances that the dorsolateral circuit receives this input to support its 
processes. 
Further, the damaged anterior PPTg is unable to convey important information about possibly 
conflicting, incoming sensory stimuli of the environment (“there are walls but I fit through”, 
“there is the edge of the glass, but behind that I find my home cage”) to the SNc. At this point, 
where the PPTg would assess whether to send the BG output further or if the sensory input 
carries information that needs to be fed back into the BG system to make a decision on a 
different motor output (“yes, the way is clear, go ahead” or “no, there are obstacles/ danger of 
falling off the walkway”), the lack of sensory information to the SNc might put a brake on the 
system because the decision on competing actions cannot be made and the rat freezes. 
Whether anterior PPTg stimulation in the combined lesion group had no effect on gait because 
there were simply not enough neurons left to have an effect on, or if the number of actual 
completed CW runs was too small (reduced by the substantial amount of FOG episodes that 
impeded the completion of CW runs) is not clear. The information, however, coming from the 
results obtained from the 6-OHDA group allow interesting assumptions about the possible 
mechanism behind the stimulation (in detail discussed in Chapter 5). Theoretically, driving 
anterior PPTg neurons that are under pathological over-inhibition from the BG could be 
expected to have a beneficial effect, implying that it is an activating, stimulating effect LFS has 
on those neurons. However, given the further aggravation of already observed deficits, it is 
more likely that the LFS is enhancing the already existing problem, which would imply that the 
stimulation in anterior PPTg is not affecting the neurons of the PPTg, but having an antidromic 
effect, driving the inhibitory afferents from the BG. These results suggest two things: (i) the 
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mechanism behind PPTg LFS might be a different one than expected, which makes it (ii) even 
more important to consider the exact stimulation site, as the differential effects presented 
here show.  
Both the lesion caused by the electrode and LFS in the anterior PPTg had negative behavioural 
effects: severe FOG in the combined lesion group and worsening in the 6-OHDA group 
respectively. Posterior stimulation on the contrary improved gait parameters in the 6-OHDA 
lesion group. Given its strong connection with the thalamus the PPTg has an important 
influence on cortical activity. Assessing the functioning of postural sensory integration in PD 
patients using a balance platform Mueller and colleagues related the results to cholinergic 
terminal loss measured by means of PET imaging. In a regression analysis controlling for 
cognitive capacity and PD motor impairments they found an association of decreased thalamic 
cholinergic innervation and decreased sensory integration measured as an increased centre of 
pressure sway speed on the balance platform. This led to the suggestion that the disrupted 
integration of sensory information from the PPTg to the thalamus is involved in postural 
disturbances (Muller and Bohnen, 2013). Ballanger and colleagues showed increased activity in 
several cortical areas with PPTg stimulation, amongst these changes in the medial 
sensorimotor area (Ballanger et al., 2009). Underactivity in this area has been suggested an 
important factor in parkinsonian motor symptoms (DeLong and Wichmann, 2009) and 
increased activation has been associated with motor improvement (Brooks and Samuel, 2000; 
Jenkins et al., 1992). Another study found increased activity in several prefrontal areas with 
PPTg-DBS, amongst others the dorsolateral prefrontal cortex, orbitofrontal cortex, anterior 
cingulate (Stefani et al., 2010). It is therefore likely that the benefits seen here after posterior 
PPTg-DBS can be attributed to influences on cortical structures. For the clinical application it 
needs to be highlighted that this effect was absent in the model that takes into account the 
PPTg degeneration that Parkinson’s patients manifest. It is however patients at later stages of 
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the disease –effected by more advanced dopaminergic and extranigral degeneration – who are 
in most need for surgical treatment and would likely be considered candidates for PPTg-DBS. 
It is clear that the PPTg is more than an BG outflow target: (i) it has influence over BG systems; 
(ii) it constitutes an interface between BG and other brainstem structures and the spinal cord; 
and (iii) it has extensive connections with brainstem structure involved in motor control such 
as the medial reticular formation: Humphries and colleagues suggested this to be a potential 
action selection system in the brainstem (Humphries et al., 2007). In addition, the very short 
latency of response to sensory input of the PPTg and its role in the startle response and 
prepulse inhibition (Diederich and Koch, 2005; Fendt et al., 2001; Koch et al., 1993) suggest 
that it has the capacity to act upon the brainstem without involving the BG. It is not only in 
receipt of sensory data but can also analyse the input. This way it can control and gate the 
information before it gets processed further in the BG: sensory information that requires quick 
action might be prioritised over incoming BG output, which gets integrated with ongoing 
sensory input. Otherwise, the sensory information gets integrated into the BG and thalamus, 
exerting influence on the cortico-basal ganglia-cortical circuits.  
The findings of this project support this view: lesions of the PPTg disturbed the system in 
different ways: interrupting the extraction of specific salient aspects of sensory input and the 
crucial and necessary interface of this information into the corticostriatal system and 
interrupting the integration of BG output activity at the level of the PPTg before it can be 
relayed to the reticular formation and other brainstem motor output sites. Severe freezing was 
the consequence. Further, the inability to integrate oral motor control and to control oral 
motor systems caused more severe AIMs in combined lesion rats than in DA depleted animals 
alone. The presumably stimulating effect of DBS on the sensory component of the PPTg 
improved gait parameters of PD rats, driving sensorimotor integration by acting on ascending 
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projections to the thalamus and midbrain DA system, but also regaining control over oral 
motor nuclei downstream, easing L-DOPA induced AIMs.  
5. Future experiments 
The new refined PD model, unresolved questions and hypotheses made regarding the 
observed behavioural results present a source for subsequent experiments.  
The lack of further deficit or worsening of existing deficits after the addition of a partial PPTg 
lesion to the 6-OHDA induced DA depletion was discordant with a study conducted on non-
human primates assessing also the behavioural effect of the combination of PPTg lesions and 
DA depletion. Furthermore, the degree of cholinergic cell loss is reported to correlate with 
disease severity according to the Hoehn and Yahr stages (Braak et al., 2003) and patients who 
suffer more frequently from falls than other PD patients were reported to show a higher cell 
loss in the PPTg (Karachi et al., 2010) and a decreased thalamic innervation of cholinergic 
afferents (Bohnen et al., 2009). The CW might not be able to detect such differences. 1) It 
would be interesting to test the combined lesion model, in comparison to the simple DA 
depleted model, in tests more focused on balance. The beam-walking test assesses the rat’s 
interlimb coordination and ability to balance on a narrow beam. Another option is the rotarod 
test: Monville and colleagues compared different testing protocols and described that testing 
the rats on different fixed speeds showed maximum sensitivity to detect small changes 
(Monville 2006). An accelerating protocol might test the animal’s ability to detect and adapt to 
the changing speed, assessing their ability to integrate constantly changing sensory input with 
their ongoing behaviour. 
2) Further, the deficits caused by PPTg lesions in rodents appear in operant tasks or other tasks 
that require the rats’ ability to form associations between action and outcome and the 
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contingencies. The deficits are of cognitive nature and have been compared to frontal lobe 
syndrome, a condition that includes cognitive deficits such as executive dysfunction and 
disorganised behaviour (Winn, 1998). FOG has been repeatedly been associated with executive 
dysfunction (Giladi and Hausdorff, 2006) and given, again, that it is suggested that patients 
who suffer from FOG have a higher loss of PPTg neurons, it sounds reasonable to ask the 
question, whether rats with combined lesions of PPTg and SNc perform worse in cognitive 
tasks than just DA depleted rats. The difficulty in designing cognitive tasks for parkinsonian rats 
lies in their severe motor impairment. Faure and colleagues successfully tested bilaterally 6-
OHDA lesioned rats in operant boxes, where the rats had to either operate levers or chains. 
The DA loss, however, was inferior to the DA degeneration caused in the experiments 
presented here (Faure et al., 2005). It would remain to be tested, whether the rats modelling a 
more severe stage of PD are able to complete the tasks in an operant box. Radial maze tasks 
would offer an alternative that does not require the skilled movement of the front limbs. With 
an adequate test, in the case of behavioural differences between the models, the effect of 
PPTg-DBS could be assessed, as well. In fact, as described in the General Introduction, 
neurosurgeons have turned to assessing the effect of PPTg-DBS on cognitive deficits in PD 
patients, as well [see (Stefani et al., 2013)]. 
3) It remains the question of the mechanism behind the effects of PPTg-DBS, or, in fact, DBS – 
LFS and HFS – in general. The mechanisms of DBS on the STN have been studied extensively 
and many different mechanisms have been described [for detailed reviews please refer to 
(Benabid et al., 2009; Nowak et al., 2011)]. Benabid and colleagues suggest a function of 
several interacting mechanisms, which all might have a different weight within this function 
(Benabid et al., 2009). Furthermore, as discussed earlier, many different factors determine on 
what and how DBS acts. Regarding the PPTg, it also needs to be considered that the ascending 
and descending motor connections of the PPTg arise largely from separate, but intermingled, 
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neurons of different neurochemical compositions (Martinez-Gonzalez et al., 2013). Most likely, 
it is inadvisable to speak about a gross effect in terms of activation or inhibition of DBS. 
However, precise tests might be able to isolate possible pathways and test their involvement 
in DBS mechanisms. a) Electrophysiological imaging of neuronal activity during PPTg-DBS could 
give first insights of its effect. To date, this has only been done in anaesthetised, but not in 
freely behaving rats. b) To test whether the improvement of gait after posterior PPTg 
stimulation was due to an activating effect of posterior ascending projections the effect of 
chemical stimulation by means of for example the GABA antagonist bicuculline or a L-
glutamatate re-uptake inhibitor instead of electrical stimulation would allow reducing the 
variability that DBS entails (electrode orientation, positioning and distance of nerves and fibres 
to the contact, current spread).  Nandi and colleagues reported that in two MPTP-treated 
monkeys microinjections of bicuculline into the PPTg significantly improved akinesia. The 
crucial factor here would be to control the spread of the compound and restrict it to the 
posterior portion of the PPTg by either tagging the compound and later verifying the spread or 
by using control groups of different placements of the compound and to compare different 
effects. c) It would be ideal if it was possible to interrupt the pedunculopontine-thalamic 
pathway to examine if stimulation of posterior PPTg would still be able to improve gait in the 
absence of cholinergic input from the PPTg into the thalamus. The fusion toxin Dtx-UII causes 
selective cholinergic lesions when injected into the PPTg. At the moment ongoing work in this 
laboratory is examining if this toxin can also lesion cholinergic terminals. Should this be 
successful, it would offer a possibility to produce selective cholinergic denervation of thalamic 
nuclei. d) The use of optogenetic techniques would allow for further control of selectively 
activating or inhibiting pathways of interest. In order to investigate whether the gait 
improvement with posterior PPTg-DBS is due to the activations of cholinergic projections to 
the thalamus this pathway can be manipulated in Chat::Cre rats (Witten et al., 2011). The 
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expression of channelrhodopsin in cholinergic neurons of the PPTg can be achived by targeting 
cholinergic terminals in the thalamus by injecting a Cre-dependent AAV virus carrying the gene 
for channelrhodopsin directly into the terminal region. Channelrhodopsin will then be 
retrogradely expressed in cholinergic neurons of the PPTg, which can then be activated using 
blue light on the the PPTg. The problem with this approach is that not only the axons directed 
at the thalamus but also collateral to other targets will be activated. Further, cholinergic 
neurons in the LDTg that project to the thalamus will equally be light sensitive and might be 
activated should the light spread to this structure. Alternatively, the entire cholinergic 
population of the PPTg can be rendered light sensitive (or as much of the population as this 
technique allows) by injection of the virus directly into the PPTg. By delivering the blue light to 
the thalamus the cholinergic terminals can be activated. The limitation of this approach might 
be a retrograde activation of the cholinergic neurons in the PPTg and subsequent activation of 
collateral projections to other regions. 
4) The administered dose of L-DOPA was too high for the here employed PD models to avoid 
the development of L-DOPA induced AIMs. However, it was observed that during the first 10 to 
15 minutes L-DOPA reduced the rats’ rigidity notably. It would be interesting to assess the 
ability of L-DOPA to correct gait deficits in the combined lesion model. Westin and colleagues 
showed improvement of stride length but not swing speed or duty cycle of bilaterally 6-OHDA 
lesioned rats tested on the CW (Westin et al., 2012). Given that the additional PPTg lesion did 
not result in worsening of gait it is likely that the gait deficits might be improved by L-DOPA in 
the same way as they could improve gait deficits of DA depleted rats alone – provided a dose 
of L-DOPA is found that can provide benefit without causing L-DOPA induced side-effects. 
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6. Conclusion 
Our understanding of the role of the PPTg has been broadened over the years: Anatomical, 
physiological and behavioural findings in rodents, non-human primates and humans have 
changed the focus from traditionally a motor structure and master switch for sleep regulation 
to the recognition of the PPTg as a heterogeneous, widely connected structure with integrative 
and complex functions that involve formation and updating of action–outcome associations 
and decision making. This work has confirmed this view and proven that it is important that 
this understanding is now also being reflected in the PPTg-DBS literature to (i) better 
understand the variable outcomes of PPTg-DBS in PD patients so far and (ii) to consider crucial 
factors concerning the effect of PPTg-DBS: the effect depends on the exact location within the 
PPTg and on the extent of survival of PPTg neurons. The actual therapeutic potential of this 
target site for DBS needs to be considered carefully, especially in consideration of PPTg 
degeneration in PD and balanced with potential adverse effects of PPTg-DBS. 
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  Appendix Supplementary material 
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Supplementary Table 3.1.: Pre-surgical data presented as means ± SEM. Univariate Anovas comparing the PPTg lesion and the sham lesion group proved that for all 
analysed parameters a pre-existing difference between groups could be ruled out. Corresponding p-values are given. 
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Supplementary Table 4.1.: Data from the two individual sets presented as means together with the range. The group numbers of the individual sets were considered 
too small for statistical testing. Inspection of the raw numbers comparing set 1 and set 2 of each experimental group considering the given range led to the 
conclusion that no systematic differences were detected that would prevent the data of both sets to be merged.  
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Supplementary Table 4.2.: Pre-surgical data presented as means ± SEM. Univariate Anovas comparing the PPTg lesion and the sham lesion group proved that for all 
analysed parameters a pre-existing difference between groups could be ruled out. Corresponding p-values are given. 
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Supplementary Table 5.1.: Pre-surgical data presented as means ± SEM. Univariate Anovas comparing the combined lesion, 6-OHDA lesion and the sham lesion group 
proved that for all analysed parameters a pre-existing difference between groups could be ruled out. Corresponding p-values are given. 
 
